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A B S T R A C T
Background
Steroid-sparing strategies have been attempted in recent decades to avoid morbidity from long-term steroid intake among kidney
transplant recipients. Previous systematic reviews of steroid withdrawal a@er kidney transplantation have shown a significant increase
in acute rejection. There are various protocols to withdraw steroids a@er kidney transplantation and their possible benefits or harms are
subject to systematic review. This is an update of a review first published in 2009.
Objectives
To evaluate the benefits and harms of steroid withdrawal or avoidance for kidney transplant recipients.
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 15 February 2016 through contact with the Information Specialist
using search terms relevant to this review.
Selection criteria
All randomised and quasi-randomised controlled trials (RCTs) in which steroids were avoided or withdrawn at any time point a@er kidney
transplantation were included.
Data collection and analysis
Assessment of risk of bias and data extraction was performed by two authors independently and disagreement resolved by discussion.
Statistical analyses were performed using the random-eMects model and dichotomous outcomes were reported as relative risk (RR) and
continuous outcomes as mean diMerence (MD) with 95% confidence intervals.
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Main results
We included 48 studies (224 reports) that involved 7803 randomised participants. Of these, three studies were conducted in children (346
participants). The 2009 review included 30 studies (94 reports, 5949 participants). Risk of bias was assessed as low for sequence generation
in 19 studies and allocation concealment in 14 studies. Incomplete outcome data were adequately addressed in 22 studies and 37 were
free of selective reporting.
The 48 included studies evaluated three diMerent comparisons: steroid avoidance or withdrawal compared with steroid maintenance, and
steroid avoidance compared with steroid withdrawal. For the adult studies there was no significant diMerence in patient mortality either in
studies comparing steroid withdrawal versus steroid maintenance (10 studies, 1913 participants, death at one year post transplantation:
RR 0.68, 95% CI 0.36 to 1.30) or in studies comparing steroid avoidance versus steroid maintenance (10 studies, 1462 participants, death
at one year a@er transplantation: RR 0.96, 95% CI 0.52 to 1.80). Similarly no significant diMerence in gra@ loss was found comparing steroid
withdrawal versus steroid maintenance (8 studies, 1817 participants, gra@ loss excluding death with functioning gra@ at one year a@er
transplantation: RR 1.17, 95% CI 0.72 to 1.92) and comparing steroid avoidance versus steroid maintenance (7 studies, 1211 participants,
gra@ loss excluding death with functioning gra@ at one year a@er transplantation: RR 1.09, 95% CI 0.64 to 1.86). The risk of acute rejection
significantly increased in patients treated with steroids for less than 14 days a@er transplantation (7 studies, 835 participants: RR 1.58, 95%
CI 1.08 to 2.30) and in patients who were withdrawn from steroids at a later time point a@er transplantation (10 studies, 1913 participants,
RR 1.77, 95% CI 1.20 to 2.61). There was no evidence to suggest a diMerence in harmful events, such as infection and malignancy, in adult
kidney transplant recipients. The eMect of steroid withdrawal in children is unclear.
Authors' conclusions
This updated review increases the evidence that steroid avoidance and withdrawal a@er kidney transplantation significantly increase the
risk of acute rejection. There was no evidence to suggest a diMerence in patient mortality or gra@ loss up to five year a@er transplantation,
but long-term consequences of steroid avoidance and withdrawal remain unclear until today, because prospective long-term studies have
not been conducted.
P L A I N   L A N G U A G E   S U M M A R Y
Steroid avoidance or withdrawal for kidney transplant recipients
What is the issue?
Each year more than 28,000 kidney transplants are performed globally. Kidney transplantation is the treatment of choice for eligible people
who have lost kidney function. Most kidney transplant recipients receive corticosteroids as part of their immunosuppression treatment.
Steroids are eMective in preventing acute rejection, which is a major problem in the early period a@er kidney transplantation. However,
steroids can also lead to serious side eMects when taken long-term. This review looked at two strategies to reduce steroid administration
a@er kidney transplantation: either discontinuing steroids soon a@er transplantation (within 14 days) or stopping steroid treatment later.
What did we do?
We searched the literature up to February 2016 and identified 48 studies (7803 patients) that were evaluated in this review. Only three
studies included children. This is an update of a review that was last published in 2009.
What did we find?
Our review looked at data relating to 7803 kidney transplant recipients. We assessed the risk of bias in all studies and found that most were
unblinded, about half did not report funding sources or how they randomised and allocated study participants.
We found that the risk of acute rejection significantly increased with both steroid-reducing treatments among adults who received kidney
transplants. There was no little or no diMerence in the numbers of deaths or loss of transplanted kidneys for both steroid-reducing strategies
within five years a@er kidney transplantation. Side eMects, such as infection, cancer or diabetes a@er transplantation did not diMer between
groups of patients whose steroids were discontinued compared with those who continued to take steroids. The eMect of steroid withdrawal
in children is unclear.
Conclusions
There was no evidence to suggest a diMerence in patient mortality or gra@ loss up to five year a@er transplantation, but longer-term
consequences of steroid avoidance and withdrawal still remain unclear.
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Summary of findings for the main comparison.   Steroid withdrawal versus steroid maintenance for kidney transplant recipients
Steroid withdrawal versus steroid maintenance for kidney transplant recipients
Patient or population: kidney transplant recipients
Intervention: steroid withdrawal
Comparison: steroid maintenance
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Steroid maintenance Steroid withdrawal
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Mortality
Follow-up: 1 year
22 per 1000 15 per 1000
(8 to 29)
RR 0.68 
(0.36 to 1.3)
1913 (10) ⊕⊕⊝⊝
low1,2
GraA loss (excluding death) 
Follow-up: 1 year
32 per 1000 38 per 1000
(23 to 62)
RR 1.17 
(0.72 to 1.92)
1817 (8) ⊕⊕⊝⊝
low2,3
Acute rejection 
Follow-up: 1 year
152 per 1000 268 per 1000
(182 to 396)
RR 1.77 
(1.2 to 2.61)
1913 (10) ⊕⊕⊕⊝
moderate1
NODAT
Follow-up: 5 years
57 per 1000 44 per 1000
(28 to 69)
RR 0.77 
(0.49 to 1.21)
1439 (6) ⊕⊕⊝⊝
low2,4
CMV infection 
Follow-up: 5 years
100 per 1000 104 per 1000
(80 to 137)
RR 1.04 
(0.8 to 1.36)
1758 (5) ⊕⊕⊝⊝
low2,5
*The assumed risk is the baseline risk in the control group treated with steroid maintenance. The corresponding risk (and its 95% confidence interval) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; NODAT: new-onset diabetes after transplantation; CMV - cytomegalovirus
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Most studies were unblinded (9 studies) and did not report details about random sequence generation or allocation concealment or both (8 studies). One study had inappropriate
random sequence generation. Four studies were industry sponsored. ITT analysis was unclear in four.
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2 Total number of events were fewer than 300.
3 Most studies were unblinded (7 studies) and did not report details about random sequence generation or allocation concealment or both (6 studies). One study had inappropriate
random sequence generation. Four studies were industry sponsored. ITT analysis was unclear in two.
4 Most studies were unblinded (5 studies) and did not report details about random sequence generation or allocation concealment or both (5 studies). Three studies were industry
sponsored. ITT analysis was unclear in three studies. One study had selective outcome reporting.
5 Most studies were unblinded (4 studies) and did not report details about random sequence generation or allocation concealment or both (4 studies). Three studies were industry
sponsored. ITT analysis was unclear in two studies. One study had selective outcome reporting.
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Steroid avoidance versus steroid maintenance for kidney transplant recipients
Patient or population: kidney transplant recipients
Intervention: steroid avoidance
Comparison: steroid maintenance
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Steroid avoidance
versus steroid main-
tenance
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Mortality
Follow-up: 1 year
31 per 1000 30 per 1000
(16 to 56)
RR 0.96 
(0.52 to 1.8)
1462 (10) ⊕⊕⊝⊝
low1,2
 
GraA loss (excluding death)
Follow-up: 1 year
42 per 1000 46 per 1000
(27 to 79)
RR 1.09 
(0.64 to 1.86)
1211 (7) ⊕⊕⊝⊝
low2,3
 
Acute rejection 
Follow-up: 1 year
204 per 1000 323 per 1000
(221 to 470)
RR 1.58 
(1.08 to 2.3)
835 (7) ⊕⊕⊕⊝
moderate4
 
NODAT
Follow-up: 5 years
107 per 1000 80 per 1000
(54 to 117)
RR 0.75 
(0.51 to 1.1)
1618 (9) ⊕⊕⊝⊝
low2,5
 
CMV Infection
Follow-up: 5 years
106 per 1000 101 per 1000
(74 to 138)
RR 0.96 
(0.7 to 1.31)
1454 (6) ⊕⊕⊝⊝
low2,6
 
*The assumed risk is the baseline risk in the control group treated with steroid maintenance. The corresponding risk (and its 95% confidence interval) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; NODAT: new-onset diabetes after transplantation; CMV - cytomegalovirus
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate
1 All studies were unblinded. Six studies were industry sponsored. In six studies random sequence generation or allocation concealment or both was unclear. In two studies ITT
was either not performed or unclear. One study had selective outcome reporting
2 Total number of events was fewer than 300
3 All studies were unblinded. Five studies were industry sponsored. In four studies random sequence generation or allocation concealment or both was unclear. ITT was unclear
in one study. One study had selective outcome reporting
4 All studies were unblinded. Five studies were industry sponsored. In four studies random sequence generation or allocation concealment or both was unclear. In three studies
ITT was either not performed or unclear. One study had selective outcome reporting
5 Most studies were unblinded (8 studies). Five studies were industry sponsored. In four studies random sequence generation or allocation concealment or both was unclear.
One study had selective outcome reporting
6 Most studies were unblinded (5 studies). Four studies were industry sponsored. One study had unclear ITT
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B A C K G R O U N D
Description of the condition
Patients with end-stage kidney disease (ESKD) have to undergo
renal replacement therapy which is available either as dialysis
or kidney transplantation. Kidney transplantation is the preferred
treatment for eligible patients with ESKD, because it oMers a
nearly normal life and is associated with better survival and
quality of life compared to dialysis treatment. More than 16,000
kidney transplants are currently performed annually in the USA
(OPTN/SRTR 2014) and more than 12,000 in Europe (ERA-EDTA
2013). Despite kidney transplants from live donors, organ demand
exceeds organ availability worldwide and the number of patients
wait listed for kidney transplantation continues to rise (ANZDATA
2012; ERA-EDTA 2013; OPTN/SRTR 2014).
Although short-term outcomes of kidney transplantation have
continuously improved since the 1980s, long-term results have
only marginally improved until today. Death with a functioning
gra@ and chronic allogra@ nephropathy are the most important
causes of gra@ loss (Pascual 2002). Thus, strategies that prolong
patient survival and gra@ patency have become a priority in kidney
transplantation.
One of the key factors that influence transplant outcomes
is immunosuppression which prohibits progressive immune
mediated injury of the allogra@. Standard immunosuppressive
protocols nowadays consist of an initial induction treatment
followed by a maintenance regimen. Immunosuppression
is induced by an intensive treatment for the initial
days a@er transplantation either with higher dosages
of the immunosuppressive drugs or by adding an
additional immunosuppressive agent, such as anti-T-cell
antibodies or interleukin 2 receptor antibodies. Maintenance
immunosuppression usually comprises a combination of three
drug groups: calcineurin inhibitors, such as cyclosporin (CsA) or
tacrolimus (TAC), anti-proliferative agents, such as azathioprine
(AZA) or mycophenolate mofetil (MMF) and corticosteroids, such as
prednisolone.
Corticosteroids are long known for their anti-inflammatory and
immunosuppressive properties and have been used to prevent
rejection since the early days of kidney transplantation. Although
steroids are eMective in preventing acute rejection, chronic steroid
use may be an important cause of morbidity and mortality (Opelz
2005). Steroids exhibit a wide range of adverse eMects, such
as skin fragility, bodyweight gain, osteoporosis and cataracts,
can adversely aMect important cardiovascular and metabolic risk
factors including hypertension, hyperglycaemia and dyslipidaemia
and may contribute to an increased risk of infection (Coutinho 2011;
Czock 2005; Matas 2005; Patel 2001). A literature review on the
safety of low dose glucocorticoid treatment in rheumatoid arthritis
suggested that the toxicity of steroids is overestimated, because
adverse eMects of chronic low dose steroid treatment (≤ 10 mg/
d prednisolone equivalent) were found to be modest and rarely
statistically significantly diMerent from placebo (Da Silva 2006).
Description of the intervention
With the aim to reduce the adverse eMects of long-term
corticosteroid therapy, there has been much eMort to limit the
exposure of kidney transplant recipients to steroids. Lessening
exposure to steroids can be achieved by either steroid avoidance
or steroid withdrawal. In steroid avoidance, steroids are either
avoided completely or withdrawn within the first days a@er kidney
transplantation and steroid withdrawal refers to discontinuation of
steroids at a certain time point in the later post-transplant phase.
This review evaluated all steroid avoidance or withdrawal strategies
in kidney transplant recipients.
How the intervention might work
Steroids show adverse cardiovascular and metabolic eMects and
therefore discontinuing steroid treatment may take eMect by
a decrease in this accelerated cardiovascular risk. However,
while steroid avoidance and withdrawal potentially reduces
post-transplant atherosclerosis, ischaemic heart disease, post-
transplant diabetes and death, it may significantly increase the risk
of acute rejection. Acute rejection is associated with late gra@ loss,
especially if rejection episodes are severe, followed by impaired
kidney function, occur late and aMect arteries (Basadonna 1993;
Massy 1996). The new immunosuppressants TAC and MMF have
led to important declines in the incidence of acute rejection and
may provide a more potent substrate to attempt safe steroid-free
immunosuppression or steroid withdrawal.
Why it is important to do this review
It is important to reduce the cardiovascular risk in kidney transplant
recipients, who area population at increased cardiovascular risk,
but at the same time it is important to avoid rejection and gra@ loss.
Steroids have been associated with increased cardiovascular risk
in kidney transplant recipients, but long-term benefits and harms
of steroid discontinuation have not yet been established with
controlled long-term data (Knight 2010). Prednisone was perceived
as the least eMective and least favoured immunosuppressive
drug compared to calcineurin inhibitors, MMF and AZA in a
survey among Canadian kidney transplant recipients and the
majority of US transplant physicians and surgeons stated that
steroid-free immunosuppression was a goal for future organ
transplant recipients (Hricik 2002; Prasad 2003). Steroid use
varies largely in clinical practice around the globe. While steroids
are discontinued in many centres worldwide, they are at the
same time frequently used for long-term treatment in kidney
transplant recipients to protect the allogra@. There is no consensus
whether discontinuation of steroids is safe, what type of patients
benefit from steroid discontinuation and at what time point a@er
transplantation steroids are best stopped. A number of RCTs
evaluating steroid avoidance or withdrawal at various time-points
a@er kidney transplantation with diMerent immunosuppressive
regimes have been performed during the last decades and were first
systematically reviewed in 2009 (Pascual 2009). Steroid avoidance
and steroid withdrawal strategies in kidney transplantation were
not associated with increased patient mortality or gra@ loss,
despite an overall higher incidence of acute rejection for steroid
withdrawal strategies compared with steroid maintenance. The aim
of this review was to update the benefits and harms of steroid
withdrawal and avoidance in kidney transplant recipients with new
evidence from RCTs.
O B J E C T I V E S
To evaluate the benefits and harms of steroid withdrawal or
avoidance for kidney transplant recipients.
Steroid avoidance or withdrawal for kidney transplant recipients (Review)
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M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs or quasi-RCTs (in which allocation to treatment was
obtained by alternation, use of alternate medical records, date
of birth or other predictable methods), whether published or
unpublished, in which steroids were avoided or withdrawn at
any time point a@er kidney transplantation were eligible for
inclusion. RCTs evaluating any other steroid-sparing strategy (i.e.
dose reduction) or attempting other interventions in addition
to steroid withdrawal (i.e. switch from AZA to MMF, induction
treatment in addition to steroid withdrawal) were excluded in this
review.
Types of participants
Adult and paediatric recipients of a first or subsequent kidney
transplant from a cadaveric or living donor. Recipients of
multiorgan transplants (kidney-pancreas, kidney-liver, kidney-
heart) were excluded.
Types of interventions• Steroid avoidance, defined as steroid use during less than 14
days a@er kidney transplantation versus steroid maintenance• Steroid withdrawal, defined as steroid use for more than 14 days
a@er transplantation versus steroid maintenance• Steroid avoidance versus steroid withdrawal.
Types of outcome measures
Outcome measures used by transplant registries to report patient
and gra@ survival were selected for this review. Outcome events
were assessed within the first year and up to five years a@er kidney
transplantation. A secondary outcome looking at infection has
been amended for this update to specify cytomegalovirus (CMV)
infection.
Primary outcomes
1. All-cause mortality
2. Gra@ loss or death with a functioning gra@; and gra@ loss
censored for death with a functioning gra@ (loss of gra@ function
resulting in either return to dialysis or retransplantation)
3. Acute rejection (clinically suspected and treated) and biopsy-
proven acute rejection.
Secondary outcomes
1. Cardiovascular events
2. New-onset diabetes a@er transplantation (NODAT)
3. Malignancy
4. Infection and CMV infection
5. Kidney function measures (serum creatinine (mg/dL); creatinine
clearance (mL/min)).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised
Register up to 15 February 2016 through contact with the
Information Specialist using search terms relevant to this review.
The Specialised Register contains studies identified from several
sources.
1. Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the proceedings
of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised Register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based on
the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the
Specialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and clinical
practice guidelines.
2. Letters seeking information about unpublished or incomplete
studies to investigators known to be involved in previous
studies.
Data collection and analysis
Selection of studies
The search strategies described was used to obtain title and
abstracts of studies relevant to this review. Three authors
independently screened titles and abstracts, and discarded reports
that were not applicable. Studies and reviews that might include
relevant data or information on studies were retained initially and
two authors independently assessed retrieved abstracts and, if
necessary the full text, of these studies to determine which studies
satisfied the inclusion criteria. Disagreement about inclusion was
resolved by discussion with a third author.
Data extraction and management
Two authors independently carried out data extraction using
standard data extraction forms. Studies reported in non-English
language journals will be translated before assessment. Where
more than one report of a study existed, reports were grouped
together and the publication with the most complete data was
used in the analyses. We examined any prior or subsequent report
for supplementary outcomes or data to ensure the inclusion of all
relevant information. If data were unclear, ambiguous or missing,
authors were contacted for further information and any provided
additional data was included in the review. Whenever necessary,
disagreements were resolved by discussion.
Assessment of risk of bias in included studies
Two authors independently assessed the following items using the
risk of bias assessment tool (Higgins 2011) (see Appendix 2).
• Was there adequate sequence generation (selection bias)?
Steroid avoidance or withdrawal for kidney transplant recipients (Review)
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• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study?* Participants and personnel (performance bias)* Outcome assessors (detection bias)• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e<ect
For dichotomous outcomes results were expressed as risk ratio
(RR) with 95% confidence intervals (CI). Where continuous scales
of measurement were used to assess the eMects of treatment,
the mean diMerence (MD) was used, or the standardised mean
diMerence (SMD) if diMerent scales had been used.
Unit of analysis issues
The unit of analysis was the study participant and not the events;
that is the number of study participants with an acute rejection
rather than the number of episodes of acute rejection.
Dealing with missing data
Any further information required from the original author was
requested by written correspondence (e.g. emailing corresponding
author) and any relevant information obtained in this manner was
to be included in the review. Evaluation of important numerical
data such as screened, randomised patients as well as intention-
to-treat, as-treated and per-protocol population will be carefully
performed. Attrition rates, for example drop-outs, losses to follow-
up and withdrawals were investigated. Issues of missing data
and imputation methods (for example, last-observation-carried-
forward) were critically appraised (Higgins 2011). If standard
deviation was not available, it was estimated using standard error
(if provided) (Higgins 2011).
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 (on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance)
and with the I2 statistic, calculated to measure the proportion
of total variation in the estimates of treatment eMect that was
due to heterogeneity beyond chance (Higgins 2003). I2 values of
25%, 50% and 75% correspond to low, medium and high levels of
heterogeneity.
Assessment of reporting biases
We assessed publication bias by constructing funnel plots for
primary outcomes if there was suMicient data available to enable
this analysis (at least 10 included studies in the meta-analysis).
Data synthesis
Data were pooled for summary estimates using the random-
eMects model but the fixed-eMect model was also to be used
to ensure robustness of the model chosen and susceptibility to
outliers. Results reported used the random-eMects model because
this is more conservative in the presence of known or unknown
heterogeneity (Deeks 2001).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were used to explore possible sources of
heterogeneity and potential eMect modifiers were defined a
priori. The main source of heterogeneity among participants
could be related to age, therefore adults and children who
were kidney transplant recipients were analysed separately.
Heterogeneity in treatments could be related to duration of
steroid therapy and concomitant immunosuppressants. Therefore
subgroup analysis was undertaken using stratified meta-analysis
for type of calcineurin inhibitor, type of antimetabolite and whether
an induction treatment was administered.
Sensitivity analysis
Sensitivity analysis was performed to demonstrate that final results
did not vary where low quality studies were included or excluded.
Low quality studies were defined based on publication type
(conference abstract or peer reviewed journal) and methodological
conduct (whether intention-to-treat analysis was assessed as
adequate or inadequate/unclear).
R E S U L T S
Description of studies
Results of the search
A search in 15 February 2016 identified 151 reports. Additionally
three previously excluded studies were re-evaluated and included;
these had been incorrectly excluded for reasons of insuMicient data
(Aswad 1998; Kacar 2004; Pisani 2001). All three are published
as abstract only. Pisani 2001 contributed data for the meta-
analysis. We also re-evaluated three previously included studies
and excluded them because they had been incorrectly included
despite a wrong co-intervention (CARMEN Study 2005; Tarantino
1991; ter Meulen 2002). In CARMEN Study 2005 and ter Meulen 2002
induction treatment with daclizumab was only given to patients in
the steroid withdrawal group and in Tarantino 1991 AZA was given
solely to patients in the steroid maintenance group. We included
21 new studies (59 reports) that involved 1854 participants, two of
these new studies (seven reports) concerned children. We found
that 88 new reports were additional reports of previously included
studies. This update includes 48 studies (224 reports) that involved
7803 participants, including three studies (11 reports) that involved
346 children. See Figure 1.
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Figure 1.   Study flow diagram.
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Included studies
See Characteristics of included studies.
The 48 included studies were published in 22 diMerent journals and
seven had preliminary abstract data only available (Aswad 1998;
Burke 2000; del Castillo 2005; INFINITY Study 2013; Kacar 2004;
Kim 2002; Pisani 2001).The eMect of steroid withdrawal compared
versus steroid maintenance was investigated in 26 studies (4022
participants) and the eMect of steroid avoidance compared
versus steroid maintenance was investigated in 19 studies (3401
participants). We identified three studies (380 participants) that
evaluated the eMect of steroid avoidance compared versus steroid
withdrawal. Numbers of participants per study varied from 21
(Aswad 1998) to 560 patients (THOMAS Study 2002). It is noteworthy
that 25 studies randomised fewer than 100 participants, 15 studies
included between 100 and 300 participants, and eight studies
randomised more than 300 participants.
Trials in adult kidney transplant recipients
This update included 45 studies (208 reports, 7457 participants)
of steroid withdrawal or avoidance in adult kidney transplant
recipients.
Participants
Trials recruited participants who were older than 18 years of
age, except two studies which recruited participants older than
12 years (Stiller 1983) or between five and 62 years (Nagib
2015). In 14 studies the age range was not further specified
(Albert 1985; Aswad 1998; Gulanikar 1991; INFINITY Study 2013;
Isoniemi 1990; Johnson 1989a; Kacar 2004; Kim 2002; RatcliMe
1993; Schulak 1989; Smak Gregoor 1999; Sola 2002; THOMAS Study
2002; Zhu 2008a).The majority of studies included cadaveric and
living kidney transplant recipients (25 studies: Ahsan 1999; ATLAS
Study 2005; Boletis 2001; Boots 2002; Burke 2000; DOMINOS Study
2012; EVIDENCE Study 2014; Farmer 2006; FREEDOM Study 2008;
Gulanikar 1991; Jankowska-Gan 2009; Kim 2002; Kumar 2005;
La@avi 2005; Lebranchu 1999; Matl 2000; Montagnino 2005; Nott
1985; Pelletier 2006; Schulak 1989; Stiller 1983; Smak Gregoor
1999; THOMAS Study 2002; Vincenti 2003a; Woodle 2005). Kidney
transplantation was limited to cadaveric donor sources in 11
studies (Bouma 1996; De Vecchi 1986; FRANCIA Study 2007;
Isoniemi 1990; Johnson 1989a; Maiorca 1988; Ponticelli 1997;
RatcliMe 1993; Sandrini 2009; Sola 2002; Zhu 2008a) and to living
donors in four studies (Aswad 1998; Nagib 2015; Nematalla 2007;
Park 1994) In 17 studies first or subsequent kidney transplant
recipients were eligible (Boots 2002; Bouma 1996; DOMINOS Study
2012; EVIDENCE Study 2014; Farmer 2006; Gulanikar 1991; Johnson
1989a; Lebranchu 1999; Montagnino 2005; Nott 1985; Pisani 2001;
Ponticelli 1997; RatcliMe 1993; Schulak 1989; Stiller 1983; THOMAS
Study 2002; Woodle 2005), while in 19 studies limited participants
to recipients of first kidney transplants (Ahsan 1999; ATLAS Study
2005; Boletis 2001; Burke 2000; del Castillo 2005; FRANCIA Study
2007; FREEDOM Study 2008; INFINITY Study 2013; Isoniemi 1990;
Kumar 2005; La@avi 2005; Maiorca 1988; Matl 2000; Nagib 2015;
Nematalla 2007; Park 1994; Pelletier 2006; Sandrini 2009; Vincenti
2003a).
Study comparisons
The 45 included studies evaluated three diMerent comparisons in
adults.
• Steroid withdrawal compared versus steroid maintenance was
investigated in 24/45 studies in adult patients (Ahsan 1999;
Albert 1985; Aswad 1998; Boletis 2001; Bouma 1996; Burke
2000; del Castillo 2005; EVIDENCE Study 2014; Farmer 2006;
Gulanikar 1991; Isoniemi 1990; Jankowska-Gan 2009; Kacar
2004; Lebranchu 1999; Maiorca 1988; Matl 2000; Park 1994;
Pelletier 2006; Pisani 2001; RatcliMe 1993; Smak Gregoor 1999;
Sola 2002; THOMAS Study 2002; Zhu 2008a). Steroids were
withdrawn three months a@er transplantation in eight studies
(Ahsan 1999; EVIDENCE Study 2014; Gulanikar 1991; Isoniemi
1990; Lebranchu 1999; Park 1994; Sola 2002; THOMAS Study
2002); six months a@er transplantation in eight studies (Albert
1985; Aswad 1998; Boletis 2001; Burke 2000; del Castillo 2005;
Pisani 2001; Smak Gregoor 1999; Zhu 2008a); one year a@er
transplantation in one study (Matl 2000), and beyond one year
a@er transplantation in six studies (Bouma 1996; Farmer 2006;
Jankowska-Gan 2009; Kacar 2004; Maiorca 1988; RatcliMe 1993).
In one study, steroids were withdrawn at diMerent time points
a@er transplantation and the time point of withdrawal was not
reported, but all patients had steroids for more than 14 days
(Pelletier 2006).• Steroid avoidance compared versus steroid maintenance was
investigated in 18/45 studies in adult kidney transplant
recipients (ATLAS Study 2005; De Vecchi 1986; FRANCIA Study
2007; FREEDOM Study 2008; Nott 1985; INFINITY Study 2013;
Johnson 1989a; Kim 2002; Kumar 2005; La@avi 2005; Stiller 1983;
Montagnino 2005; Nagib 2015; Nematalla 2007; Ponticelli 1997;
Schulak 1989; Vincenti 2003a; Woodle 2005). In two studies
steroids were not given at any time point before, during or a@er
transplantation (FREEDOM Study 2008; Stiller 1983). Steroids
were withdrawn until day seven a@er transplantation in 12
studies (ATLAS Study 2005; De Vecchi 1986; FRANCIA Study 2007;
Nott 1985; Johnson 1989a; Kim 2002; Kumar 2005; La@avi 2005;
Montagnino 2005; Nematalla 2007; Ponticelli 1997; Vincenti
2003a) and between day 8 and day 14 in two studies (Schulak
1989; Woodle 2005).• Steroid avoidance was compared versus steroid withdrawal
in 3/45 studies with adults (Boots 2002; DOMINOS Study
2012; Sandrini 2009). In all of these three studies, steroids
were withdrawn until day seven a@er transplantation in the
avoidance group and between three to six months a@er
transplantation in the withdrawal group.
Immunosuppression
CsA was used in 34 studies evaluating steroid withdrawal or steroid
avoidance (Ahsan 1999; Albert 1985; Boletis 2001; Bouma 1996;
Burke 2000; del Castillo 2005; De Vecchi 1986; DOMINOS Study 2012;
EVIDENCE Study 2014; Farmer 2006; FRANCIA Study 2007; FREEDOM
Study 2008; Gulanikar 1991; INFINITY Study 2013; Isoniemi 1990;
Jankowska-Gan 2009; Johnson 1989a; Kim 2002; Kumar 2005;
Lebranchu 1999; Maiorca 1988; Matl 2000; Montagnino 2005; Nott
1985; Park 1994; Pelletier 2006; Pisani 2001; Ponticelli 1997; RatcliMe
1993; Sandrini 2009; Schulak 1989; Smak Gregoor 1999; Vincenti
2003a). TAC was used in 10 studies investigating steroid withdrawal
or steroid avoidance (Aswad 1998; ATLAS Study 2005; Boots 2002;
La@avi 2005; Nagib 2015; Nematalla 2007; Sola 2002; THOMAS
Study 2002; Woodle 2005; Zhu 2008a). One study provided no
information about the baseline immunosuppression used (Kacar
2004). Of the three studies comparing steroid avoidance with
steroid withdrawal, two used a CsA-based immunosuppression
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(DOMINOS Study 2012; Sandrini 2009) and one used a TAC-based
immunosuppression (Boots 2002).
Five studies investigated steroid withdrawal compared versus
steroid maintenance in patients without an additional
antiproliferative immunosuppressant (either MMF or enteric-
coated mycophenolate sodium or AZA or mTOR-inhibitor) (Albert
1985; Bouma 1996; Gulanikar 1991; Maiorca 1988; Park 1994)
and five studies investigated steroid avoidance compared versus
steroid maintenance without an additional antiproliferative (De
Vecchi 1986; Johnson 1989a; Nott 1985; Stiller 1983; Ponticelli
1997). Steroid avoidance compared versus steroid withdrawal in
patients without an antiproliferative was investigated in Boots
2002. An immunosuppressive regimen including an additional
antiproliferative agent was used in 18 studies that investigated
steroid withdrawal compared versus steroid maintenance (Ahsan
1999; Aswad 1998; Boletis 2001; Burke 2000; del Castillo 2005;
EVIDENCE Study 2014; Farmer 2006; Isoniemi 1990; Jankowska-
Gan 2009; Lebranchu 1999; Matl 2000; Pelletier 2006; Pisani 2001;
RatcliMe 1993; Smak Gregoor 1999; Sola 2002; THOMAS Study
2002; Zhu 2008a). Of these 18 studies, 12 used MMF (Ahsan
1999; Boletis 2001; del Castillo 2005; Burke 2000; Jankowska-
Gan 2009; Pelletier 2006; Pisani 2001; Smak Gregoor 1999; Sola
2002; THOMAS Study 2002; Lebranchu 1999; Zhu 2008a), five
used AZA (Aswad 1998; Farmer 2006; Isoniemi 1990; Matl 2000;
RatcliMe 1993), and one used Everolimus (EVIDENCE Study 2014).
Steroid avoidance compared versus steroid maintenance using
an additional antiproliferative immunosuppressant was used in
13 studies (ATLAS Study 2005; FRANCIA Study 2007; FREEDOM
Study 2008; INFINITY Study 2013; Kim 2002; Kumar 2005; La@avi
2005; Montagnino 2005; Nagib 2015; Nematalla 2007; Schulak
1989; Vincenti 2003a; Woodle 2005). Of these, nine used MMF
(ATLAS Study 2005; FRANCIA Study 2007; Kim 2002; Kumar 2005;
La@avi 2005; Nagib 2015 Nematalla 2007; Vincenti 2003a; Woodle
2005), two used enteric-coated mycophenolate sodium (FREEDOM
Study 2008; INFINITY Study 2013), one used AZA (Schulak 1989),
and one used everolimus (Montagnino 2005). Steroid avoidance
compared versus steroid withdrawal in patients treated with
an additional antiproliferative was investigated in two studies
(DOMINOS Study 2012; Sandrini 2009). One study used enteric-
coated mycophenolate sodium (DOMINOS Study 2012) and one
used sirolimus (Sandrini 2009) as the third immunosuppressant.
Induction treatment was administered in 17 studies with adult
kidney transplant recipients in three studies comparing steroid
withdrawal with steroid maintenance (EVIDENCE Study 2014;
Pelletier 2006; Pisani 2001), in 12 studies comparing steroid
avoidance with steroid maintenance (FRANCIA Study 2007;
FREEDOM Study 2008; INFINITY Study 2013; Kim 2002; Kumar
2005; La@avi 2005; Montagnino 2005; Nagib 2015; Nematalla 2007;
Schulak 1989; Vincenti 2003a; Woodle 2005), and in two studies
comparing steroid avoidance with steroid withdrawal (DOMINOS
Study 2012; Sandrini 2009). In 12 studies an IL-2 receptor antagonist
was used for induction treatment (DOMINOS Study 2012; EVIDENCE
Study 2014; FREEDOM Study 2008; INFINITY Study 2013; Kim 2002;
Kumar 2005; Montagnino 2005; Nagib 2015; Nematalla 2007; Pisani
2001; Sandrini 2009; Vincenti 2003a), in three studies an anti-
lymphocytic depleting antibodies was used (FRANCIA Study 2007;
La@avi 2005; Schulak 1989) and two studies allowed the type of
induction treatment to be chosen by the investigator (Pelletier
2006; Woodle 2005).
Studies in child kidney transplant recipients
This update included three studies (11 reports, 346 participants)
of steroid withdrawal or avoidance in child kidney transplant
recipients (Benfield 2005; Höcker 2009; Mericq 2013).
Participants
Studies recruited participants who were younger than 20 years
of age. All three studies included cadaveric and living kidney
transplant recipients. In Benfield 2005 and Mericq 2013 only first
kidney transplant recipients were eligible; in Höcker 2009 first or
subsequent kidney transplantation was included.
Study comparisons
The three studies evaluated two diMerent comparisons in children.
Benfield 2005 and Höcker 2009 investigated steroid withdrawal
versus steroid maintenance; Mericq 2013 investigated steroid
avoidance versus steroid withdrawal.
Immunosuppression
All three studies used a calcineurin inhibitor-based
immunosuppressive regimen including an additional
antiproliferative agent. Höcker 2009 used CsA and MMF, Benfield
2005 allowed either CsA or TAC to be used with sirolimus and Mericq
2013 used TAC in combination with MMF. Benfield 2005 and Mericq
2013 also used basiliximab for induction treatment, but Benfield
2005 was terminated early when the Data Safety Monitoring Board
noted an excess risk of post-transplant lymphoproliferative disease
in both treatment groups.
Reported outcome measures
The reporting of outcome measures varied across studies. Of
the 45 included studies, 34 reported patient mortality and 23
reported acute rejection (see Figure 1). Reporting of harms was
more limited and inconsistent among studies (six studies reported
cardiovascular events with varying definitions of cardiovascular
events or definitions not reported). Frequently, studies reported
incomplete data for harm outcomes or expressed their results as
'episodes', which complicated meaningful use of such data in the
meta-analysis.
Excluded studies
We excluded a total of 48 studies because studies: were not
randomised (12), concerned ineligible populations (3), involved
ineligible interventions ( 11) or ineligible co-interventions (22).
Risk of bias in included studies
Reporting of details of study methodology regarding design
and conduct of the study was incomplete in most studies. The
assessment of risk of bias is shown in Figure 2 and Figure 3. Figure
2 shows the risk of bias indicators for individual studies. Figure 3
shows the proportion of studies assessed as low, high or unclear
risk of bias for each risk of bias indicator.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study
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Figure 2.   (Continued)
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
 
Allocation
Random sequence generation was judged to be at low risk of
bias in 19 studies (Ahsan 1999; ATLAS Study 2005; Benfield 2005;
DOMINOS Study 2012; EVIDENCE Study 2014; FRANCIA Study 2007;
FREEDOM Study 2008; Gulanikar 1991; Höcker 2009; Johnson
1989a; Kumar 2005; La@avi 2005; Mericq 2013; Montagnino 2005;
Nematalla 2007; Ponticelli 1997; Schulak 1989; Stiller 1983; Woodle
2005) and considered at high risk in two studies (Aswad 1998; Matl
2000). Randomisation methods were not reported in 27 studies
(Albert 1985; Boletis 2001; Boots 2002; Bouma 1996; Burke 2000;
del Castillo 2005; De Vecchi 1986; Farmer 2006; INFINITY Study
2013; Isoniemi 1990; Jankowska-Gan 2009; Kacar 2004; Kim 2002;
Lebranchu 1999; Maiorca 1988; Nagib 2015; Nott 1985; Park 1994;
Pelletier 2006; Pisani 2001; RatcliMe 1993; Sandrini 2009; Smak
Gregoor 1999; Sola 2002; THOMAS Study 2002; Vincenti 2003a; Zhu
2008a).
Allocation concealment was assessed to be at low risk of bias
in 14 studies (ATLAS Study 2005; Boots 2002; De Vecchi 1986;
DOMINOS Study 2012; Farmer 2006; FRANCIA Study 2007; Gulanikar
1991; Isoniemi 1990; Mericq 2013; Montagnino 2005; Nematalla
2007; Smak Gregoor 1999; Stiller 1983; Woodle 2005); no study
was judged to be at high risk of bias. Methods used for allocation
concealment were unclear in the remaining 34 studies (Ahsan 1999;
Albert 1985; Aswad 1998; Benfield 2005; Boletis 2001; Bouma 1996;
Burke 2000; del Castillo 2005; EVIDENCE Study 2014; FREEDOM
Study 2008; Höcker 2009; INFINITY Study 2013; Jankowska-Gan
2009; Johnson 1989a; Kacar 2004; Kim 2002; Kumar 2005; La@avi
2005; Lebranchu 1999; Maiorca 1988; Matl 2000; Nagib 2015; Nott
1985; Park 1994; Pelletier 2006; Pisani 2001; Ponticelli 1997; RatcliMe
1993; Sandrini 2009; Schulak 1989; Sola 2002; THOMAS Study 2002;
Vincenti 2003a; Zhu 2008a).
Blinding
Participants and investigators were blinded in only five studies
(Ahsan 1999; Benfield 2005; Burke 2000; Gulanikar 1991; Woodle
2005). The absence of blinding was judged as high risk of bias
because clinical management could be influenced by knowledge of
treatment group. Blinding of outcome assessment was considered
as low risk of bias because outcomes were objective and therefore
more robust against influence by knowledge of treatment group
(e.g. death, gra@ loss, serum creatinine).
Incomplete outcome data
Incomplete outcome data was judged to be at low risk of bias in 22
studies (Ahsan 1999; ATLAS Study 2005; Benfield 2005; Boots 2002;
Bouma 1996; del Castillo 2005; DOMINOS Study 2012; FRANCIA
Study 2007; FREEDOM Study 2008; Gulanikar 1991; Höcker 2009;
Isoniemi 1990; Kumar 2005; Matl 2000; Montagnino 2005; Ponticelli
1997; RatcliMe 1993; Schulak 1989; Smak Gregoor 1999; THOMAS
Study 2002; Vincenti 2003a; Woodle 2005). Exclusion of participants
a@er randomisation and attrition were considered at high risk
in four studies (Boletis 2001; Burke 2000; De Vecchi 1986; Nagib
2015). Methods for addressing incomplete outcome data remained
unclear in 22 studies (Albert 1985; Aswad 1998; EVIDENCE Study
2014; Farmer 2006; INFINITY Study 2013; Jankowska-Gan 2009;
Johnson 1989a; Kacar 2004; Kim 2002; La@avi 2005; Lebranchu
1999; Maiorca 1988; Mericq 2013; Nematalla 2007; Nott 1985; Park
1994; Pelletier 2006; Pisani 2001; Sandrini 2009; Sola 2002; Stiller
1983; Zhu 2008a).
Selective reporting
Selective outcome reporting was judged as low risk in 37 studies
(Ahsan 1999; Aswad 1998; ATLAS Study 2005; Benfield 2005; Boots
2002; Bouma 1996; del Castillo 2005; De Vecchi 1986; DOMINOS
Study 2012; EVIDENCE Study 2014; FRANCIA Study 2007; FREEDOM
Study 2008; Höcker 2009; INFINITY Study 2013; Isoniemi 1990;
Jankowska-Gan 2009; Kacar 2004; Kumar 2005; Lebranchu 1999;
Maiorca 1988; Matl 2000; Mericq 2013; Montagnino 2005; Nagib
2015; Nematalla 2007; Park 1994; Pelletier 2006; Pisani 2001;
Ponticelli 1997; Sandrini 2009; Schulak 1989; Smak Gregoor 1999;
Sola 2002; Stiller 1983; THOMAS Study 2002; Vincenti 2003a; Woodle
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2005). Eleven studies did not report all hard clinical outcomes
that were considered primary outcomes for this review and were
assessed as high risk of bias for selective outcome reporting (Albert
1985; Boletis 2001; Burke 2000; Farmer 2006; Gulanikar 1991; Nott
1985; Johnson 1989a; Kim 2002; La@avi 2005; RatcliMe 1993; Zhu
2008a).
Other potential sources of bias
Funding from academic independent sources was considered as
low risk of bias in four studies (De Vecchi 1986; Isoniemi 1990;
Matl 2000; Mericq 2013). In 16 studies a pharmaceutical company
was reported as funding source, which was judged as high risk of
bias (Ahsan 1999; ATLAS Study 2005; Benfield 2005; Bouma 1996;
DOMINOS Study 2012; FRANCIA Study 2007; FREEDOM Study 2008;
Kumar 2005; Montagnino 2005; Gulanikar 1991; Smak Gregoor
1999; Stiller 1983; THOMAS Study 2002; Vincenti 2003a). In 27
studies funding sources were not disclosed (Albert 1985; Aswad
1998; Boletis 2001; Boots 2002; Burke 2000; del Castillo 2005;
EVIDENCE Study 2014; Farmer 2006; Höcker 2009; INFINITY Study
2013; Jankowska-Gan 2009; Johnson 1989a; Kacar 2004; Kim 2002;
La@avi 2005; Lebranchu 1999; Maiorca 1988; Nematalla 2007; Nott
1985; Park 1994; Pelletier 2006; Pisani 2001; Ponticelli 1997; RatcliMe
1993; Sandrini 2009; Schulak 1989; Sola 2002; Woodle 2005; Zhu
2008a). Publication bias was assessed by constructing funnel plots
for three comparisons that included at least 10 studies in the meta-
analysis (death and acute rejection for steroid withdrawal versus
steroid maintenance and acute rejection for steroid avoidance
versus steroid maintenance). All funnel plots are symmetric and do
not indicate publication bias (see Figure 4).
 
Figure 4.   Funnel plot of comparisons that included at least 10 studies in the meta-analysis
 
E<ects of interventions
See: Summary of findings for the main comparison Steroid
withdrawal versus steroid maintenance for kidney transplant
recipients; Summary of findings 2 Steroid avoidance versus
steroid maintenance for kidney transplant recipients
Studies in adults with kidney transplant recipients
Steroid withdrawal versus steroid maintenance
Steroid withdrawal may lead to little of no diMerence in patient
mortality at either one year (Analysis 1.1.1 (10 studies, 1913
participants): RR 0.68, 95% CI 0.36 to 1.30; I2 = 0%) or one to
five years post transplantation (Analysis 1.1.2 (7 studies, 1118
participants): RR 1.26, 95% CI 0.73 to 2.17; I2 = 0%). Likewise
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steroid withdrawal may lead to little or no diMerence in gra@
loss excluding death at either one year (Analysis 1.1.5 (8 studies,
1817 participants): RR 1.17, 95% CI 0.72 to 1.92; I2 = 0%) or one
to five years post transplantation (Analysis 1.1.6 (7 studies, 1092
participants): RR 1.61, 95% CI 0.98 to 2.64; I2 = 0%).
The risk of acute rejection significantly increased by 77% in patients
withdrawn from steroids compared versus patients maintained on
steroids within the first year a@er transplantation (Analysis 1.2.1 (10
studies, 1913 participants): RR 1.77, 95% CI 1.20 to 2.61; I2 = 54%),
but there was no diMerence in the incidence of biopsy-proven acute
rejection (Analysis 1.2.2 (5 studies, 1292 participants): RR 1.32, 95%
CI 0.78 to 2.22; I2 = 65%).
The incidence of NODAT (Analysis 1.3.1 (6 studies, 1439
participants): RR 0.77, 95% CI 0.49 to 1.21; I2 = 0%) as well as
the incidence of cardiovascular events (Analysis 1.3.2 (2 studies,
607 participants): RR 0.98, 95% CI 0.42 to 2.33; I2 = 0%) up to five
years a@er transplantation were not significantly diMerent between
groups, mainly because of the low number of studies reporting
these rarely occurring outcomes. Likewise data was sparse for
harmful events, such as infection (Analysis 1.4.1 (5 studies, 1819
participants): RR 1.02, 95% CI 0.84 to 1.22; I2 = 30%), CMV infection
(Analysis 1.4.2 (RR 1.04, 95% CI 0.80 to 1.36; participants = 1758;
studies = 5; I2 = 0%), and malignancy (Analysis 1.4.3 (3 studies, 756
participants): RR 0.77, 95% CI 0.41 to 1.46; I2 = 0%) and a diMerence
in these outcomes could not be demonstrated up to five years a@er
transplantation. There was also no evidence of diMerence in kidney
function as determined by measurement of serum creatinine and
creatinine clearance up to one as well as up to five years a@er
transplantation (Analysis 1.5) (See also Summary of findings for the
main comparison).
Sensitivity and subgroup analyses for steroid withdrawal versus
steroid maintenance studies
Results of the sensitivity and subgroup analyses are summarised in
Table 1.
We have performed sensitivity analysis to assess the impact of
publication status and use of intention-to-treat-analysis on primary
endpoints (mortality, death censored gra@ loss, acute rejection and
biopsy-proven acute rejection) using data from studies reporting
these outcomes at any time point within the first year a@er
transplantation. There was no evidence to suggest a diMerence in
eMect estimates of mortality, gra@ loss and biopsy-proven acute
rejection for studies depending on whether they have performed
intention-to-treat analysis or whether the study was published in
a peer-reviewed journal. The significant increase in risk for acute
rejection in patients withdrawn from steroids compared versus
those maintained on steroids was further increased in studies
published in a peer-reviewed journal (8 studies, 1741 participants:
RR 2.02, 95% CI 1.26 to 3.23) and in studies that applied intention-
to-treat analysis (6 studies, 1199 participants: RR 2.07, 95% CI 1.10
to 3.91), but was lost in studies published as abstract-only and in
studies where intention-to-treat analysis was either not used or
unclear.
We performed subgroup analysis stratified by calcineurin-inhibitor
type, type of antimetabolite and induction treatment on primary
endpoints (mortality, death censored gra@ loss, acute rejection and
biopsy-proven acute rejection) using data from studies reporting
these outcomes at any time point within the first year a@er
transplantation. There was no diMerence in mortality and gra@
loss in any of the subgroups. The risk of acute rejection a@er
steroid withdrawal was further increased in patients treated
with CsA (9 studies, 1357 participants: RR 2.08, 95% 1.29 to
3.35), especially among those who did not receive an additional
antimetabolite (2 studies, 150 participants: RR 5.80, 95% CI 2.16
to 15.57) and in patients who did not receive induction treatment
(8 studies, 1765 participants: RR 1.93, 95% CI 1.26 to 2.94), but
was decreased in patients who received either MMF or enteric-
coated mycophenolate sodium (6 studies, 1612 participants: RR
1.41, 95% CI 1.02 to 1.94) or any type of antimetabolite (8 studies,
1763 participants: RR 1.46, 95% CI 1.07 to 1.98).
Steroid avoidance versus steroid maintenance
Results are summarised in Summary of findings 2.
Steroid avoidance did not show a significant eMect on patient
mortality at either one year (Analysis 2.1.1 (10 studies, 1462
participants): RR 0.96, 95% CI 0.52 to 1.80; I2 = 0%) or one to
five years post transplantation (Analysis 2.1.2 (7 studies, 1201
participants): RR 0.57, 95% CI 0.32 to 1.01; I2 = 0%). Likewise
steroid avoidance did not show any significant eMects on gra@
loss excluding death at either one year (Analysis 2.1.5 (7 studies,
1211 participants): RR 1.09, 95% CI 0.64 to 1.86; I2 = 0%) or one
to five years post transplantation (Analysis 2.1.6 (7 studies, 1245
participants): RR 0.98, 95% CI 0.66 to 1.45; I2 = 0%).
Steroid avoidance significantly increased the risk of acute rejection
within the first year a@er transplantation by 58% compared versus
patients maintained on steroids (Analysis 2.2.1 (7 studies, 835
participants): RR 1.58, 95% CI 1.08 to 2.30; I2 = 63%). This eMect of
steroid avoidance was also demonstrated for biopsy-proven acute
rejection with a risk increase of 94% within the first year a@er
transplantation (Analysis 2.2.2 (6 studies, 1073 participants): RR
1.94, 95% CI 1.26 to 2.98; I2 = 45%).
There was no evidence of diMerence in the occurrence of NODAT,
cardiovascular events, infection, CMV infection and malignancy
between groups up to five years a@er transplantation (Analysis 2.3;
Analysis 2.4). Kidney function determined as serum creatinine and
creatinine clearance up to one year as well as up to five years a@er
transplantation was not diMerent for patients treated with steroids
for less than 14 days compared versus patients maintained on
steroids (Analysis 2.5).
Sensitivity and subgroup analysis for steroid avoidance versus steroid
maintenance - studies
We performed sensitivity analysis to assess the impact of use
of intention-to-treat-analysis on primary endpoints (mortality,
death censored gra@ loss, acute rejection and biopsy-proven acute
rejection) using data from studies reporting these outcomes at any
time point within the first year a@er transplantation. There was
no study investigating steroid avoidance compared versus steroid
maintenance that was published as abstract only, consequently
the influence of publication status on the eMect estimates could
not be tested. There was no evidence to suggest a diMerence in
eMect estimates of mortality and gra@ loss for studies depending
on whether they have performed intention-to-treat analysis. The
increased risk for acute rejection and biopsy-proven acute rejection
in patients treated with steroids for less than 14 days a@er kidney
transplantation compared versus those maintained on steroids was
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further increased in studies that applied intention-to-treat analysis
(acute rejection: 4 studies, 655 participants: RR 1.92, 95% CI 1.18
to 3.14; biopsy-proven acute rejection: 4 studies, 918 participants:
RR 2.31, 95% CI 1.47 to 3.63), but lost significance in studies where
intention-to-treat analysis was either not used or unclear.
We have performed subgroup analysis stratified by type of
calcineurin inhibitor, type of antimetabolite and induction
treatment on primary endpoints (mortality, death censored gra@
loss, acute rejection and biopsy-proven acute rejection) using data
from studies reporting these outcomes at any time point within
the first year a@er transplantation. Stratified analysis did not reveal
any diMerence in patient mortality and gra@ loss. The significant
increase in risk for biopsy-proven acute rejection persisted in
patients treated with CsA (3 studies, 615 participants: RR 1.89, 95%
CI 1.29 to 2.79), while patients treated with TAC did not have an
increased risk for biopsy-proven acute rejection (See Table 2).
Steroid avoidance versus steroid withdrawal
Only three studies investigating the eMect of steroid avoidance
compared versus steroid withdrawal were identified, wherefore
data is specifically sparse for this comparison. There is no evidence
to suggest a diMerence in any outcome (death: Analysis 3.1;
rejection: Analysis 3.2; NODAT, infection, malignancy: Analysis 3.3;
kidney function: Analysis 3.4). Sensitivity and subgroup analysis
could not be performed due to the small number of studies
identified.
Studies in children with kidney transplant recipients
Steroid withdrawal versus steroid maintenance
We identified only two studies that investigated the eMect of steroid
withdrawal compared versus steroid maintenance in children
(Benfield 2005; Höcker 2009). Death and gra@ loss at five years were
significantly lower for children withdrawn from steroids, but these
results were drawn from Benfield 2005 only, since neither death
nor gra@ loss were observed in Höcker 2009 (Analysis 4.1.2: RR
0.16, 95% CI 0.02 to 1.35). The eMect of steroid withdrawal on acute
rejection is unclear due to the small number of studies and wide
confidence intervals (Analysis 4.2). Kidney function was reported
in Höcker 2009 only and was not significantly diMerent between
groups (Analysis 4.3).
Benfield 2005 was terminated early due to an unanticipated
high incidence of post-transplant lymphoproliferative disease.
Of the 274 enrolled participants, 19 developed post-transplant
lymphoproliferative disease, 10 before randomisation. Sensitivity
and subgroup analysis could not be performed due to the small
number of studies identified.
Steroid avoidance versus steroid maintenance
Only Mericq 2013 investigated the eMect of steroid avoidance
compared versus steroid maintenance in children. Neither death
nor gra@ loss was observed in this study, and due to sparse
data, a diMerence in biopsy-proven acute rejection could not be
demonstrated. Kidney function was not reported. Sensitivity and
subgroup analysis could not be performed on a single study.
D I S C U S S I O N
Summary of main results
The aim of this review was to provide updated evidence addressing
the benefits and harms of steroid avoidance and withdrawal in
kidney transplant recipients. All identified studies concerned one
of the three comparisons defined for this review. The majority of
studies compared steroid withdrawal versus steroid maintenance
(24 adult studies, 2 studies in children). Steroid avoidance was
compared versus steroid maintenance in 19 studies, one of which
was conducted in child kidney transplantation. Of the three studies
that compared steroid avoidance versus steroid withdrawal, none
involved children. In adult kidney transplantation meta-analysis
could be carried out for all three comparisons, but data was
particularly scarce for the comparison of steroid avoidance with
steroid withdrawal. The low number of studies with child kidney
transplant recipients did not enable data synthesis through meta-
analysis.
We were unable to demonstrate clear beneficial eMects, such
as a reduction in mortality or NODAT within five years a@er
transplantation for steroids withdrawal or avoidance in adult
kidney transplant recipients. Both steroid withdrawal and steroid
avoidance showed little or no eMect on mortality, gra@ loss, and
CMV infection. The risk of acute rejection did significantly increase
by 77% a@er steroid withdrawal and by 58% a@er steroid avoidance
compared to steroid maintenance (see Summary of findings for the
main comparison, Summary of findings 2).
The eMect of steroid withdrawal in children is uncertain. The
available data allowed only one meta-analysis for acute rejection
in children, which found no significant diMerence. Death and gra@
loss had not been observed in one of the two studies in children and
outcomes such as biopsy-proven acute rejection and malignancy
were only reported in one of the two studies which further reduced
the quantity of the available data. Only one study investigated the
eMect of steroid avoidance compared versus steroid maintenance
in children, thus a meta-analysis was not possible.
Overall completeness and applicability of evidence
An extensive literature review was performed to identify studies
that assessed the benefits and harms of steroid withdrawal
or avoidance in kidney transplant recipients. In general, two
parameters are particularly relevant for assessing benefits and
harms of steroid withdrawal in kidney transplant recipients: firstly,
the time-point of steroid withdrawal a@er kidney transplantation
and secondly, the duration of follow-up to observe outcome events
in kidney transplant patients.
Steroids are withdrawn at various time points a@er kidney
transplantation in clinical practice and this fact was reflected by
the variety of time points used to investigate the eMects of steroid
withdrawal in clinical studies. We used a cut-oM of 14 days a@er
transplantation to discriminate between steroid withdrawal and
steroid avoidance. With this approach we were able to combine
diMerent time points for steroid withdrawal within these clinically
relevant time frames. The majority of steroid avoidance studies
used steroids for seven days or less, and the majority of the steroid
withdrawal studies withdrew steroids between three to six months
a@er transplantation. Thus, our findings may not be applicable for
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patients who are withdrawn from steroids at other time-points a@er
transplantation.
Most studies had between one and three years of follow-up a@er
either steroid avoidance or withdrawal which constitutes a major
limitation for conclusions regarding long-term consequences for
patient and gra@ survival. Acute rejection is a major risk factor
for reduced long-term gra@ survival and typically occurs within
the first year a@er transplantation. The impact of acute rejection
on long-term gra@ outcomes depends on the severity, recurrence
and treatment of the acute rejection. While particularly severe and
recurrent rejections increase the risk of gra@ loss, a single early
acute rejection with complete functional recovery a@er treatment
appears to be less harmful for long-term gra@ outcomes. Most
of the acute rejections reported in the included studies occurred
early a@er transplantation and were mild and easily controlled with
steroids which could be an argument to conclude that an increased
risk of long-term gra@ loss a@er steroid withdrawal is unlikely.
However, recognizing that potential harms arising from steroid
withdrawal may remain hidden for up to five years a@er steroid
withdrawal (Gulanikar 1991); follow-up periods of the included
studies were too short to determine long-term gra@ survival.
Furthermore, it is important to stress that only half of the studies
reported acute rejection. Consequently, potential harmful eMects of
steroid withdrawal on long-term gra@ survival cannot be ruled out
with this review with suMicient confidence.
Reporting of harmful events was especially limited and
inconsistent. More than half of the studies did not report adverse
events such as infection and CMV infection and less than a third
of the studies reported malignancy and cardiovascular events.
Even though we did not find evidence to suggest a diMerence in
harmful events, it is important to point out that the absence of
evidence does not mean there is evidence for absence of eMect. It
is unclear which outcomes occurred in the studies that provided no
data. Although we believe this is the most comprehensive evidence
summary on this topic, interpretation of our findings must consider
the limitations of available data from this cohort. The value of
increasing available evidence of potential harms associated with
interventions has been widely recognised and is also not a problem
peculiar to this review, but is common to many randomised studies
and systematic reviews (Cuervo 2003; Tunis 2003).
Only one study investigating steroid avoidance included an
mTOR-inhibitor as baseline immunosuppression. Consequently,
we cannot extrapolate the safety of steroid avoidance or withdrawal
to protocols including mTOR-inhibitors.
The inclusion and exclusion criteria for participation in the included
studies may mean that our findings are not generalizable to all
kidney transplant recipients. Eight studies did not specify any
exclusion criteria, of which four did not specify any inclusion
criteria. In three studies only recipients of a living kidney
transplant were included and 11 studies included solely recipients
of a cadaveric kidney transplant. Seventeen studies limited
participation for patients who received their first kidney transplant
and 16 studies excluded kidney transplant recipients who had
experienced previous acute rejection. Kidney transplant recipients
with a PRA > 50% were excluded in 13 studies. It is unclear whether
the findings of this review apply to kidney transplant recipients with
a higher immunologic transplant risk.
Although almost all studies included participants of a wide range
of adult ages, none of the studies reported results for diMerent age
groups. Therefore we were unable to determine whether there is
any diMerence in results depending on age. Due to the low number
of studies in child kidney transplantation, our findings need to be
interpreted with great caution in the light of a clear lack of evidence
in children.
Quality of the evidence
The quality of the included studies was rather variable. The
main limitations in the quality of the studies were allocation
concealment, incomplete outcome data, blinding of participants
and personnel and disclosure of funding. Of the 48 included
studies only five studies blinded participants and personnel. This
was considered a high risk of bias because clinical decision
making could be influenced by knowledge of the treatment,
such as for example that patients withdrawn from steroids were
more closely monitored for signs of acute rejection. Adequate
allocation concealment was reported in 14 studies and 19
studies demonstrated adequate sequence generation. The lack of
adequate sequence generation and allocation concealment can
lead to biased estimates of treatment eMects in the original study
and thus in a systematic review (Hollis 1999; Juni 1999; Moher 1998;
Schulz 1995). All hard clinical outcomes (mortality, gra@ loss, acute
rejection) were reported in 37 studies, but incomplete reporting of
relevant data for a meta-analysis in many studies hampered use of
the provided data in our analysis. Comparison of kidney function
was only possible in a limited number of studies because frequently
either the number of participants in whom kidney function was
measured or a measure of variability of the eMect estimate were not
provided. It might be more informative to compare the number of
patients at risk of gra@ loss with a low creatinine clearance rather
than assessing mean data. However, these data were not provided
in any of the studies. Similarly dichotomous outcomes, especially
infection and acute rejection were frequently reported as rates or
episodes which complicated the use of such data for meta-analysis.
For disclosure of funding sources, 16 studies reported receiving
of funding from pharmaceutical companies and 28 studies did
not disclose their sponsor. We found that blinding of outcome
assessors was adequate in 43 studies where the primary outcome
were hard-clinical endpoints (mortality, gra@ loss, acute rejection)
and considered unlikely to be influenced by lack of blinding.
Potential biases in the review process
We searched multiple databases without language restriction in
attempt to reduce publication bias. The Cochrane Kidney and
Transplant's Specialised Register contains handsearched reports
of studies presented at conferences and meetings, but there is a
possibility that we missed unpublished data presented at smaller
conferences or studies published in foreign language journals and
low impact journals. Studies may have been added since our
last search of the register. Not all included studies reported all
outcomes which may have aMected the results of the meta-analysis.
Agreements and disagreements with other studies or
reviews
Several previous systematic reviews have addressed steroid
avoidance and withdrawal a@er kidney transplantation. The
first review included three steroid withdrawal and four steroid
avoidance studies in patients on CsA with or without AZA and
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showed a significant increase in acute rejection with an incidence
of acute rejection of 48% in those withdrawn from steroids versus
30% in those maintained on steroids (P = 0.012) (Hricik 1993).
The review published seven years later (Kasiske 2000) included
10 studies and showed an increased proportion of patients with
acute rejection by 0.14 (95% CI 0.10 to 0.17; P < 0.001) and an
increase in gra@ failure a@er steroid withdrawal by 40% (RR 1.40,
95% CI 1.09 to 1.70; P = 0.012). Most studies included in this meta-
analysis used CsA-based immunosuppression with either no anti-
metabolite added or in combination with AZA. Only two studies
with MMF were included and subgroup analysis showed similar
results for these studies compared versus those that did not
include MMF. A review of six studies of steroid withdrawal in kidney
transplant recipients on triple therapy with calcineurin inhibitors
and MMF showed an increase in acute rejection and no diMerence
in gra@ failure (Pascual 2004). Due to the relative short follow-up
in these six studies long-term consequences for gra@ survival given
the observed increase in acute rejection a@er steroid withdrawal is
unclear. A meta-analysis published in 2012 by Knight 2010 found an
increased risk of acute rejection and a reduced cardiovascular risk
a@er steroid withdrawal or avoidance, but these findings resulted
from a combined analysis of all steroid withdrawal or avoidance
time points and were based on surrogate outcomes such as
hypercholesterolaemia, hypertension and NODAT. Another review
(Pascual 2012) with nine studies comparing steroid avoidance to
steroid maintenance in kidney transplant recipients who received
an immunosuppressive regimen consisting of antibody induction,
either CsA or TAC and MMF reported that the increased risk of acute
rejection in steroid avoidance was lost when patients received TAC-
based immunosuppression.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Steroid avoidance and steroid withdrawal a@er kidney
transplantation significantly increased the risk of acute rejection.
We found no evidence to suggest a diMerence in patient and gra@
survival up to five years a@er transplantation, but the data to
support the absence of harm is limited due to the low number of
events observed in rather small studies. Follow-up periods were too
short to draw any conclusions on long-term outcomes in kidney
transplant recipients a@er steroid withdrawal or avoidance. In child
kidney transplant recipients data is very limited and does not
allow any conclusions about steroid withdrawal, but caution is
warranted with induction treatment that may increase the risk of
post-transplant lymphoproliferative disease in children.
Implications for research
Proving that steroid avoidance or withdrawal a@er kidney
transplantation is safe and beneficial requires demonstration of
beneficial eMects, such as a reduction in patient mortality or
cardiovascular events while at the same time gra@ survival is not
reduced in the long-term. Until now, only short-term data exist that
demonstrate an increased risk of acute rejection and the absence
of evidence of harm, but there is no long-term data to draw any
conclusions about the harms and benefits of steroid avoidance
or withdrawal beyond five years a@er transplantation. Long-term
RCTs are needed to determine whether steroid withdrawal and
avoidance a@er kidney transplantation are safe and beneficial.
Child kidney transplant recipients constitute a target population in
a clear need of well-conducted steroid withdrawal studies.
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* Indicates the major publication for the study
 
C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Study design: parallel RCT• Study duration: not reported• Follow-up period: 1 year• Primary endpoint: biopsy-proven or presumptive acute rejection episode or treatment failure within
1 year post-transplant
Participants • Country: USA• Setting: multicentre (21 centres)• Health status: first cadaveric or living kidney transplant; > 18 years; SCr < 2.4 mg/dL or CrCl > 50 mL/
min• Number: withdrawal group (134); maintenance group (132)• Median age, range (years): withdrawal group: (50, 20 to 71); maintenance group (50, 18 to 74)• Sex (female): withdrawal group (34%); maintenance group (45%)• Donor source (living donor): withdrawal group (45%); maintenance group (41%)• Exclusion criteria: acute rejection; proteinuria > 2 g/d; significant gastrointestinal disorder; WCC <
2500/mm3, Hb < 6.5 g/dL; immunosuppression other than CsA + MMF + steroids
Interventions Withdrawal group
• Steroid withdrawal (prednisone) 3 months after transplantation
Ahsan 1999 
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• Prednisone 10 to 15 mg/d before randomisation, after randomisation: days 1 to 21: 15 mg/d, days 22
to 28: 12.5 mg/d, days 29 to 35: 10 mg/d, days 36 to 42: 7.5 mg/d, days 43 to 49: 5 mg/d, days 50 to
56: 2.5 mg/day, then withdrawn
Maintenance group
• Steroid maintenance (prednisone)• Prednisone: days 1 to 21: 15 mg/d; days 22 to 42: 12.5 mg/d; days 43 to 365: 10 mg/d
Baseline immunosuppression
• CsA: 5 to 15 mg/kg/d• MMF: months 1 to 3: 2000 mg/d, adjusted to centre practice
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• Infection• Kidney function measures: SCr (mg/dL), CrCl (mL/min)
Notes • Did not report number screened for eligibility• The study was stopped on 22 July 1998 due to statistically significant difference in the incidence of
acute rejection• Funding source: Roche Laboratories• Contact with study authors for additional information: authors contacted 28 August 2013; response
received 28 August 2013
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'Randomization was stratified by centre and was done centrally to maintain a
1:1 ratio at each centre'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Double-blind placebo controlled. Stated 'After randomisation, recipients re-
ceived blister packs containing tablets for their 'prednisone' dose. Neither re-
cipients nor physicians knew whether a randomised patient was in the with-
drawal group'
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blind placebo controlled. Stated 'After randomisation, recipients re-
ceived blister packs containing tablets for their 'prednisone' dose. Neither re-
cipients nor physicians knew whether a randomised patient was in the with-
drawal group'
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Double-blind placebo controlled. Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all participants were followed for the primary end-
point until study closure on 22 July 1998
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Ahsan 1999  (Continued)
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Other bias High risk The study was supported by Roche Laboratories
Ahsan 1999  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1983 to 1984• Follow-up period: 13 (2 to 23) months• Primary endpoint: not reported
Participants • Country: Germany• Setting: single centre• Inclusion criteria: not reported• Number analysed: avoidance group (25); withdrawal group (25)• Mean age, range (years): avoidance group (38, 10 to 51); withdrawal group (36, 21 to 54)• Sex (female): avoidance group (44%); withdrawal group (32%)• Exclusion criteria: not reported
Interventions Avoidance group
• CsA monotherapy
Withdrawal group
• Steroid withdrawal 3 to 6 months after transplantation
Baseline immunosuppression
• CsA* Started with 15 mg/kg, divided into two daily doses, adjusted to trough levels 250 to 700 ng/mL• Steroids* Steroid avoidance group: no steroids* Steroid withdrawal group: oral fluocortolone: 0.5 mg/kg, withdrawn 3 to 6 months after transplan-
tation
Outcomes • Mortality• Gra@ loss
Notes • Did not report the number screened for eligibility or randomised• Number of patients discontinued treatment* Switched from avoidance group to withdrawal group: 13* Switched from withdrawal group to avoidance group: 1* 4 patients in avoidance group and 5 patients in withdrawal group switched to AZA and steroids
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk not reported
Blinding (performance
bias and detection bias) 
High risk Open-label
Albert 1985 
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All outcomes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed, total number of patients by group
analysed not reported, results presented as percentages/rates
Selective reporting (re-
porting bias)
High risk Acute rejection not reported
Other bias Unclear risk Funding sources not reported
Albert 1985  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported• Follow-up period: not reported• Primary endpoint: not reported
Participants • Country: USA• Setting: single centre• Living kidney transplant, no further inclusion criteria provided• Number analysed: withdrawal group (11); maintenance group (10)• Mean age ± SD (years): not reported• Sex: not reported• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• TAC: adjusted to trough levels month 1: 10 to 15 ng/mL; thereafter: 5 to 10 ng/mL• AZA: no further information provided• Prednisone: no further information provided
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr
Notes • Did not report the number screened for eligibility or randomised
Aswad 1998 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Stated 'randomly assigned' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of patients by group not reported for outcomes; unclear if ITT analysis
performed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Abstract-only publication
Aswad 1998  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported, but before 2005• Follow-up period: 3 years• Primary endpoint: incidence of and time to first biopsy-proven acute rejection within 6 months after
transplantation
Participants • Country: 10 European countries• Setting: multicentre (21 centres)• First cadaveric or living kidney transplant; aged 18 to 65 years• Number (randomised/analysed): withdrawal group (152/147); maintenance group (151/151)• Mean age ± SD (years): withdrawal group (44 ± 12); maintenance group (43 ± 13)• Sex (female): withdrawal group (35%); maintenance group (40%)• Donor source (living donor): withdrawal group (13%); maintenance group (12%)• Exclusion criteria: PRA ≥ 50% in previous 6 months; previous organ transplant; non-heart beating kid-
ney donor; requiring any other immunosuppression; HIV infection; uncontrolled infection; significant
liver disease; malignancy; severe diarrhoea; vomiting; active peptic ulcer
Interventions Treatment group
ATLAS Study 2005 
Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
44
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• TAC: started within 12 hours before transplantation with 0.2 mg/kg divided in two doses, adjusted to
trough levels day 28: 10 to 20 ng/mL, thereafter: 5 to 15 ng/mL• MMF: day 0: 1000 mg, day 1 to 14: 2000 mg, thereafter: 1000 mg• Steroids* IV methylprednisone: day 0: 500 mg or less* Withdrawal group: no further steroids* Maintenance group: IV methylprednisone day 1: 125 mg, or prednisone day 2 to 14: 20 mg; day 15
to 28: 15 mg; day 29 to 42: 10 mg; thereafter: 5 mg
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• NODAT• Infection• CMV infection• Malignancy• Cardiovascular events• SCr (µM)• CrCl (mL/min)
Notes • This study had a third arm with basiliximab induction followed by TAC monotherapy (154 patients)• Did not report number screened for eligibility• Number of patients excluded from analysis* Withdrawal group: 1 (either did not receive study drug or did not undergo transplantation)* Maintenance group: 4 (either did not receive study drug or did not undergo transplantation)• Number of patients discontinued study* Withdrawal group: 8 (primarily because of protocol violation) within the first year* Maintenance group: 13 (primarily because of protocol violation) within the first year• 3-year follow-up: data of 278 patients available (139/139)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stated 'Randomization was performed with a 1:1 ratio stratified by centre. The
randomization list was generated by the Data Operation Department of Fuji-
sawa GmbH. Each centre received a unique sequence of patient numbers and
a set of sealed envelopes.'
Allocation concealment
(selection bias)
Low risk Stated 'sealed envelopes'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Open-label
ATLAS Study 2005  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review have been reported
Other bias High risk Sponsored by a grant from Fujisawa GmbH
The investigator-initiated 1-year follow-up was supported by an unrestricted
grant from Astellas, Munich, Germany
ATLAS Study 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2001 to 2004• Follow-up period: 3 years• Primary endpoint: change in standardised height z score
Participants • Country: Mexico, USA• Setting: multicentre (17 centres)• Age: 0 to 20 years• First cadaveric or living kidney transplant; enrolment at transplantation; randomisation 6 months af-
ter transplantation of participants without previous rejection if clinical or histologic evidence of re-
jection in protocol biopsy absent• Number: withdrawal group (73); maintenance group (59)• Mean age ±SD (years): withdrawal group (11 ± 5); maintenance group (12 ± 6)• Sex (female): withdrawal group (44%); maintenance group (37%)• Donor source (living donors): withdrawal group (64%); maintenance group (69%)• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 to 12 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4• CsA or TAC* CsA trough level: weeks 1 to 2: 175 to 400 ng/mL; week 3 to month 3: 175 to 300 ng/mL; thereafter:
50 to 250 ng/mL;* TAC trough level: weeks 1 to 4: 10 to 15 ng/mL; thereafter: 5 to 10 ng/mL• SRL: starting on day 1 with 6 mg/m2/d adjusted to trough level: 10 to 20 ng/mL
Benfield 2005 
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• Steroids* IV methylprednisone: day 0 and 1: 10 mg/kg* Oral prednisone: starting on day 2 with 2 mg/kg/d, tapered to 0.15 mg/kg/d by day 74□ Withdrawal group: withdrawal by end of month 12 after transplantation□ Maintenance group: maintained on 0.15 mg/kg/d
Outcomes • Mortality• Gra@ loss• Acute rejection• CrCl (mL/min)• Malignancy (PTLD)
Notes • The study was terminated on 13 August 2004 due to an unanticipated high incidence of post-trans-
plant lymphoproliferative disease; 19 patients developed PTLD (before randomisation: 10)• Did not report number screened for eligibility• 142/274 enrolled participants were not randomised (52% drop out before randomisation), because of
rejection (40), gra@ loss (9), death (2), had not yet reached 6 month protocol biopsy when study was
stopped (35), adverse events (16). protocol violation (4), lost to follow-up/withdrawal of consent (5),
other reasons (31)• Contact with study authors for additional information: authors contacted 8 July 2013; no response
received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stated 'centrally randomised' but no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Stated 'in a placebo controlled double-blinded fashion' but no further infor-
mation provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Stated 'in a placebo controlled double-blinded fashion' but no further infor-
mation provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Stated 'in a placebo controlled double-blinded fashion' but no further infor-
mation provided. Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Total number of patients by group not reported for outcomes; ITT analysis per-
formed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review have been reported
Other bias High risk High drop-out rate before randomisation (52%)
Choice of calcineurin inhibitor was centre specific (TAC or CsA)
Support provided by NIH UO1-A1-46135 and Wyeth Pharmaceuticals
Benfield 2005  (Continued)
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The study was terminated early due to an unanticipated high incidence of
PTLD
Benfield 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1996 to 1998• Follow-up period: 1 year• Primary endpoint: not reported
Participants • Country: Greece• Setting: single centre• First cadaveric or living kidney transplant* CsA ≥ 3 mg/kg with C0 levels of > 150 ng/mL and C2 levels > 600 ng/mL without signs of nephrotox-
icity* MMF 2 g or 1.5 g if body weight < 50 kg• Number randomised: withdrawal group (34); maintenance group (/32)• Mean age ±SD (years): withdrawal group (43 ± 11); maintenance group (38 ± 11)• Sex (female): withdrawal group (41%); maintenance group (19%)• Donor source (living donors): withdrawal group (53%); maintenance group (38%)• Exclusion criteria: previous acute rejection; SCr > 2 mg/dL; proteinuria > 0.5 g/24 h
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance with alternate day steroid
Baseline immunosuppression
• CsA: no further information provided.• MMF: no further information provided.• Methylprednisone: no further information provided
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr (mg/dL)
Notes • Did not report number screened for eligibility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomly assigned' but no further information provided
Allocation concealment
(selection bias)
Unclear risk not reported
Blinding (performance
bias and detection bias) 
High risk Open-label
Boletis 2001 
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All outcomes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Number of patients in whom the outcome were measured is ambiguous (two
reports with different number of patients in each group); 14% failed to comply
with follow-up protocol; unclear if ITT analysis performed
Selective reporting (re-
porting bias)
High risk Death and gra@ loss are only reported in one of the two published reports, but
number of participants in each group vary between reports
Other bias Unclear risk Unclear whether informative censoring is present, because the two published
reports are different in regard to number of participants and time period of
study
Funding source not reported
Boletis 2001  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1997 to 2000, excluding October 1998 to October 1999 (a different multicentre study dur-
ing that period)• Follow-up period: 2.7 years (range 0.9 to 3.4) years• Primary endpoints: patient survival, gra@ survival, incidence of first acute rejection in first 6 months
after transplantation
Participants • Country: The Netherlands• Setting: multicentre (number of centres not reported)• First and second cadaveric or living kidney transplant; Previous gra@ loss not because of immunolog-
ical causes; PRA < 50%; 18 to 65 years• Number (randomised/analysed): avoidance group (28/28); withdrawal group (34/34)• Mean age ± SD (years): avoidance group (54 ±14); withdrawal group (48 ± 13)• Sex (female): avoidance group (61%); withdrawal group (35%)• Donor source (living donors): avoidance group (14%); withdrawal group (12%)• Exclusion criteria: HLA identical living donor; mismatch on HLA-B or HLA-DR locus
Interventions Avoidance group
• Steroid withdrawal 7 days after transplantation or after TAC levels > 15 ng/mL
Withdrawal group
• Steroid withdrawal 3 to 5 months after transplantation
Baseline immunosuppression
• TAC: started within 12 hours before transplantation with 0.1 to 0.15 mg/kg twice daily adjusted to
trough levels: week 1 to 2: 15 to 20 ng/mL; week 3 to 4: 10 to 15 ng/mL; thereafter: reduced to 5 to 7
ng/mL 6 months after transplantation
Boots 2002 
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• Steroids* IV methylprednisone: day 0: 125 mg* Avoidance group: oral prednisone: day 1 to 8: 10 mg, then stopped* Withdrawal group: oral prednisone: month 1: 10 mg; month 2: 7.5 mg; month 3: 5 mg; then with-
drawn within 1 to 3 months
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• SCr (mg/dL)• CrCl (mL/min)• NODAT• Infection
Notes • Number screened for eligibility: 76
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation was performed by opening a closed opaque numbered enve-
lope
Allocation concealment
(selection bias)
Low risk Stated 'closed opaque envelopes'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients followed up or accounted for; ITT analysis performed ('Analyses
were made on an ITT basis.'
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review have been reported
Other bias Unclear risk Funding source not reported
Boots 2002  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1993 to 1995• Follow-up period: 1 year
Bouma 1996 
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• Primary endpoint: proportion of successful steroid withdrawal defined as lack of prednisone reinsti-
tution for any reason
Participants • Country: The Netherlands• Setting: multicentre (2 centres)• First and second cadaveric kidney transplant 1 year after transplantation on CsA + steroids• Number (analysed): withdrawal group (42); maintenance group (42)• Mean age ± SD (years): withdrawal group (48 ± 13); maintenance group (54 ± 12)• Sex (female): withdrawal group (31%); maintenance group (31%)• Exclusion criteria: CrCl < 40 mL/min; immunosuppression with AZA; steroid requirement for other dis-
ease; PRA > 50%; previous gra@ loss within 3 months after transplantation because of irreversible re-
jection; > 2 acute rejections of current transplant
Interventions Treatment group
• Steroid withdrawal at least 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: twice daily, adjusted to whole blood level 80 to 150 µg/mL• Steroids* Oral prednisone: 10 mg/d□ Withdrawal group: week 1 to 2: 7.5 mg/d; week 3 to 5: 5 mg/d; week 6 to 8: 2.5 mg/d; then with-
drawn□ Maintenance group: unchanged
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• NODAT• Infection• Malignancy• Cardiovascular event• CrCl (mL/min)
Notes • Did not report number screened for eligibility; 86 randomised; 84 analysed• 28/42 patients in treatment group had successful steroid withdrawal• Contact with study authors for additional information: authors contacted: 21 June 2013; response
received: 4 July 2013
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk not reported
Blinding (performance
bias and detection bias) 
High risk Open-label
Bouma 1996  (Continued)
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All outcomes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk This study was supported by a grant from Sandoz, The Netherlands
Bouma 1996  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported, but before 2000• Follow-up period: 3 years• Primary endpoint: not reported
Participants • Country: USA• Setting: single centre• First cadaveric or living kidney transplant; aged 18 to 65 years• Number (randomised/analysed): withdrawal group (26/14); maintenance group (25/15)• Mean age (years): withdrawal group (46.5); maintenance group (47.1)• Sex: not reported• Donor source (living donors): withdrawal group (42%); maintenance group (28%)• Exclusion criteria: > 1 acute rejection during the first 3 months; previous gra@ loss because of immuno-
logical causes; PRA > 50%
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation (completed 6 months after transplantation)
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: 8 to 10 mg/kg/d adjusted to blood levels 250 to 350 ng/mL• MMF: 2 to 3 g/d• Steroids* Prednisone: day 0: 200 mg; day 1 to 5: tapered to 20 mg/d; day 6 to 90: 20 mg/d* Withdrawal group: month 4 to 6: reduced by 5 mg/mo until complete withdrawal at month 6* Maintenance group: month 4 to 6: reduced to 10 mg/d at month 6; month 7 to 12: reduced to 15
mg every other day at month 12
Burke 2000 
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Outcomes • SCr (mg/dL)
Notes • Did not report number screened for eligibility• Number of patients discontinued study: 22 patients were withdrawn from the study because of non-
compliance (6), MMF intolerance (2), patient request for steroid withdrawal (4), pulmonary disease
requiring steroids (3), second acute rejection (2), PTLD (1), hepatitis B (1), death (3)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'all patients were randomised' but no further information provided.
Allocation concealment
(selection bias)
Unclear risk not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Double-blind placebo controlled, but partially unblinded for interim analysis
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blind placebo controlled, but partially unblinded for interim analysis
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Double-blind placebo controlled, outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 43% of patients were withdrawn from the study for various reasons; patients
who died/lost their gra@ were excluded from the study; unclear if ITT analysis
performed
Selective reporting (re-
porting bias)
High risk Primary endpoints for this review not reported, primarily surrogate outcomes
reported
Other bias Unclear risk Abstract data only available
Funding source not reported
Burke 2000  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported but before 1986• Follow-up period: 2 years• Primary endpoint: not reported
Participants • Country: Italy• Setting: single centre• Cadaveric kidney transplantation, no further inclusion criteria provided• Number (randomised/analysed): withdrawal group (25/25); maintenance group 26/26)• Mean age ± SD (years): withdrawal group (36 ± 12); maintenance group (36 ± 10)• Sex (female): withdrawal group (48%); maintenance group (35%)
De Vecchi 1986 
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• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0 to 3: 5 mg/kg/d IV; from day 4: 15 mg/kg/d PO; tapered by 2 mg/kg every 16 days until
maintenance dose of 5 mg/kg/d at month 4, given as single morning dose• Steroids* IV methylprednisone: 500 mg during transplantation* Withdrawal group: no further steroids.* Maintenance group: methylprednisone: day 1: 160 mg IV; day 2: 120 mg IV; day 3: 16 mg; reduced
by 4 mg every 2 months until maintenance dose of 8 mg/d by the end of month 6
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Number of patients discontinued treatment* 18 patients in the withdrawal group had steroids added* 6 patients in withdrawal group switched to AZA or triple immunosuppression and were excluded* 5 patients in maintenance group switched to AZA or triple immunosuppression and were excluded
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomly assigned' but no further information provided
Allocation concealment
(selection bias)
Low risk Stated 'assigned by sealed envelopes'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
High risk ITT analysis not performed; 6 patients in treatment group and 5 patients in
control group excluded because of switch to different immunosuppression
De Vecchi 1986  (Continued)
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Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Low risk Funded by grant of the Consiglio Nazionale delle Richerche
De Vecchi 1986  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2002 to 2004• Follow-up period: 1 year• Primary endpoint: not reported
Participants • Country: Spain, Portugal• Setting: multicentre (16 centres)• First kidney transplant, no further inclusion criteria provided• Number (randomised/analysed): withdrawal group (70/70); maintenance group (72/72)• Mean age ± SD (years): withdrawal group (47 ± 11); maintenance group (47 ± 11)• Sex (female): withdrawal group (53%); maintenance group (26%)• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: not reported• MMF: not reported• Prednisone: not reported
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• SCr (mg/dL)• CrCl (mL/min)
Notes • Did not report number screened for eligibility• 4 patients were excluded post randomisation but pre-intervention because they did not fulfil the in-
clusion criteria• 2 control patients lost to follow-up during the 12 months
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
del Castillo 2005 
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Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed-up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported; abstract data only
del Castillo 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2007 to 2009• Follow-up period: 6 months• Primary endpoint: incidence of treatment failure month 6, defined as clinical biopsy-proven acute
rejection, gra@ loss, death or loss to follow-up
Participants • Country: France• Setting: multicentre (14 centres)• First or second cadaveric or living kidney transplant; PRA < 20%; 18 to 70 years• Number (randomised/analysed): avoidance group (112/112); withdrawal group (110/110)• Mean age ± SD (years): avoidance group (51 ± 10); withdrawal group (51 ± 12)• Sex (female): avoidance group (32%); withdrawal group (36%)• Donor source (living donor): avoidance group (0%); withdrawal group (2%)• Exclusion criteria: multi-organ transplant; previous non-kidney transplant; cold ischaemia time > 36
hours; non-heart beating donor
Interventions Treatment group
• Avoidance group* Steroid withdrawal day 1 after transplantation
Control group
• Withdrawal group* Steroid withdrawal 4 to 6 months after transplantation
Baseline immunosuppression
• IL-2RA: according to centre protocol
DOMINOS Study 2012 
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• CsA: started within 24 hours of transplantation with 8mg/kg/d, divided into 2 single doses, adjusted
to C2 levels: month 1: 1100 to 1300 ng/mL; month 2 to 3: 800 to 1000 ng/mL; month 4 to 6: 600 to 800
ng/mL• EC-MPS: week 1 to 6: 2160 mg/d divided in two doses; after week 6: 1440 mg/d divided in two doses• Steroids* IV methyl prednisone: day -1 and 0: 250 mg* Avoidance group: no further steroids unless 'clinically mandated'* Withdrawal group: prednisone: week 1: 1 mg/kg/d (max 80 mg/d); week 2: 0.5 mg/kg/d (max 40 mg/
d); decreased by 5 mg/wk until dose 20 mg/d; decreased by 2.5 mg/wk until dose 10 mg/d; 10 mg/
d maintained for 4 weeks and at least until month 3, biopsy at month 3: with rejection continued
at 10 mg/d, without rejection decreased by 2.5 mg/15 days until stopped
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• SCr (µmol/L)• CrCl (mL/min)• eGFR (mL/min)
Notes • Did not report number screened for eligibility• Number of patients discontinued study* Avoidance group (20); adverse events (9); unsatisfactory therapeutic effect (11)* Withdrawal group (20); adverse events (11); unsatisfactory therapeutic effect (9)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'Patients were randomised using a block size of 4 with no stratification by the
contract research organization using a validated automated system.'
Allocation concealment
(selection bias)
Low risk 'With sealed envelopes distributed to the participating centers...opened after
randomization by the investigator.'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed, all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk The study was funded by Novartis Pharma SAS, Rueil-Malmaison, France
DOMINOS Study 2012  (Continued)
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The manuscript was prepared with editorial support from a freelance medical
writer funded by Novartis Pharma SAS
DOMINOS Study 2012  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2009 to 2012• Follow-up period: 9 months• Primary endpoint: treatment failure rate (mortality, gra@ loss, biopsy-proven acute rejection, loss to
follow-up) between randomisation (month 3) and month 12 after transplantation
Participants • Country: Italy• Setting: multicentre (number of centres not reported)• First or second kidney transplant from a donor aged > 14 years; aged > 18 years• Number: withdrawal group (68); maintenance group (71)• Mean age ± SD (years): withdrawal group (48 ± 12); maintenance group (49 ± 13)• Sex (female): withdrawal group (32%); maintenance group (28%)• Donor source (living donor): withdrawal group (4%); maintenance group (1%)• Exclusion criteria: > 25% PRA, severe thrombocytopenia; leucopenia or anaemia; history of malignan-
cy within 5 years; viral hepatitis; pregnancy; severe adverse events including active infections requir-
ing hospitalisation• Enrolled patients were not randomised if CrCl < 40 mL/min, proteinuria > 0.8 g/24 h; severe adverse
events or infections; poor adherence; withdrawal of consent; development of anti-HLA antibodies
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation, tapered by 1 mg/wk until stopped within 5 to 6
weeks• CsA: dose adjusted to C2 levels 300 to 500 ng/mL• EVL: dose adjusted to C0 levels 6 to 10 ng/mL
Control group
• Steroid maintenance with oral prednisone 5 mg/d• CsA: dose adjusted to C2 levels 200 to 450 ng/mL• EVL: dose adjusted to C0 levels 6 to 10 ng/mL
Baseline immunosuppression
• Basiliximab: day 0 and 4• CsA: within 48 hours of gra@ reperfusion at 4mg/kg/d twice daily; dose adjusted to C2 levels: until day
30: 500 to 700 ng/mL; day 30 to 90: 300 to 500 ng/mL• EVL: within 48 hours of gra@ reperfusion at 1.5 mg/d twice daily; dose adjusted to C0 levels: day 3 to
7: 3 to 8 ng/mL; after day 7: 8 to 12 ng/mL• Steroids* IV methyl prednisone: day 0: 500 mg; day 1: 40 mg* Oral prednisone: day 2 to 7: 20 mg; day 8 to 15: 15 mg; day 16 to 22: 12.5 mg; day 23 to 30: 10 mg;
day 30 to 45: 7.5 mg; day 46 to 90: 5 mg
Outcomes • Treatment failure rate (mortality, gra@ loss, biopsy-proven acute rejection, loss to follow-up)• Mortality• Gra@ loss• Biopsy-proven acute rejection• Change in CrCl (mL/min)
EVIDENCE Study 2014 
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• Change in eGFR (mL/min)• NODAT
Notes • Screened for eligibility (332), randomised (184), analysed in ITT population (184); PP population (135)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk '...eligible patients were randomised 1:1 to 1 of the treatment arms. Random-
ization was stratified according to centre, recipient age at transplantation (<60
and 60 years) and creatinine clearance at month 3 (55 and >55 mL/min), ac-
cording to a biased coin design.'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis for primary analysis, but total number of patients by group for
outcomes not reported
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk Difference in CsA levels between groups (higher levels in treatment group)
The study was sponsored by Novartis according to ClinicalTrials.gov. 'Editorial
assistance was provided by Mary Hines, Springer Healthcare Communications,
and funded by Novartis Farma, Italy.'
EVIDENCE Study 2014  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported but before 2006• Follow-up period: 1 year• Primary endpoint: incidence of biopsy-proven acute cellular rejection 1 year following steroid with-
drawal
Participants • Country: UK• Setting: single centre• First or second cadaveric or living kidney transplant with functioning gra@ > 1 year; < 10% rise in SCr
within preceding 6 months; SCr < 200 µmol/L; < 15% variability in CsA levels; CsA levels between 80
to 120 µg/L; aged 18 to 80 years
Farmer 2006 
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• Number: withdrawal group (44); maintenance group (48)• Mean age ± SD (years): withdrawal group (44 ± 15); maintenance group (45 ± 13)• Sex (female): withdrawal group (32%); maintenance group (40%)• Donor source (living donor): withdrawal group (28%); maintenance group (25%)• Exclusion criteria: malignancy; previous rejection on steroid withdrawal; history of Addison's disease;
bilateral adrenalectomy; multi-organ transplant; recurrence of focal and segmental glomerulosclero-
sis; treatment with Sandimmun; ischaemic heart disease; malnutrition; recent severe infection
Interventions Treatment group
• Steroid withdrawal > 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: no further information provided• AZA: no further information provided• Steroids:* Withdrawal group: steroids withdrawn at a rate of 1 mg/mo* Maintenance group: prednisolone unchanged
Outcomes • Biopsy-proven acute cellular rejection• SCr (µmol/L)
Notes • Screened for eligibility (572); randomised (92); did not reported number analysed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided.
Allocation concealment
(selection bias)
Low risk 'Using sealed envelopes'.
Blinding (performance
bias and detection bias) 
All outcomes
High risk 'Patients were informed to which arm of the trial they had been allocated.'
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk "The patients randomised to the withdrawal group were followed with more
frequent serum creatinine estimation." A rise in serum creatinine prompted
kidney biopsy to detect biopsy proven acute cellular rejection which is the pri-
mary endpoint of this study
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Total number of patients by group for outcomes not reported. Number of pa-
tients who were lost to follow up is unclear
Farmer 2006  (Continued)
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Selective reporting (re-
porting bias)
High risk Patient and gra@ survival are not reported
Other bias Unclear risk Time lead bias, because follow up started with date steroids were completely
withdrawn in treatment group but with randomisation for control group
Funding source not reported
Farmer 2006  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2001 to 2005• Follow-up period: 1 year• Primary endpoint: acute rejection during first year after transplantation
Participants • Country: France• Setting: multicentre (6 centres)• First cadaveric kidney transplantation; aged 18 to 65 years• Number (randomised/analysed): withdrawal group (98/103); maintenance group 103/99)• Mean age, range (years): withdrawal group (48, 19 to 65); maintenance group (48, 17 to 65)• Sex (female): withdrawal group (28%); maintenance group (35%)• Exclusion criteria: PRA > 20%; cold ischaemia time > 36 hours; malignancy; immunosuppressive ther-
apy before transplantation; wait listed for another transplant; leucocytes < 2000/mm3; platelets <
50000/mm3; underlying kidney disease; focal and segmental glomerular sclerosis
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance until at least 6 months after transplantation, thereafter according to centre prac-
tice
Baseline immunosuppression
• ATG: day 0: 9 mg/kg; day 1, 3, 5, 7: 3 mg/kg• CsA: starting on day 5 with 8 mg/kg/d, divided into 2 single doses, adjusted to trough levels 150 to
200 ng/mL• MMF: 1000 mg/d twice daily, adjusted to centre practice• Steroids* IV methylprednisone day 0: 500 mg* Withdrawal group: no further steroids* Maintenance group: prednisone: day 0 to 5: 1 mg/kg/d; day 6 to 10: 0.5 mg/kg/d; day 11 to 15: 0.25
mg/kg/d; day 16 to 30: 0.2 mg/kg/d; day 31 to 180: 0.1 mg/kg/d; after day 180 according to centre
practice
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr (µmol/L)
Notes • Did not report number screened for eligibility• Number of patients excluded from analysis: maintenance group (4) because of substantial deviations
from the immunosuppressant therapy protocol
FRANCIA Study 2007 
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• Number of patients discontinued study: 3 patients were excluded after randomisation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'Eligible patients were assigned to CS or non-CS treatment at a 1:1 ratio using
block randomization with stratification according to the recipient's age and
cold ischaemia time.'
Allocation concealment
(selection bias)
Low risk 'Treatment codes were provided in sealed envelopes'.
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; 4 patients in control group excluded from analysis for
acute rejection but included for patient and gra@ survival analysis.
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported.
Other bias High risk TAC, SRL, EVL, AZA could be introduced according to centre practice
Steroid dosing after 6 months according to centre practice, unclear whether
patients were withdrawn from steroids or maintained on steroids
Study was sponsored by the Nantes University Hospital
Statistical analysis of study data was supported by Fresenius Biotech GmbH,
Germany
FRANCIA Study 2007  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2001 to 2005• Follow-up period: 1 year• Primary endpoint: eGFR at 1 year post-transplant
Participants • Country: North America, South Africa, Europe, Australia, Asia• Setting: multicentre (40 centres)• First cadaveric or living kidney transplantation; aged 18 to 75 years• Number (randomised/analysed): treatment group 1 (112/111); treatment group 2 (116/115); control
group (109/109)• Mean age ± SD (years): treatment group 1 (43 ± 13); treatment group 2 (46 ± 12); control group (47 ± 13)
FREEDOM Study 2008 
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• Sex (female): treatment group 1 (35%); treatment group 2 (27%); control group (36%)• Donor source (living donor)• Treatment group 1 (48%); treatment group 2 (30%); control group (41%)• Exclusion criteria: donor age > 60 years; non heart beating donor; previous organ transplant; current
PRA > 20%; cold ischaemia time > 24 h
Interventions Treatment group 1
• No steroids at any time
Treatment group 2
• Steroid withdrawal day 7 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg• CsA: starting within 24 h of transplantation with 10 mg/kg/d adjusted to C2 levels month 1: 1500 to
2000 ng/mL; month 2: 1300 to 1700 ng/mL; month 3: 1100 to 1500 ng/mL; month 4 to 6: 900 to 1300
ng/mL; thereafter: 800 to 1000 ng/mL• EC-MPS: day 0: 720 to 1440 mg; thereafter 1440 mg/day divided in two doses• Steroids (for treatment group 2 and control group)* IV methyl prednisone: day 0: 500 mg; day 1: 250 mg; day 2: 125 mg* Oral prednisolone: day 3: 60 mg; day 4: 40 mg; day 5: 30 mg; day 6: 20 mg* Treatment group 2: no further steroids* Control group: month 1: 10 to 30 mg; month 2: 10 to 20 mg; thereafter: 5 to 10 mg
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• NODAT• Infection• CMV infection• Malignancy• CrCl (mL/min)• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Number of patients excluded from analysis* Did not undergo transplantation: treatment group 1 (1); treatment group 2 (1); control group (0)• Number of patients discontinued treatment: treatment group 1 (38, 25%); treatment group 2 (34,
34%); 20 patients in control group (20, 20%)• Number of patients discontinued study* Treatment group 1 (8%): loss to follow-up (2), withdrawal of consent (2), death (5)* Treatment group 2 (10%):loss to follow-up (4), withdrawal of consent (5), death (2)* Control group (9%): loss to follow-up (3), withdrawal of consent (5), death (2)
Risk of bias
Bias Authors' judgement Support for judgement
FREEDOM Study 2008  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Stated 'Randomization was undertaken in a 1:1:1 ratio using a validated sys-
tem that automates the random assignment of treatment groups to random-
ization numbers.'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary endpoints for this review reported
Other bias High risk The study was funded by Novartis Pharma AG
FREEDOM Study 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1982 to 1992• Follow-up period: 5 years
Participants • Country: Canada• Setting: multicentre (14)• First and subsequent cadaveric or living kidney transplant; functioning gra@ 90 days after transplan-
tation, with SCr < 2.5 mg/d• Number (randomised/analysed): withdrawal group (260/260); maintenance group (263/263)• Mean age ± SD (years): withdrawal group (39 ± 1); maintenance group (40 ± 1)• Sex (female): withdrawal group (35%); maintenance group (41%)• Donor source (% living donors): not reported• Exclusion criteria: acute rejection in previous 2 weeks; malignancy
Interventions Treatment group
• Steroid withdrawal after at least 90 days
Control group
• Steroid maintenance
Baseline Immunosuppression
• CsA: twice daily adjusted to 12-h trough levels between 75 to 200 ng/mL
Gulanikar 1991 
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• Steroids* Prednisone: from day 1 after transplantation 1 mg/kg on alternate days, reduced by 5 mg (when
clinical conditions allowed) until a dosage of 0.3 mg/kg
Outcomes • Mortality• Gra@ loss• NODAT• Infection• CMV infection• Malignancy• Cardiovascular event• SCr (mg/dL)• CrCl (mL/min)
Notes • Did not report number screened for eligibility• Number of patients discontinued treatment* Withdrawal group: 143 patients; cessation by physician (45), decoded on request (34), no test drug
given (33), CsA stopped (15), noncompliance (15), technical withdrawal (1)* Maintenance group: 123 patients; because of cessation by physician (33), decoded on request (32),
no test drug given (25), CsA stopped (18), noncompliance (14), technical withdrawal (1)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stated 'randomised blocks of various sizes were generated and used to attain
a balanced, restricted randomization according to treatment centre. The order
of randomization did not have a repeating sequence'
Allocation concealment
(selection bias)
Low risk Stated 'Physicians did not know the randomization number until the patient
was enrolled, and the code was not broken until the analysis'
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Stated '...the code was not broken until the analysis. Patients were randomly
assigned at 90 days to receive either a placebo or prednisone by means of a
process that prevented prior knowledge of their treatment group'
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Stated 'The study was doubly blinded. The placebo and prednisone were pre-
pared in an indistinguishable form and dispensed as coded therapy'
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Double-blinded placebo controlled, outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Stated 'No patients were excluded after entry (as distinct from withdrawals in
the survival analysis) or lost to follow-up.'; ITT analysis performed
Selective reporting (re-
porting bias)
High risk Acute rejection not reported
Other bias High risk This work was supported by Sandoz Ltd., Basel, Switzerland, Sandoz Cana-
da Inc., Dorval, Que., Upjohn Ltd., Kalamazoo, Mich., the Richard and Jean
Ivey Fund, London, Ont., the Michael Fung Endowment Fund, London, Ont.,
the Claudine Keown Endowment Fund, London, Ont., the University Hospital
Gulanikar 1991  (Continued)
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Transplant Research Fund, London, Ont., Robarts Research Institute endow-
ment funds and the City of London, Ont
Gulanikar 1991  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2000 to 2006• Follow-up period: 2 years• Primary endpoint: standardised longitudinal growth
Participants • Country: Germany• Setting: multicentre (8 centres)• Aged < 18 years; 12 to 24 months after first or second cadaveric or living kidney transplant; triple im-
munosuppression at study entry with CsA, MMF and steroids• Number (analysed/randomised): withdrawal group (23/23); maintenance group (19/17)• Mean age ± SD (years): withdrawal group (10 ± 1); maintenance group (11 ± 1)• Sex (female): withdrawal group (35%); maintenance group (32%)• Donor source (living donors): withdrawal group (22%); maintenance group (32%)• Exclusion criteria: irreversible acute rejection of a previous gra@; PRA > 80% within 12 months before
study entry; any previous steroid-resistant acute rejection; > 2 acute rejections; biopsy-proven acute
rejection; GFR < 40 mL/min; SCr increase > 20% within the last 6 months before study entry; growth
hormone therapy
Interventions Treatment group
• Steroid withdrawal 12 to 24 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: 5 to 10 mg/kg/d divided into 2 or 3 single doses adjusted to trough level 70 to 140 µg/L• MMF: 1200 mg/m2 body surface area/d, divided into two single doses• Steroids* Either prednisone 5 mg/m2/d or methylprednisolone 4 mg/m2/d□ Withdrawal group: tapered over 12 weeks by either 0.35 mg/m2/wk or by 0.7 mg/m2/2 wk until
withdrawal□ Maintenance group: unchanged
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• Infection• CrCl (mL/min)
Notes • Did not report number screened for eligibility• Number of patients discontinued treatment* Withdrawal group: switched to different immunosuppression (mTOR-inhibitor (2), TAC (2), MMF
withdrawal (1))* Maintenance group: withdrew MMF (1)
Höcker 2009 
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• Number of patients discontinued study* Withdrawal group: were lost to follow-up (2)* Maintenance group: withdrew consent after randomisation (2); received growth hormone (1)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stated 'central randomization by the principal investigator', stated 'block ran-
domization stratified by pubertal status'.
Allocation concealment
(selection bias)
Unclear risk Stated 'concealed allocation' but not further information provided
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk 'Because recruitment of patients for this study was more difficult than antici-
pated (because some patient's parents and covering physicians had a strong
bias pro or con steroid withdrawal, we performed an interim analysis, which
revealed a significant difference in growth between both groups. Hence, the
study was finished prematurely.'
Funding source not reported
Höcker 2009  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported• Follow-up period: 6 month• Primary endpoint: Treatment failure (biopsy-proven acute rejection, gra@ loss, death or loss to fol-
low-up)
Participants • Country: France• Setting: multicentre (number of centres not reported)• De novo kidney transplant recipients at low immunological risk (PRA < 20%, cold ischaemia time <
36 h)• Number: 131 analysed, no further data available• Age: not reported
INFINITY Study 2013 
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• Mean age ± SD (years): not reported• Sex (% female): not reported• Donor source (% living donor): not reported• Exclusion criteria: not reported
Interventions Treatment group
• Steroid avoidance, no further information provided
Control group
• Steroid maintenance, no further information provided
Baseline immunosuppression
• IL-2RA: no further information provided• CsA: no further information provided• Intensified enteric-coated mycophenolate sodium: 2160 mg/d to week 6; 1440 mg/d thereafter• Steroids: no further information provided
Outcomes • Treatment failure (biopsy-proven acute rejection, gra@ loss, death or loss to follow-up)• Mortality• Gra@ loss• Biopsy-proven acute rejection• CrCl (mL/min)
Notes • Did not report number screened for eligibility or randomised• Abstract-only publication
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if ITT analysis conducted
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
INFINITY Study 2013  (Continued)
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Other bias High risk Funding source not reported but authors disclose 'Grant/Research Support,
Novartis (Myfortic)', Co-authors affiliated with Novartis Pharma SAS, Rueil-Mal-
maison, France
Abstract data only
Lack of important information regarding design and conduct of study
INFINITY Study 2013  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1986 to 1987• Follow-up period: 4 years• Primary endpoint: not reported
Participants • Country: Finland• Setting: single centre• First cadaveric kidney transplant• Number (randomised/analysed): withdrawal group (32/32); /maintenance group (32/29)• Mean age ± SD (years): withdrawal group (49 ± 13); maintenance group (47 ± 11)• Sex (female): withdrawal group (53%); maintenance group (38%)• Exclusion criteria: living donor kidney transplants; ineligibility for triple immunosuppression with CsA
+ AZA + steroids
Interventions Treatment group
• Steroid withdrawal 10 weeks after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0: 5 mg/kg; thereafter: 10 mg/kg/d adjusted to trough levels, but no further information pro-
vided• AZA: day 0 to 14: 2mg/kg/d* Withdrawal group: from day 15: 1 mg/kg/d but temporarily increased to 2 mg/kg/d during
steroid withdrawal and thereafter adjusted to WCC* Maintenance group: from day 15: 1 mg/kg/d• Steroids:* Methylprednisone: day 0: 1 mg/kg/d tapered in 3-day intervals to 0.25 mg/kg by day 10□ Withdrawal group: withdrawal over 1 to 2 weeks□ Maintenance group: tapered to 4 to 12 mg/d during the first year
Outcomes • Mortality• Gra@ loss• Acute rejection• Infection• SCr (µmol/L)
Notes • Screened for eligibility: 184• This had two additional arms (in total 128 patients randomised)* Arm 3 with withdrawal of CsA (32 patients)* Arm 4 with withdrawal of AZA (32 patients)
Isoniemi 1990 
Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
69
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Number of patients discontinued treatment* Withdrawal group: switched immunosuppression within 2 year follow-up; AZA withdrawn (7), CsA
withdrawn (3), steroids reinitiated (3)* Maintenance group: switched immunosuppression within 2 year follow-up; AZA withdrawn (6), CsA
withdrawn (3), steroids withdrawn (1)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided.
Allocation concealment
(selection bias)
Low risk Stated 'using the sealed envelope method'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Low risk 'The study was supported by a grant from the Sigrid Juselius Foundation.'
AZA dose was increased during and after steroid withdrawal in treatment
group while it remained unchanged in maintenance group
Isoniemi 1990  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2002• Follow-up period: 3 years• Primary endpoint: incidence of allograft rejection (original primary endpoint: gra@ function)
Participants • Country: USA• Setting: single centre RCT• Aged ≥ 55 years; living or cadaveric kidney transplantation > 1 year ago; CNI + MMF + prednisone since
transplantation; SCr < 1.8 mg/dL or CrCl > 55 mL/min; stable cardiovascular function; HCT ≥ 32%; WCC
≥ 3.0 K/µL• Number (randomised/analysed): withdrawal group (32/32); maintenance group (10/10)• Mean age (± SD): not reported
Jankowska-Gan 2009 
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• Sex (female): withdrawal group (36%); maintenance group (10%)• Donor source (% living donors): withdrawal group (60%); maintenance group (60%)• Exclusion criteria: acute rejection within past 12 months; > 1 rejection episode; steroid dependency
due to pre-existing disease; African-American
Interventions Treatment group
• Steroid withdrawal > 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CNI: no further information provided• MMF: no further information provided• Steroids* Steroid withdrawal group: slow withdrawal during 3 months, then stopped
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Enrolment lagged due to difficulty in enrolling older transplant patients and was terminated at 32
(target was 75)• Contact with study authors for additional information: authors contacted 4 July 2013; response re-
ceived 5 September 2013
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed; number of patients by group not re-
ported for outcomes
Jankowska-Gan 2009  (Continued)
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Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Patients in treatment group were enrolled later after transplantation com-
pared to control group
Jankowska-Gan 2009  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: started in 1981• Follow-up period: 7 years• Primary endpoint: not reported
Participants • Country: UK• Setting: single centre RCT• First or second cadaveric kidney transplantation• Number (randomised): withdrawal group (376); maintenance group (182)• Mean age ± SD (years): not reported• Sex (female): not reported• Exclusion criteria: diabetes mellitus, urine output < 50 mL/h within the first 6 hours after transplanta-
tion
Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: started with 6 mg/kg IV over 12 hours until oral administration accepted; oral: 15mg/kg/d in di-
vided doses; reduced after 2 weeks or if signs of toxicity to achieve target levels between 80 to 500 ng/
mL before the end of the first month• Steroids* IV methylprednisone: during transplantation: 500 mg* Withdrawal group: no further steroids* Maintenance group: oral prednisone: 0.25 mg/kg, maximum 30 mg/d
Outcomes • Mortality• Gra@ loss• CMV infection
Notes • Screened for eligibility (700); did not report the number analysed• This study had a third arm with AZA + steroids (112 patients)• Number of patients discontinued treatment* Withdrawal group: received steroids permanently (125); switched to AZA + steroids (19); AZA added
(27)
Risk of bias
Johnson 1989a 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'The recipient was entered into the trial by drawing a card to determine im-
munosuppressive therapy.'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if ITT analysis performed; total number of patients by group not re-
ported for outcomes, results presented as rates and percentages
Selective reporting (re-
porting bias)
High risk Acute rejection not reported
Other bias Unclear risk Funding sources not reported
465 patients included in first publication (1989), 700 patients included in sec-
ond publication in (1990). Patients in third arm (AZA + steroids) remained
equal in size, while the treatment group (steroid avoidance = CsA monothera-
py) gained most of the additional patients, which was the group with the bet-
ter outcomes in first publication.
Immunosuppressive protocol differs between these two publications with low-
er CsA target levels and more steroids in 2nd publication.
Johnson 1989a  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported, but before 2004• Follow-up period: not reported• Primary endpoint: not reported
Participants • Country: Turkey• Setting: single centre• Kidney transplantation > 2 years ago; stable kidney function• Number (randomised/analysed): withdrawal group (31/31); maintenance group (30/30)• Mean age ± SD (years): not reported• Sex (female): not reported• Exclusion criteria: acute rejection within last 6 months
Interventions Treatment group
Kacar 2004 
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• Steroid withdrawal > 2 years after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• No further information provided
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr
Notes • Did not report number screened for eligibility• Number of patients discontinued treatment* Withdrawal group: reintroduced steroids because of discontinuation of AZA, increase of SCr or
acute rejection (7)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed; total number of patients by group for
outcomes not reported
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Abstract-only publication
Kacar 2004  (Continued)
 
 
Methods • Study design: parallel RCTKim 2002 
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• Time frame: 1998 to 1999• Follow-up period: 2 years• Primary endpoint: not reported
Participants • Setting: multicentre (2 centres)• Country: USA• Cadaveric or living kidney transplant• Number (randomised/analysed): withdrawal group (12/11); maintenance group (12/12)• Mean age (years): withdrawal group (48); maintenance group: (48)• Sex (% female): not reported• Donor source (% living donors): not reported• Exclusion criteria: PRA > 5%
Interventions Treatment group
• Steroid withdrawal 4 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0, 4: 20 mg• CsA: 8 to 10 mg/kg/d• MMF: 2 to 3 g/d• Steroids* IV methylprednisone: day 0: 500 mg; day 1: 250 mg; day 2: 125mg* Withdrawal group: day 3: 60 mg; day 4: 30 mg* maintenance group: day 3 to 21: tapered to 20 to 30 mg/d; day 22 to 91: tapered to 5 to 10 mg/d
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• SCr (mg/dL)
Notes • Did not report number screened for eligibility• 54% in withdrawal group (6/11 patients) oM steroids at 2 years• Loss to follow-up: withdrawal group (1/12)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised 1:1 ratio' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Kim 2002  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk One patient lost to follow up in withdrawal group (8%), unlikely to affect re-
sults; unclear if ITT analysis performed
Selective reporting (re-
porting bias)
High risk Gra@ loss not reported
Other bias Unclear risk Funding source not reported
Abstract-only publication
Kim 2002  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2000 to 2002• Follow-up period: 1 year• Primary endpoint: not reported
Participants • Country: USA• Setting single centre• Age > 20 years; first cadaveric or living kidney transplant• Number (randomised/analysed): withdrawal group (45/45); maintenance group (32/32)• Mean age ± SD (years): withdrawal group (50 ± 13); maintenance group (54 ± 13)• Sex (female): withdrawal group (28%); maintenance group (28%)• Donor source (living donors): withdrawal group (18%); maintenance group (9%)• Exclusion criteria: PRA > 10%; HIV seropositivity; HBsAG seropositivity
Interventions Treatment group
• Steroid withdrawal 7 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0, 4: 20 mg* Withdrawal group: the first 17 patients received additionally 20 mg on day 60 and 64• CsA: starting day 1 with 2 to 5 mg/kg twice daily, adjusted to trough blood levels: day 1 to 100: 250 to
300 ng/mL; day 101 to 365: 200 to 250ng/mL; thereafter: 150 to 200 ng/mL• MMF: 2 to 3 g/d* MMF intolerance: SRL: started with 5 mg/d adjusted to blood level 6 to 10 ng/mL
Kumar 2005 
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• Steroids:* IV methylprednisone: day 0: 250 mg; day 1: 125 mg* Oral prednisone□ Withdrawal group: first 17 patients: day 2: 30 mg, tapered by 5 mg/d until withdrawal on day 7;
remaining 28 patients: no further steroids□ Maintenance group: day 2: 30 mg; tapered to 5 mg/d at month 1
Outcomes • Mortality• Gra@ loss• Acute rejection• NODAT• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Study was closed after 77 patients were randomised, because patients refused to be randomised in
the maintenance group. Nevertheless 300 patients were enrolled through patient's choice. This sys-
tematic review only includes data on the randomised first 77 patients• 7 patients in withdrawal group and 3 patients in maintenance group received SRL because of MMF
intolerance• Contact with study authors for additional information: authors contacted 5 July 2013; no response
received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'Randomization was completed using the first generator plan from randomiza-
tion.com.'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk First 17 patients (38%) in withdrawal group received steroids until day 7 and
two additional doses of basiliximab, the remaining 28 patients (62%) received
steroids until day 2 and no additional basiliximab
Kumar 2005  (Continued)
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'The study was funded internally by clinical revenue. The manuscript was sup-
port by an unrestricted educational grant from Novartis Pharm. Corp.'
Kumar 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2002 to 2004• Follow-up period: 1 year• Primary endpoint: not reported
Participants • Country: USA• Setting: single centre• First cadaveric or living kidney transplant• Number (randomised): withdrawal group (32); maintenance group (28)• Mean age (± SD): withdrawal group (50 ± 13); maintenance group (51 ± 12)• Sex (female): withdrawal group (35%); maintenance group (36%)• Donor source (living donor): withdrawal group (16%); maintenance group (21%)• Exclusion criteria: PRA > 30%
Interventions Treatment group
• Steroid withdrawal day 7 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Rabbit ALG: 1mg/kg per day for 3 to 5 doses• TAC: day 0: 0.5 to 1 mg twice daily adjusted to whole blood level: by day 7 to 10: 10 ng/mL; month 1
to 6: 10 to 15 ng/mL; thereafter: 8 to 10 ng/mL• MMF: starting on day 0: 2 g/d divided in 2 to 4 doses.• Steroids* IV methylprednisone: day 0: 250 mg; day 1: 125mg* Withdrawal group: prednisone: day 2: 30 mg/d; rapidly titrated down to a dose of 5 mg/d and with-
drawn on day 7* Maintenance group: prednisone: day 2: 30 mg/d, rapidly titrated down to a dose of 5 mg/d by end
of month 1 and thereafter maintained at 5 mg/d
Outcomes • Acute rejection• Biopsy-proven acute rejection• CrCl (mL/min)
Notes • Did not report number screened for eligibility or number analysed• Number of patients discontinued study* Clinical adverse events, biopsy findings or subsequent pancreas transplantation: withdrawal
group (10); maintenance group (6)
Risk of bias
Bias Authors' judgement Support for judgement
LaAavi 2005 
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Random sequence genera-
tion (selection bias)
Low risk 'Patients were randomised by a blinded nurse coordinator according to ran-
dom numbers.'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk 'A single pathologist who was blinded to the treatment arms, evaluated biopsy
specimens for severity of rejection and fibrosis.'
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed. In treatment group 16 of 32 patients
and in control group 14 of 28 patients completed 1 year follow-up
Selective reporting (re-
porting bias)
High risk Mortality and gra@ loss are not reported
Other bias Unclear risk Funding source not reported
Unclear whether groups were similar at baseline, because 'steroid withdrawal
patients were at greater risk for rejection, having a higher average number of
HLA mismatches and a greater number of African American patients'
LaAavi 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1996 to 1997• Follow-up period: 12 months• Primary endpoint: biopsy-proven acute rejection 6 months after transplantation
Participants • Country: Europe, Australia, South Africa• Setting: multicentre (75 centres)• First or second cadaveric or living kidney transplant; > 18 years• Number (randomised/analysed): withdrawal group (252/252); maintenance group (248/248)• Mean age, range (years): withdrawal group (45, 18 to 69); maintenance group (46, 18 to 71)• Sex (female): withdrawal group (43%); maintenance group (41%)• Donor source (living donor): withdrawal group (10%); maintenance group (8%)• Exclusion criteria: immunosuppression other than CsA + MMF + steroids (induction with OKT 3 and
ATG was allowed); historical PRA ≥ 80%; seropositivity for HTLV-1/HIV/HBsAG; WCC < 2.5 x 109/L; Hb <
5 g/dL; malignancy; systemic infection; severe gastrointestinal disorders; psychiatric problems; sub-
stance use
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation
Lebranchu 1999 
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Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: started with 5 to 15 mg/kg/d adjusted to normal trough levels for participating centres• MMF: 1000 mg twice daily• Steroids* IV prednisolone: preoperative and postoperative dose: 500 mg* Withdrawal group: day 1 to 14: 15 mg; day 15 to 70: 10 mg; day 71 to 84: 5 mg; then no further
steroids* Maintenance group: day 1 to 14: 30 mg; day 15 to 56: 20 mg; day 57 to 70: 15 mg; beyond day 71:
10 mg
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• Infection• CMV infection• SCr (µmol/L)
Notes • Did not report number screened for eligibility• Number of patients discontinued study (at 12 months)* Withdrawal group (25%): adverse events (35), unsatisfactory response to study treatment (6), re-
quired prohibited medication (4), death (4), other reasons (14)* Maintenance group (17%): adverse events (17), unsatisfactory response to study treatment (3), re-
quired prohibited medication (1), death (5), other reasons (15)• Completed 6 months follow-up double-blind period according to protocol: withdrawal group (174);
maintenance group (193)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'Patients were randomly assigned to one of two treatment groups in a
1:1 ratio, with stratification by cadaveric/ living related donor transplant recip-
ient and by type of cyclosporine' but random sequence generation unclear
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Stated 'Treatment continued in a blinded fashion for 6 months, after which the
study was to be unblinded during a further 6 months, for a total study length of
1 year'
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Stated 'Treatment continued in a blinded fashion for 6 months, after which the
study was to be unblinded during a further 6 months, for a total study length of
1 year'
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Lebranchu 1999  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed; stated 'At 12 months 17% in the con-
trol group and 25% in the treatment group were prematurely withdrawn from
the study'
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Lebranchu 1999  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1983 to 1986• Follow-up period: 27 ± 9 months• Primary endpoint: not reported
Participants • Country: Italy• Setting: single centre• First cadaveric kidney transplant; functioning gra@ 6 months after transplantation• Number (randomised/analysed): withdrawal group (35/35): maintenance group (31/31)• Mean age ± SD (years): withdrawal group (33 ± 10); maintenance group (35 ± 9)• Sex (female): withdrawal group (30%); maintenance group (29%)• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation (completed 13 months after transplantation)
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: no further information provided• Steroids* Withdrawal group: prednisone: reduced by 2 mg/wk until complete withdrawal 13 months after
transplantation* Maintenance group: prednisone: continued 8 mg/d
Outcomes • Mortality• Gra@ loss• Acute rejection• NODAT
Notes • Did not report number screened for eligibility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated' randomised' but no further information provided
Maiorca 1988 
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Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All patients followed up or accounted for; unclear if ITT analysis performed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Maiorca 1988  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported, but before 2000• Follow-up period: 1 year• Primary endpoint: not reported
Participants • Country: Czech Republic• Setting: single centre• First cadaveric or living kidney transplant; stable gra@ function one year after transplantation; 18 to
65 years• Number (randomised/analysed): withdrawal group (46/45); maintenance group (42/42)• Mean age ± SD (years): withdrawal group (50 ± 9); maintenance group (47 ± 13)• Sex (female): withdrawal group (45%); maintenance group (26%)• Donor source (% living donors): not reported• Exclusion criteria: SCr > 1.8 mg/dL
Interventions Treatment group
• Steroid withdrawal 1 year after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: adjusted to blood levels in the upper half of the therapeutic range• AZA: minimum of 1.5 mg/kg/d
Matl 2000 
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• Steroids* Withdrawal group: gradually withdrawn over a period of 6 months* Maintenance group: unchanged, no further information provided
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Number of patients discontinued study* Withdrawal group: excluded after randomisation before steroid withdrawal (1)• Number of patients discontinued treatment* Withdrawal group: did not withdraw steroids because of rejection (3), leucopenia (1)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Patients were randomised according to the month of birth
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients followed up or accounted for; ITT analysis performed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Low risk The study was supported by grant N°3631-3 awarded by the Internal Grant
Agency of the Ministry of Health of the Czech Republic
Matl 2000  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2008 to 2009• Follow-up period: 1 year• Primary endpoint: stimulation of growth after 12 months
Mericq 2013 
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Participants • Country: Chile• Setting: multicentre RCT (2 centres)• First cadaveric or living kidney transplant; < 16 years with a bone age ≤ 15 years in boys and ≤ 13 years
in girls• Number (randomised/analysed): withdrawal group (14/12); maintenance group (16/12)• Mean age ± SD (years) (only reported for prepubertal patients); withdrawal group (6 ± 3); maintenance
group (6 ± 4)• Sex (female) (only for prepubertal patients reported): withdrawal group (50%); maintenance group
(42%)• Donor source (% living donor) not reported• Exclusion criteria: treatment with recombinant human growth hormone or bisphosphonate
Interventions Treatment group
• Steroid withdrawal 6 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0, 4: 20 mg/m2• TAC: started with 0.15 mg/kg twice daily when creatinine < 2 mg/dL; adjusted to basal levels until day
30: 10 to 15 ng/mL; thereafter: 5 to 7 ng/mL• MMF: until day 30: 800 mg/m2/d; day 31 to month 3: 600 mg/m2/d; thereafter: 400 mg/m2/d• Steroids* Withdrawal group: methylprednisone: day 0 to 2: 2 mg/kg/d; prednisone: day 3: 2 mg/kg/d; day 4:
1 mg/kg/d; day 5: 0.5 mg/kg/d; day 6: 0.25 mg/kg/d; then no further steroids* Maintenance group: methylprednisone: day 0 to 2: 2 mg/kg/d; prednisone: day 3 and 4: 2 mg/kg/
d; day 5 to month 1: 1.5 mg/kg/d; reduced to 0.12 mg/kg/d until study end
Outcomes • Mortality• Gra@ loss• Acute rejection
Notes • Did not report number screened for eligibility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stated 'central randomization by the principle investigator'.
Allocation concealment
(selection bias)
Low risk Stated 'stratified treatment allocation on the basis of block randomization car-
ried out by a statistician who was not participating in this study using num-
bered containers by a computerized statistical program'.
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Mericq 2013  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed; outcomes for prepubertal patients
only reported. Number of events and per group not reported
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Low risk This study was supported by Fondecyt 1080166 (National Fund for Scientific
and Technological Development)
Mericq 2013  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported, but before 2005• Follow-up period: 3 years• Primary endpoint: gra@ survival
Participants • Country: Italy• Setting: multicentre (number of centres not reported)• First and second cadaveric or living kidney transplant; 18 to 65 years• Number (randomised/analysed): withdrawal group (65/65); maintenance group (68/68)• Mean age ± SD (years): withdrawal group (44 ± 10); maintenance group (46 ± 12)• Sex (female): withdrawal group (31%); maintenance group (38%)• Donor source (living donors): withdrawal group (5%); maintenance group (6%)• Exclusion criteria: ischaemia time > 40 hours; PRA > 50%
Interventions Treatment group
• Steroid withdrawal 7 days after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0 and 4: 20 mg• CsA: twice daily 3 to 5 mg/kg adjusted to trough levels; week 1 to 4: 150 to 300 ng/mL; month 2 to 6:
100 to 250 ng/mL; thereafter: 100 to 200ng/mL* Amendment to study protocol after availability of new evidence: CsA levels < 100 ng/mL• EVL: 1.5 mg twice daily• Steroids* Withdrawal group: prednisone: day 1 to 5: 20 mg/d; day 6: 5 mg; day 7: 5 mg; then stopped* Maintenance group: prednisone: week 1 to 2: 20 mg/d; week 3 to 4: 15 mg/d; week 5 to 6: 10 mg/d;
week 7 to month 12: 5 to 10 mg/day; thereafter: 2.5 to 5 mg/d
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• NODAT• Malignancy
Montagnino 2005 
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• Infection• CMV infection• SCr (mg/dL)• CrCl (mL/min)
Notes • Did not report number screened for eligibility• Number of patients discontinued treatment* Withdrawal group: reintroduced steroids (28)• Contact with study authors for additional information: authors contacted 2 September 2013; no re-
sponse received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Centralised randomisation by a randomisation list, stratified within centres us-
ing an interactive voice-response system
Allocation concealment
(selection bias)
Low risk 'The sequence was concealed until interventions were assigned.'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients followed up or accounted for; ITT analysis performed ('All the
analyses considered all the randomised patients, grouped originally by ran-
domised treatment as per ITT concept.')
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk Supported by grant from Novartis
Montagnino 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2003 to 2014• Follow-up period: median follow-up was 66 ± 41 months• Primary endpoint: incidence of a first biopsy-proven acute rejection (BanM type 1 or higher) within 36
months after transplantation
Participants • Country: Egypt• Setting: single centre• Primary kidney transplantation from living donors between 21 and 60 years of age with compatible
ABO blood groups
Nagib 2015 
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• Number (randomised): avoidance group (214); maintenance group (214)• Age range: 5 to 62 years• Mean age ± SD (years): avoidance group (30 ± 12); maintenance group (24 ± 13)• Sex (female): avoidance group (24%); maintenance group (26%)• Exclusion criteria: lost follow-up; pretransplantation diabetes mellitus; other immunosuppressive
protocols
Interventions Treatment group
• Steroid avoidance on day 4
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: days 0 and 4• TAC: no further information provided• MMF: no further information provided• Steroids* IV methylprednisone: days 0 and 1: 500 mg; day 2: 250 mg; day 3: 100 mg* Avoidance group: steroids stopped at day 4 provided that an acceptable TAC level was achieved* Maintenance group: 1.5 mg/kg/d methylprednisolone days tapered gradually to 0.15 mg/kg/d by
the 9 months post-transplantation
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• SCr (µmol/L)
Notes • Did not report number screened for eligibility or analysed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk '...patients were randomised to receive...' but no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
High risk Unclear if ITT analysis performed; total number of patients by group for out-
comes not reported
Nagib 2015  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Nagib 2015  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2004 to 2005• Follow-up period: 1 year• Primary endpoint: incidence of biopsy-proven acute rejection within 12 months after transplantation
Participants • Country: Egypt• Setting: single centre• First living kidney transplant; recipient age 22 to 56 years; donor age 21 to 60 years• Number (randomised/analysed): withdrawal group (50/50); maintenance group (50/50)• Mean age ± SD (years): withdrawal group (30 ± 11); maintenance group (29 ± 10)• Sex (female): withdrawal group (20%); maintenance group (36%)• Exclusion criteria: mismatch at HLA-DR locus
Interventions Treatment group
• Steroid withdrawal day 4 after transplantation (if TAC levels in target range)
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg• TAC: starting on day -2 with 0.1 mg/kg/d adjusted to trough levels week 1 to 2: 10-15 ng/mL; thereafter:
5 to 10 ng/mL• MMF: week 1 to 2: 1000 mg twice daily; thereafter 750 mg twice daily• Steroids* IV methylprednisone: day 0: 500 mg* Withdrawal group: methylprednisone: day 1: 500 mg; day 2: 250 mg; day 3: 100 mg; thereafter no
further steroids* Maintenance group: methylprednisone: day 1, 3, 7, 14: 3.5 mg/kg/d; followed by gradual tapering
to 0.15 mg/kg/d by month 9
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• NODAT• Infection• CMV infection• SCr (µmol/L)• eGFR (mL/min)
Notes • Did not report number screened for eligibility
Nematalla 2007 
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• Contact with study authors for additional information: authors contacted 9 July 2013; no response
received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk '100 similar closed opaque envelopes were made, each containing a slip of
opaque paper with the type of maintenance immunosuppression. Therefore,
50 envelopes were with steroid and the rest were without. All envelopes were
kept closed until the morning of the transplant day, when one envelope was
selected for each patient'.
Allocation concealment
(selection bias)
Low risk 'Similar closed opaque envelopes, each containing a slip of opaque paper'.
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed; number of patients in groups varies
slightly between reports
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Different protocol between groups for steroid dosing before withdrawal
Funding source not reported
Nematalla 2007  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1982• Follow-up period: 14 to 39 months• Primary endpoint: not reported
Participants • Country: UK• Setting: single centre• All ages; first or subsequent cadaveric or living kidney transplant• Number (randomised): withdrawal group (59); maintenance group (58)• Mean age (± SD): not reported• Sex (% female): not reported• Donor source (% living donors): 0.05%• Exclusion criteria: none
Nott 1985 
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Interventions Treatment group
• Steroid withdrawal day 1 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: 17 mg/kg/d divided in 2 doses, reduced by 2 mg/kg every 2 weeks adjusted to whole blood level
250 to 700 ng/mL. Dose reduction to 15 mg/kg after the first 20 patients due to nephrotoxicity• Steroids* IV methylprednisone: day 0: 500 mg* Oral prednisolone: starting on day 2 with 2 mg/kg/d; tapered to 0.15 mg/kg/d by day 74□ Withdrawal group: no further steroids□ Maintenance group: from day 1: 0.3 mg/kg/d as divided dose; reduced by 5 mg/mo to a main-
tenance dose of 10 to 15 mg/d
Outcomes • Mortality• Gra@ loss• Cardiovascular event• Infection• SCr (mmol/L)
Notes • Did not report number screened for eligibility or analysed• Number of patients discontinued treatment* Withdrawal group: switched to different immunosuppression (steroid added (13), converted to AZA
+ steroids (19))
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation was achieved by drawing a card
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Total number of patients by group not reported for outcomes; ITT analysis per-
formed
Nott 1985  (Continued)
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Selective reporting (re-
porting bias)
High risk Acute rejection not reported
Other bias Unclear risk Immunosuppressive protocol differs between publications
No patient characteristics shown, unclear whether the groups were similar at
baseline
Funding source not reported
Nott 1985  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported, but before 1994• Follow-up period: 1 year (6 years for 68 patients)• Primary endpoint: patient and gra@ survival rates
Participants • Country: Korea• Setting: multicentre (number of centres not reported)• First living kidney transplant; 18 to 65 years• Number (randomised): withdrawal group (141); maintenance group (153)• Mean age ± SD (years): not reported• Sex (% female): not reported• Exclusion criteria: SCr > 1.5 mg/dL 3 months after transplantation; active hepatitis; HBsAG seroposi-
tivity
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0 to 2: 3 mg/kg IV; day 3: 10 mg/kg PO; reduced to 3 to 5 mg/kg/d adjusted to trough levels:
month 1 to 3: 200 to 400 ng/mL; thereafter: 100 to 200 ng/mL• Steroids* IV methylprednisone: day 0: 1000 mg; day 1: 200 mg; reduced to 60 mg by day 4* Oral prednisone: day 5: 30 mg/d; reduced to 10 mg/d by end of month 3□ Withdrawal group: prednisone reduced by 2.5 mg every 2 weeks until complete withdrawal 6 to
8 weeks after randomisation
Outcomes • Mortality• Gra@ loss• Acute rejection• NODAT• Infection• SCr (mg/dL)• CrCl (mL/min)
Notes • Did not report number screened for eligibility; randomised (294); analysed in 1998 (68)
Park 1994 
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• Number of patients discontinued study* At 1 year 18 patients withdrawn from study because of regimen failure, death, gra@ loss, compli-
ance, adverse events
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of patients in which the outcome was measured are not reported, sur-
vival only reported as rates; unclear if ITT analysis performed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
There's a substantial difference between number of participants in first pub-
lished report (1994) (294) and second report (1998) (68) which is not explained
Park 1994  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1997 to 2002• Follow-up period: mean 3.7 years• Primary endpoints: incidence of acute rejection, chronic rejection and gra@ loss within 1 year of con-
sent
Participants • Country: USA• Setting: single centre• First cadaveric or living kidney transplant; > 18 years; MMF > 2 g (unless intolerant) and CsA > 2 mg/
kg/d or trough levels > 150 ng/mL• Number (randomised/analysed): withdrawal group (60/59); maintenance group (60/59)• Mean age ± SD (years): withdrawal group (45 ± 14); maintenance group (45 ± 14)• Sex (female): withdrawal group (22%); maintenance group (31%)• Donor source (living donors): withdrawal group (36%); maintenance group (37%)
Pelletier 2006 
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• Exclusion criteria: SCr > 2.5 mg/dL; previous acute rejection; proteinuria > 600 mg/24 h; presence of
steroid treated disease
Interventions Treatment group
• Steroid withdrawal at different time points after transplantation (exact time point of steroid withdraw-
al unclear, but all patients had steroids for > 14 days)
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab (54 patients): day 0 and 4: 20 mg• OKT3 (40 patients): day 3 to 5: 5 mg/d• Thymoglobulin (6 patients): day 3 to 5• No induction: 14 patients• CsA: starts with 5 to 6 mg/kg/d adjusted to trough levels: year 1: 250 ng/mL; thereafter: 150• MMF: 2 g/d• Steroids* Prednisone: starts with 2 mg/kg, tapered to 0.2 mg/kg at month 1; tapered to 0.15 mg/kg at month
12* Steroid withdrawal: reduced by 2.5 mg/2 wk
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr (mg/dL)• NODAT
Notes • Did not report number screened for eligibility• Number of patients discontinued study* Withdrawal group: 1 patient* Maintenance group: 1 patients withdrawn from study shortly after consent because of proteinuria
> 600 mg/24 h and non-compliance
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
Low risk Outcomes are objective hard endpoints
Pelletier 2006  (Continued)
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if ITT analysis performed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Steroids have been withdrawn at different time points after transplantation
and the time point of steroid withdrawal is unclear
Different induction treatments used, 14% of patients did not receive any in-
duction treatment
Pelletier 2006  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported• Follow-up period: not reported• Primary endpoint: incidence of acute rejection
Participants • Country: Italy• Setting: single centre• First or second kidney transplant• Number (analysed): withdrawal group (15); maintenance group (15)• Mean age: withdrawal group (41 years); maintenance group (45 years)• Sex (female): withdrawal group (33%); maintenance group (30%)• Donor source (% living donors): not reported• Exclusion criteria: not reported
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg• CsA: started with 8 mg/kg/d adjusted to blood levels in month 1 to 2: 350 to 400 ng/mL; month 3: 250
to 300 ng/mL• MMF: 1500 mg/d• Steroids* IV methylprednisone day 0: 500 mg* Oral prednisone: month 1: 20 mg/d; tapered to 5 mg/day at month 3
Outcomes • Mortality• Gra@ loss• Acute rejection• SCr (µmol/L)• NODAT
Pisani 2001 
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• Infection• CMV infection
Notes • Did not report number screened for eligibility; randomised (46); analysed (30)• Steroids withdrawn in 8/15 patients in withdrawal group at time of preliminary report• This study had a third arm with 'standard immunosuppression' CsA + MMF + steroids (17 patients)• Contact with study authors for additional information: authors contacted 9 July 2013; no response
received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis was performed; number of patients per group
and in total vary between reports
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Abstract-only data
Lack of important information regarding design and conduct of study
Pisani 2001  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1990 to 1993• Follow-up period: 9 years• Primary endpoint: not reported
Participants • Country: Italy• Setting multicentre (number of centres not reported)• First or second cadaveric kidney transplant; 16 to 70 years
Ponticelli 1997 
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• Number (randomised): withdrawal group (115); maintenance group (117)• Mean age ± SD (years): withdrawal group (41 ± 11); maintenance group (41 ± 11)• Sex (female): withdrawal group (39%); maintenance group (32%)• Exclusion criteria: PRA > 50%; acute rejection or need for dialysis within 5 days after transplantation
Interventions Treatment group
• Steroid withdrawal day 5 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: day 0 and 1: 5 mg/kg IV; day 2 to 14: 12 mg/kg/d divided in two doses; day 15: 10 mg/kg then
tapered every fortnight by 2 mg/kg to maintenance dose 4-5 mg/kg/d; adjusted to target level: month
1 to 3: 175 to 400 ng/mL; month 4 to 6: 125 to 300 ng/mL; month 7 to 12: 100 to 225 ng/mL; thereafter:
75 to 200 ng/mL• Steroids* IV methylprednisone day 0: 500 mg; day 1: 200 mg; day 2: 50 mg* Withdrawal group: day 3 and 4: 16 mg/d; then steroids withdrawn* Maintenance group: month 1 to3: 16 mg/d; then gradually tapered to 8 mg/d by end of month 6
Outcomes • Mortality• Gra@ loss• Acute rejection• Cardiovascular events• NODAT• Malignancy• Infection• CrCl (mL/min)
Notes • Number screened for eligibility: 547; did not report number analysed• This study had a third arm with CsA + AZA + steroids (122 patients)• Number of patients discontinued treatment* Withdrawal group: switched to different immunosuppression: steroids added (37), steroids + AZA
added (20), AZA added (2), conversion to AZA + steroids (1)* Maintenance group: switched to different immunosuppression: AZA added (23), steroids with-
drawn (1)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'Random assignments were made according to a randomization list balanced
per centre through a telephone call to the coordinating centre.'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Open-label
Ponticelli 1997  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Sandoz Prodotti Farmaceutici SpA provided logistic support for the SIMTRE
group meetings
Ponticelli 1997  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1988 - 1991• Follow-up period: 1 year (another 24 months uncontrolled)
Participants • Country: UK• Setting: single centre• First and second cadaveric kidney transplant; stable kidney function 1 to 6 years after transplantation• Number (randomised/analysed): withdrawal group (49/49); maintenance group (51/51)• Mean age ± SD (years): withdrawal group (48 ± 14); maintenance group (48 ± 14)• Sex (female): withdrawal group (35%); maintenance group (31%)• Exclusion criteria: not on triple immunosuppression; history of steroid resistant rejection; rejection
after the first year following transplantation or within 6 months of eligibility assessment; SCr > 2.8 mg/
dL
Interventions Treatment group
• Steroid withdrawal 1 to 6 years after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: no further information provided• AZA: no further information provided• Prednisone: no further information provided
Outcomes • Mortality• Gra@ loss• SCr (mg/dL)• CrCl (mL/min)
Notes • Did not report number screened for eligibility
Ratcli<e 1993 
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• Number of patients discontinued treatment* Withdrawal group: did not stop steroids because of increased SCr (3), severe myalgia (2), death (2)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients followed up or accounted for; ITT analysis performed ("Unless oth-
erwise stated, data were analysed with groups assigned on the basis of "inten-
tion-to-treat")
Selective reporting (re-
porting bias)
High risk Acute rejection is not reported
Other bias Unclear risk Funding source not reported
Ratcli<e 1993  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2002 to 2004• Follow-up period: 4 years• Primary endpoint: percentage of patients who could be successfully withdrawn from steroids at 12
and 48 months
Participants • Country: Italy• Setting: single centre• First cadaveric kidney transplant; PRA < 50%; all ages• Number (randomised/analysed): avoidance group (49/44); /withdrawal group (47/46)• Mean age ± SD (years): avoidance group (50 ± 11); withdrawal group (51 ± 11)• Sex (% female): not reported• Exclusion criteria: underlying disease requiring steroids; HIV seropositivity
Interventions Avoidance group
• Steroid withdrawal day 5 after transplantation
Sandrini 2009 
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Withdrawal group
• Steroid withdrawal 6 months after transplantation
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20 mg• CsA: started on day 0 with 5 mg/kg/d divided into 2 doses, adjusted to C2 levels month 1 to 6: 800 to
1000 g/L; month 7 to 12: 600 to 800 g/L; thereafter: 400 to 500 g/L• Sirolimus: started on day 2 with 6 mg/d, then 2 mg/d, adjusted to blood levels 5 to 10 ng/mL• Steroids* IV methylprednisone: day 0: 500 mg* Avoidance group: methylprednisone: day 1: 200 mg; day 2: 100 mg; day 3: 50 mg; day 4: 20 mg; then
no further steroids* Withdrawal group: methylprednisone: day 1: 200 mg; day 2: 200 mg; day 3: 150 mg; day 4: 100 mg;
day 5: 50 mg; day 6: 20 mg; day 7 to month 1: 16 mg; month 2: 12 mg; month 3 to 5: 8 mg; month
6: withdrawn but only in selected patients with stable kidney function (proteinuria < 1g/d, SCr <
2.0 mg/dL, < 3 acute rejections)
Outcomes • Mortality• Gra@ loss• Acute rejection• NODAT• Malignancy• Infection• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Number of patients excluded from analysis* Avoidance group protocol violation (continued to take steroids) (1)• Number of patients discontinued study* Avoidance group: lost to follow-up at 1 year (4)* Withdrawal group: lost to follow-up at 1 year (1)• Patients discontinued treatment* Avoidance group: 38%* Withdrawal group: not withdrawn from steroids at 1 year because of acute rejection, delayed gra@
function, patient 'unsuitability' (33%)• Contact with study authors for additional information: authors contacted 14 January 2013; no re-
sponse received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Open-label
Sandrini 2009  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label, primary study endpoint was the percentage of patients who could
be successfully withdrawn from steroids at 1 and 4 years after transplantation
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Stated ' The results were analyzed on an ITT basis' but patients were exclud-
ed from analysis due to protocol violation; reasons for loss to follow-up not re-
ported
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Lack of important information regarding design and conduct of study
High percentage of protocol failure (38% in avoidance group and 33% in with-
drawal group not withdrawn from steroids at 1 year after transplantation)
Sandrini 2009  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1987 to 1989• Follow-up period: 2 years
Participants • Country: USA• Setting: single centre• First and second cadaveric or living kidney transplant• Number (randomised/analysed): withdrawal group 32/32); maintenance group (35/35)• Mean age ± SD (years): withdrawal group (44 ± 13); maintenance group (43 ± 12)• Sex (female): withdrawal group (50%); maintenance group (34%)• Donor source (living donors): withdrawal group (16%); maintenance group (9%)• Exclusion criteria: previous gra@ lost due to rejection; ongoing steroid therapy for other diseases
Interventions Treatment group
• Steroid withdrawal after 6 to 20 days after transplantation (most had steroids < 14 days), steroids were
withdrawn shortly after CsA initiation
Control group
• Steroid maintenance
Baseline immunosuppression
• ALG: 10 mg/kg day 1; 20 mg/kg day 5 to 12 depending on gra@ function• CsA: starting on last day of ALG administration with 10 mg/kg/d adjusted to blood levels between 100
to 250 ng/mL during first 3 months; tapered to 3 to 5 mg/kg/d by 6 months• AZA: 5 mg/kg once prior to transplantation; 1.5 to 2.0 mg/kg daily after transplantation• Steroids* IV methylprednisone: day 0: 250 mg; day 1 to 3: tapered doses* Oral prednisone: day 4: 1mg/kg/d; tapered to 30 mg/d by week 2; tapered to 15 mg/d at month
3 to 4
Outcomes • Mortality
Schulak 1989 
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• Gra@ loss• Acute rejection• Infection• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Number of patients discontinued treatment* Withdrawal group: returned to steroid maintenance (18)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'Patients were randomised using a table of random numbers'
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients followed up or accounted for; ITT analysis performed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Groups at baseline were different regarding gender, race and causes of kid-
ney failure with more females, less African-Americans, more diabetics in the
steroid avoidance group
Funding source not reported
Schulak 1989  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1997 to 1999• Follow-up period: 18 months• Primary endpoint: first biopsy-proven acute or chronic rejection between 6 months and 24 months
after transplantation
Participants • Country: The Netherlands• Setting: multicentre (3 centres)
Smak Gregoor 1999 
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• Cadaveric or living kidney transplant with stable gra@ function 6 months after transplantation• Number (randomised/analysed): withdrawal group (76/76); maintenance group (73/73)• Mean age, range (years): withdrawal group (52, 19 to 68); maintenance group (51, 19 to 70)• Sex (female): withdrawal group (32%); maintenance group (37%)• Donor source (% living donor): not reported• Exclusion criteria: ≥ 2 acute rejections; biopsy-proven acute vascular rejection; proteinuria > 3 g/d;
immunosuppression other than CsA + MMF + steroids
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: adjusted to trough levels: 125 to 175 ng/mL (from 3 months after transplantation)• MMF: 1000 mg twice daily• Steroid:* Prednisone: 0.1 mg/kg/d* Withdrawal group: steroids tapered over 10 weeks and then withdrawn* Maintenance group: no further details provided
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• Infection• CMV infection• Malignancy• SCr (mg/dL)• CrCl (mL/min)
Notes • Number screened for eligibility: 313• This study had a third arm with CsA withdrawal (63 patients)• Number of patients discontinued treatment* Withdrawal group: never stopped steroids (1); returned to steroids (4)• Contact with study authors for additional information: authors contacted 3 September 2013; no re-
sponse received
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'Patients were randomly assigned to one of the three treatment groups
in a 1:1:1 ratio, with stratification for cadaveric/living related transplant, for
centre, and for the number of acute rejections during the first 6 mo after trans-
plantation' but random sequence generation not reported
Allocation concealment
(selection bias)
Low risk Stated 'Randomization was carried out by opening a sealed envelope with the
lowest available study number'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Smak Gregoor 1999  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk The study was supported by Roche Pharmaceuticals, Mijdrecht, the Nether-
lands
Smak Gregoor 1999  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported, but before 2002• Follow-up period: 2 years• Primary endpoint: acute rejection and kidney function 2 years after steroid withdrawal
Participants • Country: Spain• Setting: single centre• Cadaver kidney transplant; stable kidney function 3 months after transplantation• number (randomised): withdrawal group (46); maintenance group (46)• Mean age (± SD): not reported• Sex (% female): not reported• Exclusion criteria: PRA > 50%; previous acute rejection
Interventions Treatment group
• Steroid withdrawal after 3 months
Control group
• Steroid maintenance
Baseline Immunosuppression
• TAC: day 0 to 15: 10 to 15 ng/mL; from day 16: 5 to 10 ng/mL• MMF: 1 g/d• Steroids* IV methylprednisone day 0: 500 mg; day 1: 125 mg* Oral prednisone: day 2 to month 2: 20 to 25 mg/d; month 2 to month 3: tapered to 5 mg/d
Outcomes • Mortality• Gra@ loss• Acute rejection• NODAT• SCr (mg/dL)
Sola 2002 
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• CrCl (mL/min)
Notes • Did not report number screened for eligibility or analysed• 28/120 were not randomised
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of events and number of patients analysed not reported; unclear if ITT
analysis performed
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Sola 2002  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1982 to 1983• Follow-up period: not reported• Primary endpoint: not reported
Participants • Country: Canada• Setting: multicentre (9 centres)• First or subsequent cadaveric or living kidney transplant; > 12 years• Number (randomised): no steroids group (33); maintenance group (36)• Mean age: no steroids group (35 years); maintenance group (35 years)• Sex (female): no steroids group (33%); maintenance group (36%)• Donor source (living donor): no steroids group (18%); maintenance group (36%)• Exclusion criteria: acute or progressive liver disease; previous generalised or metastatic malignancy;
localised malignancy within the previous year; disease requiring maintenance steroid
Stiller 1983 
Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
104
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Interventions Treatment group
• No steroids at any time
Control group
• Steroid maintenance
Baseline immunosuppression
• CsA: prior to transplantation: 15 mg/kg, thereafter 7.5 mg/kg twice daily adjusted to trough levels: day
1 to 60: 100 to 300 ng/mL; thereafter: 50 to 200 ng/mL• Steroids* Maintenance group: prednisone: 1 mg/kg alternate day reduced by 5 mg every other day to 0.3 mg/
kg/d
Outcomes • Mortality• Gra@ loss• Acute rejection• Infection• CMV infection• Malignancy• SCr (mg/dL)
Notes • Did not report number screened for eligibility or analysed• Number of patients discontinued treatment* No steroids group: switched to different immunosuppression: AZA + steroids (6), steroids added
(12)* Maintenance group: switched to AZA + steroids (3)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'A computer-derived randomised blocks of varying size was generated and
noted in a series of opaque envelopes held by the research pharmacist at each
participating centre.'
Allocation concealment
(selection bias)
Low risk Stated 'opaque envelopes'
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether ITT analysis performed and whether all patients have been
followed up or accounted for
Stiller 1983  (Continued)
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Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk The study was supported by Medical Research Council of Canada; Richard
and Jean Ivey Fund, London, Ontario; Sandoz Ltd, Basel; the Micheal Fung En-
dowment Fund, London, Ontario; the University Hospital Transplant Research
Fund, London, Ontario
Stiller 1983  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1998 to 2000• Follow-up period: 6 months• Primary endpoint: not reported
Participants • Country: 11 European countries• Setting: multicentre (47 centres)• First or second cadaveric or living kidney transplant; adults• Number (randomised/analysed): withdrawal group (281/279); maintenance group (279/277)• Mean age: withdrawal group (46 years); maintenance group (47 years)• Sex (female): withdrawal group (33%): maintenance group (38%)• Donor source (living donor): withdrawal group (8%); maintenance group (8%)• Exclusion criteria to enter study: previous organ transplant other than kidney transplantation; loss of a
previous kidney transplant due to early acute rejection; PRA ≥ 50%; requirement for immunosuppres-
sion besides kidney transplantation; HIV seropositivity; familial hypercholesterolaemia; malignancy;
ongoing infection• Exclusion criteria to enter steroid withdrawal phase after 3 months: steroid resistant rejection; gra@
loss; dose of steroids or MMF modified > 10 consecutive days; stopped TAC < 1 day; protocol violation
during the first 3 months
Interventions Treatment group
• Steroid withdrawal 3 months after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• TAC: started with 0.2 mg/kg/d divided in two doses adjusted to trough levels day 0 to 14: 10 to 20 ng/
mL; thereafter: 5 - 15 ng/mL• MMF: 1000 mg daily divided in two doses• Steroids* IV methylprednisone: day 0: 500 mg or less; day 1: 125 mg* Prednisone: day 2 to 14: 20 mg; day 15 to 28: 15 mg; day 29 to 92: 10 mg* Withdrawal group: steroids tapered over 2 weeks and then withdrawn* Maintenance group: steroids maintained with 10 mg
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• NODAT
THOMAS Study 2002 
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• Infection• CMV infection• SCr (mg/dL)
Notes • Did not report number screened for eligibility; 446 entered steroid withdrawal phase (221/225)• This study had a third arm with MMF withdrawal (278 patients)• Number of patients excluded from analysis: 2 patients in withdrawal group and 2 patients in mainte-
nance group because they did not undergo transplantation• Number of patients discontinued study (before the steroid withdrawal phase)* Withdrawal group: steroid resistant acute rejection (11), gra@ loss (13), protocol violation (14), oth-
er reasons (18); withdrawn from study in the steroid withdrawal phase because of protocol viola-
tion (10), other reasons (11)* Maintenance group: steroid resistant acute rejection (16), gra@ loss (6), protocol violation (13), oth-
er reasons (14); withdrawn from study in the steroid withdrawal phase because of protocol viola-
tion (6), other reasons (5)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'Randomization (1:1:1) was stratified by centre and donor type' but ran-
dom sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Stated 'The investigators were blinded with respect to randomization until the
month-3 visit.' which is the time before start of the intervention, but thereafter
investigators were unblinded, thus this is an open-label study
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Stated 'The investigators were blinded with respect to randomization until the
month-3 visit.' which is the time before start of the intervention, but thereafter
investigators were unblinded, thus this is an open-label study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed-up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk Unclear whether the rather short follow-up period allows sufficient time for
endpoints to occur
This study was supported by Fujisawa GmbH, Munich, Germany
THOMAS Study 2002  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: not reported but before 2003• Follow-up period: 12 months
Vincenti 2003a 
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• Primary endpoint: incidence of biopsy-proven acute rejection episodes within the first 12 months
Participants • Country: not reported• Setting: multicentre (5 centres)• First cadaveric or living kidney transplant; 18 to 70 years• Number (randomised/analysed) withdrawal group (40/40); maintenance group (43/43)• Mean age ± SD (years): withdrawal group (49 ± 11); maintenance group (49 ± 12)• Sex (female): withdrawal group (55%); maintenance group (28%)• Donor source (living donor): withdrawal group (55%); maintenance group (44%)• Exclusion criteria: previous or multiple organ transplant; non-heart beating cadaveric donor; PRA >
50%; planned induction with an antilymphocyte preparation; malignancy within five years; medical
conditions likely to affect the safety of the subject
Interventions Treatment group
• Steroid withdrawal day 5 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Basiliximab: day 0 and 4: 20mg• CsA: started on day 1 with 4 to 5 mg/kg twice daily adjusted to trough levels week 1 to 2: 150 - 450
ng/mL; week 3 to 12: 150 to 300 ng/mL; thereafter: 150 to 250 ng/mL (for patients with delayed gra@
function CsA was started with 3 mg/kg twice daily or delayed for up to 48 h)• MMF: 2000 mg daily divided in two doses (African-Americans and patients during delayed gra@ func-
tion received 3000 mg/d)• Steroids* IV methylprednisone: day 0: 500 mg; day 1: 250 mg; day 2: 125 mg* Withdrawal group: prednisone or methylprednisone: day 3: 60 mg; day 4 or until CsA levels in target
range: 30 mg; then no further steroids (steroid withdrawal delayed in patients with delayed gra@
function until SCr < 50% of pretransplant value)* Maintenance group: prednisone: day 3 to 21: tapered to 20 to 30 mg; day 22 to 90: tapered to 5 to
20 mg day 91 to 180: 5 to 10 mg
Outcomes • Mortality• Gra@ loss• Acute rejection• Biopsy-proven acute rejection• Infection• SCr (mg/dL)
Notes • Did not report number screened for eligibility• Number of patients discontinued treatment: 28% of patients in withdrawal group were not withdrawn
from steroids at 6 months
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Vincenti 2003a  (Continued)
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Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias High risk The study was supported by Novartis Pharmaceuticals Corporation, East
Hanover, NJ
Vincenti 2003a  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 1999 to 2007• Follow-up period: 5 years• Primary endpoint: treatment failure defined as composite of death, gra@ loss or acute rejection at 5
years
Participants • Country: USA• Setting: multicentre (26 centres)• First or subsequent cadaveric or living kidney transplant; during days 3 to 7 decrease in SCr ≥ 30%
from pretransplant value; 18 to 70 years• Number (randomised/analysed): withdrawal group (197/191); maintenance group (200/195)• Mean age (± SD): withdrawal group (47 ± 12); maintenance group (46 ± 13)• Sex (female): withdrawal group (31%); maintenance group (36%)• Donor source (living donor): withdrawal group (57%); maintenance group (57%)• Exclusion criteria: acute rejection within the first 7 days after transplantation; current PRA ≥ 25%; peak
PRA ≥ 50%; cold ischaemia time > 36 hours; multiple organ transplant; non heart beating donor; pae-
diatric donor; dual kidney transplant; reasons for loss of previous kidney transplant other than tech-
nical reasons or recurrence of disease with low risk of recurrence; dialysis post-transplant; require-
ment for systematic steroids for other disease; HIV seropositivity
Interventions Treatment group
• Steroid withdrawal day 8 after transplantation
Control group
• Steroid maintenance
Baseline immunosuppression
• Antilymphocytic or anti-IL2 antibodies according to centre preference
Woodle 2005 
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• TAC: started within 72 hours post-transplant with 0.15 to 0.2 mg/kg divided in two doses, adjusted to
blood levels by day 7 to 90: 10 to 20 ng/mL; thereafter: 5 to 15 ng/mL• MMF: day 0: 1000 mg; day 1: 2000 mg, day 2 to 14: 3000 mg, thereafter: 2000 mg• Steroids* IV corticosteroid: day 0: 10 mg/kg (max 500 mg); day 1: 5 mg/kg (max 500 mg); day 2: 3 mg/kg (max
300 mg)* Corticosteroid: day 3: 2 mg/kg (max 200 mg); day 4: 1 mg/kg (max 100 mg); day 5: 0.7 mg/kg (max
70 mg); day 6: 0.5 mg/kg (max 50 mg); day 7: 0.4 mg/kg (max 40 mg)* Withdrawal group: no further steroids* maintenance group: day 8 to 14: 0.4 mg/kg; day 15 to 29: 0.3 mg; day 30 to 89: 0.2 mg/kg; day 90
to 119: 0.15 mg/kg; thereafter: 0.1 mg/kg
Outcomes • Mortality• Gra@ loss• Biopsy-proven acute rejection• New-onset of diabetes after transplantation• Infection• CMV infection• Malignancy• Cardiovascular event• SCr (mg/dL)• CrCl (mL/min)
Notes • Did not report number screened for eligibility• Induction treatment* Withdrawal group: thymoglobulin (65%); basiliximab (31%); daclizumab (3%)* Maintenance group: thymoglobulin (70%); basiliximab (27%); daclizumab (3%)• Number of patients excluded from analysis* Withdrawal group: rejection or dialysis within the first 7 days (3), withdrawal of consent (1), did not
meet eligibility criteria (2)* Maintenance group : rejection or dialysis within the first 7 days (2), protocol violation (1), did not
meet eligibility criteria (2)• Number of patients discontinued treatment* Withdrawal group: 67 patients (35%)* Maintenance group: 73 patients (37%)• Number of patients discontinued study* Withdrawal group: 25 patients were lost to follow-up or withdrew consent (13%)* Maintenance group: 31 patients were lost to follow-up or withdrew consent (16%)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stated 'Randomization was based on a permuted block design with block sizes
of 6 within each clinical site. Randomization was performed using a central
randomization service at the EMMES Corporation (Potomac, Md, US). Patients
were randomised 1:1 stratified by race and donor type'
Allocation concealment
(selection bias)
Low risk Stated 'The EMMES Corporation generated the allocation sequence and main-
tained the allocation code. The randomization order did not have a repeat-
ing sequence, and the randomization code was not broken or revealed to pa-
tients/investigators until subjects completed study'
Blinding (performance
bias and detection bias) 
Low risk Stated 'Patients received a blinded study drug beginning on posttransplant
day 8'
Woodle 2005  (Continued)
Steroid avoidance or withdrawal for kidney transplant recipients (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
110
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
All outcomes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Stated 'Study subjects, investigators, study personnel, and those assessing
outcomes remained blinded throughout 5-year duration of the study, unless
medical necessity to unblind occurred'
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Stated 'Study subjects, investigators, study personnel, and those assessing
outcomes remained blinded throughout 5-year duration of the study, unless
medical necessity to unblind occurred'
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis performed; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk Primary outcomes for this review reported
Other bias Unclear risk Funding source not reported
Woodle 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Time frame: 2003 to 2005• Follow-up period: 2 years• Primary endpoint: not reported
Participants • Country: China• Setting: single centre• Cadaveric kidney transplant• Number (randomised): 45 total• Median age (range): 44 (26 to 65) years• Sex (% female): not reported• Exclusion criteria: PRA > 10%; multi-organ transplantation; serious infections (e.g. AIDS); malignancy
Interventions Treatment group
• Steroid withdrawal 6 months after transplantation
Control group
• Steroid maintenance
Baseline Immunosuppression
• TAC: day 0 to 14: adjusted to blood levels between 10 to 20 ng/mL; thereafter: 5 to 15 ng/mL• MMF: 1.5 to 2.0 g/d• Steroids* IV methylprednisone: day 0: 500 mg; day 1: 300mg; day 2: 200 mg* Oral prednisone: day 3 to 14: 20 mg/d; day 15 to 28: 15 mg/d* Withdrawal group: day 29 to 92: tapered to 5 mg/d; withdrawn on day 183* Maintenance group: day 29 to study end: 10 mg/d
Outcomes • Mortality• Acute rejection
Zhu 2008a 
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• NODAT• Infection• SCr (µmol/L)
Notes • Did not report number screened for eligibility or analysed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated 'randomised' but no further information provided
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes are objective hard endpoints
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of patients and number of events per group not reported; unclear
whether ITT analysis was performed. Number of patients lost to follow up not
reported
Selective reporting (re-
porting bias)
High risk Gra@ loss not reported
Other bias Unclear risk Funding source not reported
It was not reported how many of the participants were randomised to either
group, whether the timing of outcome assessment is similar in all groups,
whether the groups were similar at baseline, whether co-interventions were
avoided or similar
Important information on design and conduct of study not reported
Zhu 2008a  (Continued)
ALG - anti-lymphocyte globulin; ATG - anti-thymocyte globulin; AZA - azathioprine; CMV - cytomegalovirus; CNI - calcineurin inhibitor; CrCl
- creatinine clearance; CsA - cyclosporin; EC-MPS - enteric-coated mycophenolate sodium; eGFR - estimated glomerular filtration rate; EVL
- everolimus; GFR - glomerular filtration rate; HBsAG - hepatitis B surface antigen; HCT - haematocrit; HIV - human immunodeficiency virus;
HLA - human leukocyte antigen; HTLV-1 - human T-lymphotropic virus type 1; IL-2RA - interleukin 2 receptor antagonist; ITT - intention-to-
treat analysis; IV - intravenous; MMF - mycophenolate mofetil; NODAT - new-onset diabetes post transplant; PO - oral; PRA - panel reactive
antibodies; PTLD - Post-transplant lymphoproliferative disease; RCT - randomised controlled trial; SCr - serum creatinine; SD - standard
deviation; SRL - sirolimus; TAC - tacrolimus; WCC - white cell count
 
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Alexander 2006 Wrong co-intervention
Anil Kumar 2005 Wrong co-intervention
Axelrod 2005 Not RCT
Berney 2004 Pancreatic islet transplantation
Birkeland 1998b Not RCT
Birkeland 2002 Pancreatic islet transplantation
Budde 2001 Wrong co-intervention
PLEASE ADD REASON FOR EXCLUSION
CAMPASIA Study 2005 Wrong co-intervention
CARMEN Study 2005 Wrong co-intervention
Citterio 2002 Wrong co-intervention
CORRETA Study 2008 No steroid withdrawal or avoidance
Curtis 1982 No steroid withdrawal or avoidance
Daniel 1985 No steroid withdrawal or avoidance
De Backer 1992 No steroid withdrawal or avoidance
de Sandes Freitas 2011 Wrong co-intervention
Delucchi 2006 Difference in co-intervention
ECSEL Study 2008 Wrong co-intervention
Hibbs 2010 Not RCT
Hilbrands 1993 Not RCT
Hodson 1989 Not RCT
Hricik 1993a Not RCT
Hricik 1993b Not RCT
John 2005 Not RCT
Juarez 2006 Not steroid withdrawal or avoidance
Kim 2004 Wrong co-intervention
Kim 2005 Not RCT
Lehmann 2004 Pancreatic islet transplantation
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Study Reason for exclusion
Li 2011a Not steroid withdrawal or avoidance
Morris 1982 Not steroid withdrawal or avoidance
MYSS Study 2004 Wrong co-intervention
NCT00089947 Wrong co-intervention
Nori 2008 Wrong co-intervention
Paczek 2003a Wrong co-intervention
Papadakis 1982 Not steroid withdrawal or avoidance
Reed 1991 Wrong co-intervention
Remport 2001 Not steroid withdrawal or avoidance
Robertson 1980 Not RCT
Sarwal 2012 Wrong co-intervention
SENIOR Study 2009 Wrong co-intervention
Shapiro 1993 Wrong co-intervention
Silverstein 2005 Not RCT
SOCRATES Study 2014 Not steroid withdrawal or avoidance
Tarantino 1991 Wrong co-intervention
Teplan 2003 Not RCT
ter Meulen 2002 Wrong co-intervention
TRIMS Study 2010 Wrong co-intervention
TWIST Study 2010 Wrong co-intervention
Weimert 2008 Wrong co-intervention
RCT - randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Unclear if this was a RCT
Participants Kidney transplant recipients not further specified, unclear time frame, but before 1989
Interventions Steroid withdrawal versus steroid maintenance plus CsA
Newstead 1989 
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Outcomes Serum creatinine and acute rejection
Notes Abstract-only data; unable to contact authors
Newstead 1989  (Continued)
CsA - cyclosporin; RCT - randomised controlled trial
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Steroid withdrawal versus steroid maintenance
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death and gra@ loss 15   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to one year 10 1913 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.36, 1.30]
1.2 Death one to five years 7 1118 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.73, 2.17]
1.3 Gra@ loss including death up
to one year
8 1817 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.64, 1.49]
1.4 Gra@ loss including death
one to five years
7 1092 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.00, 2.01]
1.5 Gra@ loss excluding death
up to one year
8 1817 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.72, 1.92]
1.6 Gra@ loss excluding death
one to five years
7 1092 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.98, 2.64]
2 Rejection 11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Acute rejection up to one
year
10 1913 Risk Ratio (M-H, Random, 95% CI) 1.77 [1.20, 2.61]
2.2 Biopsy-proven acute rejec-
tion up to one year
5 1292 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.78, 2.22]
3 New-onset diabetes after
transplantation and cardiovas-
cular events
6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 New onset diabetes after
transplantation up to five years
6 1439 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.49, 1.21]
3.2 Cardiovascular events up to
five years
2 607 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.42, 2.33]
4 Infection and malignancy 7   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Infection (all) up to five years 5 1819 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.22]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.2 CMV infection up to five
years
5 1758 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.80, 1.36]
4.3 Malignancy up to five years 3 756 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.41, 1.46]
5 Kidney function 8   Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Serum creatinine (mg/dL)
up to one year
4 644 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.21, 0.13]
5.2 Serum creatinine (mg/dL)
one to five years
5 762 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.06, 0.23]
5.3 Creatinine clearance (mL/
min) up to one year
2 215 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.35, 0.21]
5.4 Creatinine clearance (mL/
min) one to five years
3 669 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.56, 0.13]
 
 
Analysis 1.1.   Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 1 Death and graA loss.
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Death up to one year  
Ahsan 1999 0/134 1/132 4.03% 0.33[0.01,7.99]
Bouma 1996 0/42 1/42 4.08% 0.33[0.01,7.96]
del Castillo 2005 1/70 0/72 4.05% 3.08[0.13,74.46]
Isoniemi 1990 3/32 4/32 20.54% 0.75[0.18,3.09]
Lebranchu 1999 4/252 8/248 29.14% 0.49[0.15,1.61]
Maiorca 1988 0/35 1/31 4.1% 0.3[0.01,7.02]
Matl 2000 1/45 0/42 4.08% 2.8[0.12,67]
Pelletier 2006 1/59 0/59 4.06% 3[0.12,72.18]
Pisani 2001 1/15 0/15 4.21% 3[0.13,68.26]
THOMAS Study 2002 3/279 6/277 21.7% 0.5[0.13,1.97]
Subtotal (95% CI) 963 950 100% 0.68[0.36,1.3]
Total events: 14 (Withdrawal), 21 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=4.51, df=9(P=0.88); I2=0%  
Test for overall effect: Z=1.16(P=0.25)  
   
1.1.2 Death one to five years  
Boletis 2001 0/36 0/36   Not estimable
Gulanikar 1991 14/260 12/263 52.39% 1.18[0.56,2.5]
Isoniemi 1990 5/32 5/32 22.84% 1[0.32,3.12]
Pelletier 2006 5/59 2/59 11.57% 2.5[0.5,12.38]
Ratcliffe 1993 2/49 1/51 5.28% 2.08[0.19,22.23]
Smak Gregoor 1999 2/76 2/73 7.92% 0.96[0.14,6.64]
Sola 2002 0/46 0/46   Not estimable
Subtotal (95% CI) 558 560 100% 1.26[0.73,2.17]
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Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 28 (Withdrawal), 22 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=1.14, df=4(P=0.89); I2=0%  
Test for overall effect: Z=0.82(P=0.41)  
   
1.1.3 GraA loss including death up to one year  
Ahsan 1999 2/134 3/132 5.8% 0.66[0.11,3.87]
Bouma 1996 1/42 1/42 2.43% 1[0.06,15.47]
del Castillo 2005 5/70 5/72 12.76% 1.03[0.31,3.4]
Isoniemi 1990 3/32 6/32 10.84% 0.5[0.14,1.83]
Lebranchu 1999 14/252 18/248 39.88% 0.77[0.39,1.5]
Matl 2000 1/45 1/42 2.43% 0.93[0.06,14.45]
Pelletier 2006 1/59 1/59 2.41% 1[0.06,15.61]
THOMAS Study 2002 15/279 7/277 23.45% 2.13[0.88,5.14]
Subtotal (95% CI) 913 904 100% 0.97[0.64,1.49]
Total events: 42 (Withdrawal), 42 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=4.73, df=7(P=0.69); I2=0%  
Test for overall effect: Z=0.12(P=0.9)  
   
1.1.4 GraA loss including death one to five years  
Boletis 2001 0/36 0/36   Not estimable
Gulanikar 1991 45/260 29/263 65% 1.57[1.02,2.42]
Isoniemi 1990 7/32 8/32 15.53% 0.88[0.36,2.13]
Maiorca 1988 2/35 1/31 2.22% 1.77[0.17,18.6]
Pelletier 2006 8/59 4/59 9.35% 2[0.64,6.28]
Ratcliffe 1993 2/49 1/51 2.18% 2.08[0.19,22.23]
Smak Gregoor 1999 3/76 4/73 5.73% 0.72[0.17,3.11]
Subtotal (95% CI) 547 545 100% 1.41[1,2.01]
Total events: 67 (Withdrawal), 47 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=2.65, df=5(P=0.75); I2=0%  
Test for overall effect: Z=1.94(P=0.05)  
   
1.1.5 GraA loss excluding death up to one year  
Ahsan 1999 2/134 2/132 6.38% 0.99[0.14,6.89]
Bouma 1996 1/42 0/42 2.4% 3[0.13,71.61]
del Castillo 2005 4/70 5/72 14.9% 0.82[0.23,2.94]
Isoniemi 1990 0/32 2/32 2.69% 0.2[0.01,4.01]
Lebranchu 1999 12/252 11/248 37.8% 1.07[0.48,2.39]
Matl 2000 0/45 1/42 2.4% 0.31[0.01,7.44]
Pelletier 2006 0/59 1/59 2.39% 0.33[0.01,8.02]
THOMAS Study 2002 15/279 7/277 31.06% 2.13[0.88,5.14]
Subtotal (95% CI) 913 904 100% 1.17[0.72,1.92]
Total events: 34 (Withdrawal), 29 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=5.08, df=7(P=0.65); I2=0%  
Test for overall effect: Z=0.64(P=0.52)  
   
1.1.6 GraA loss excluding death one to five years  
Boletis 2001 0/36 0/36   Not estimable
Gulanikar 1991 31/260 17/263 76.64% 1.84[1.05,3.25]
Isoniemi 1990 2/32 3/32 8.29% 0.67[0.12,3.73]
Maiorca 1988 2/35 0/31 2.73% 4.44[0.22,89.16]
Pelletier 2006 3/59 2/59 8% 1.5[0.26,8.65]
Ratcliffe 1993 0/49 0/51   Not estimable
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Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Smak Gregoor 1999 1/76 2/73 4.34% 0.48[0.04,5.18]
Subtotal (95% CI) 547 545 100% 1.61[0.98,2.64]
Total events: 39 (Withdrawal), 24 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=2.67, df=4(P=0.61); I2=0%  
Test for overall effect: Z=1.89(P=0.06)  
Test for subgroup differences: Chi2=6.11, df=1 (P=0.3), I2=18.18%  
Favours withdrawal 2000.005 100.1 1 Favours maintenance
 
 
Analysis 1.2.   Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 2 Rejection.
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Acute rejection up to one year  
Ahsan 1999 26/134 7/132 12.52% 3.66[1.65,8.14]
Bouma 1996 11/42 1/42 3.3% 11[1.49,81.44]
del Castillo 2005 17/70 13/72 15.4% 1.35[0.71,2.56]
Isoniemi 1990 6/32 1/32 3.14% 6[0.77,47.05]
Lebranchu 1999 76/252 52/248 22.83% 1.44[1.06,1.95]
Maiorca 1988 16/35 3/31 8.14% 4.72[1.52,14.69]
Matl 2000 3/45 2/42 4.2% 1.4[0.25,7.97]
Pelletier 2006 3/59 3/59 5.04% 1[0.21,4.75]
Pisani 2001 1/15 2/15 2.6% 0.5[0.05,4.94]
THOMAS Study 2002 67/279 60/277 22.83% 1.11[0.82,1.51]
Subtotal (95% CI) 963 950 100% 1.77[1.2,2.61]
Total events: 226 (Withdrawal), 144 (Maintenance)  
Heterogeneity: Tau2=0.15; Chi2=19.74, df=9(P=0.02); I2=54.4%  
Test for overall effect: Z=2.89(P=0)  
   
1.2.2 Biopsy-proven acute rejection up to one year  
Bouma 1996 9/42 1/42 5.69% 9[1.19,67.93]
del Castillo 2005 16/70 12/72 23.7% 1.37[0.7,2.69]
Farmer 2006 1/6 2/4 5.6% 0.33[0.04,2.56]
Lebranchu 1999 63/252 36/248 32.67% 1.72[1.19,2.49]
THOMAS Study 2002 42/279 47/277 32.34% 0.89[0.61,1.3]
Subtotal (95% CI) 649 643 100% 1.32[0.78,2.22]
Total events: 131 (Withdrawal), 98 (Maintenance)  
Heterogeneity: Tau2=0.18; Chi2=11.38, df=4(P=0.02); I2=64.85%  
Test for overall effect: Z=1.04(P=0.3)  
Test for subgroup differences: Chi2=0.79, df=1 (P=0.37), I2=0%  
Favours withdrawal 1000.01 100.1 1 Favours maintenance
 
 
Analysis 1.3.   Comparison 1 Steroid withdrawal versus steroid maintenance,
Outcome 3 New-onset diabetes aAer transplantation and cardiovascular events.
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 New onset diabetes after transplantation up to five years  
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Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouma 1996 8/42 6/42 22.02% 1.33[0.51,3.51]
Gulanikar 1991 9/260 15/263 31.59% 0.61[0.27,1.36]
Maiorca 1988 0/35 0/31   Not estimable
Pelletier 2006 4/59 6/59 14.04% 0.67[0.2,2.24]
Sola 2002 2/46 2/46 5.62% 1[0.15,6.8]
THOMAS Study 2002 8/279 12/277 26.72% 0.66[0.27,1.59]
Subtotal (95% CI) 721 718 100% 0.77[0.49,1.21]
Total events: 31 (Withdrawal), 41 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=1.81, df=4(P=0.77); I2=0%  
Test for overall effect: Z=1.13(P=0.26)  
   
1.3.2 Cardiovascular events up to five years  
Bouma 1996 4/42 6/42 52.57% 0.67[0.2,2.19]
Gulanikar 1991 6/260 4/263 47.43% 1.52[0.43,5.31]
Subtotal (95% CI) 302 305 100% 0.98[0.42,2.33]
Total events: 10 (Withdrawal), 10 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=0.87, df=1(P=0.35); I2=0%  
Test for overall effect: Z=0.03(P=0.97)  
Test for subgroup differences: Chi2=0.24, df=1 (P=0.62), I2=0%  
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Analysis 1.4.   Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 4 Infection and malignancy.
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Infection (all) up to five years  
Ahsan 1999 49/134 42/132 20.98% 1.15[0.82,1.61]
Bouma 1996 13/42 20/42 9.58% 0.65[0.37,1.13]
Gulanikar 1991 106/260 110/263 37.11% 0.97[0.79,1.2]
Lebranchu 1999 18/252 22/248 8.34% 0.81[0.44,1.46]
THOMAS Study 2002 68/221 55/225 23.98% 1.26[0.93,1.7]
Subtotal (95% CI) 909 910 100% 1.02[0.84,1.22]
Total events: 254 (Withdrawal), 249 (Maintenance)  
Heterogeneity: Tau2=0.01; Chi2=5.69, df=4(P=0.22); I2=29.68%  
Test for overall effect: Z=0.17(P=0.87)  
   
1.4.2 CMV infection up to five years  
Gulanikar 1991 10/260 13/263 11.07% 0.78[0.35,1.74]
Lebranchu 1999 55/252 54/248 65.29% 1[0.72,1.4]
Pisani 2001 3/15 1/15 1.56% 3[0.35,25.68]
Smak Gregoor 1999 1/76 2/73 1.27% 0.48[0.04,5.18]
THOMAS Study 2002 24/279 18/277 20.81% 1.32[0.74,2.38]
Subtotal (95% CI) 882 876 100% 1.04[0.8,1.36]
Total events: 93 (Withdrawal), 88 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=2.53, df=4(P=0.64); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.4.3 Malignancy up to five years  
Bouma 1996 3/42 6/42 23.41% 0.5[0.13,1.87]
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Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gulanikar 1991 12/260 13/263 69.4% 0.93[0.43,2.01]
Smak Gregoor 1999 1/76 2/73 7.19% 0.48[0.04,5.18]
Subtotal (95% CI) 378 378 100% 0.77[0.41,1.46]
Total events: 16 (Withdrawal), 21 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=0.81, df=2(P=0.67); I2=0%  
Test for overall effect: Z=0.81(P=0.42)  
Test for subgroup differences: Chi2=0.75, df=1 (P=0.69), I2=0%  
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Analysis 1.5.   Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 5 Kidney function.
Study or subgroup Withdrawal Maintenance Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.5.1 Serum creatinine (mg/dL) up to one year  
del Castillo 2005 65 1.7 (0.8) 67 1.6 (0.5) 21.99% 0.15[-0.19,0.49]
Isoniemi 1990 28 1.6 (0.7) 26 1.5 (0.6) 9.56% 0.15[-0.38,0.69]
Lebranchu 1999 162 1.5 (0.5) 180 1.6 (0.6) 48.84% -0.18[-0.39,0.03]
Pelletier 2006 57 1.6 (0.5) 59 1.6 (0.5) 19.61% 0[-0.36,0.36]
Subtotal *** 312   332   100% -0.04[-0.21,0.13]
Heterogeneity: Tau2=0; Chi2=3.35, df=3(P=0.34); I2=10.56%  
Test for overall effect: Z=0.47(P=0.64)  
   
1.5.2 Serum creatinine (mg/dL) one to five years  
Burke 2000 14 1.7 (0.5) 15 1.5 (0.5) 3.74% 0.39[-0.35,1.13]
Gulanikar 1991 260 2 (0.8) 263 2 (0.8) 68.93% 0[-0.17,0.17]
Isoniemi 1990 25 1.5 (0.5) 24 1.4 (0.5) 6.42% 0.2[-0.36,0.76]
Pelletier 2006 35 1.9 (0.5) 29 1.7 (0.6) 8.22% 0.36[-0.14,0.86]
Ratcliffe 1993 47 1.7 (0.5) 50 1.6 (0.4) 12.69% 0.22[-0.18,0.62]
Subtotal *** 381   381   100% 0.08[-0.06,0.23]
Heterogeneity: Tau2=0; Chi2=3.38, df=4(P=0.5); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
   
1.5.3 Creatinine clearance (mL/min) up to one year  
Bouma 1996 42 66 (33) 41 63 (20) 39.7% 0.11[-0.32,0.54]
del Castillo 2005 65 59.1 (21.3) 67 62.9 (19.4) 60.3% -0.19[-0.53,0.16]
Subtotal *** 107   108   100% -0.07[-0.35,0.21]
Heterogeneity: Tau2=0; Chi2=1.1, df=1(P=0.29); I2=9.05%  
Test for overall effect: Z=0.48(P=0.63)  
   
1.5.4 Creatinine clearance (mL/min) one to five years  
Gulanikar 1991 260 54.5 (30.4) 263 54.6 (29.8) 47.22% -0[-0.17,0.17]
Isoniemi 1990 25 57 (20) 24 62 (19) 22.03% -0.25[-0.81,0.31]
Ratcliffe 1993 47 47 (17) 50 56 (18) 30.75% -0.51[-0.91,-0.1]
Subtotal *** 332   337   100% -0.21[-0.56,0.13]
Heterogeneity: Tau2=0.06; Chi2=5.43, df=2(P=0.07); I2=63.13%  
Test for overall effect: Z=1.22(P=0.22)  
Test for subgroup differences: Chi2=3.29, df=1 (P=0.35), I2=8.85%  
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Comparison 2.   Steroid avoidance versus steroid maintenance
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death and gra@ loss 13   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to one year 10 1462 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.52, 1.80]
1.2 Death one to five years 7 1201 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.32, 1.01]
1.3 Gra@ loss including death up
to one year
7 1211 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.72, 1.62]
1.4 Gra@ loss including death
one to five years
7 1245 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.53, 1.18]
1.5 Gra@ loss excluding death
up to one year
7 1211 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.64, 1.86]
1.6 Gra@ loss excluding death
one to five years
7 1245 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.66, 1.45]
2 Rejection 9   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Acute rejection up to one
year
7 835 Risk Ratio (M-H, Random, 95% CI) 1.58 [1.08, 2.30]
2.2 Biopsy-proven acute rejec-
tion up to one year
6 1073 Risk Ratio (M-H, Random, 95% CI) 1.94 [1.26, 2.98]
3 New-onset diabetes after
transplantation and cardiovas-
cular events
9   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 New onset diabetes after
transplantation up to five years
9 1618 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.51, 1.10]
3.2 Cardiovascular events up to
five years
4 1013 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.30, 1.05]
4 Infection and malignancy 11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Infection (all) up to five years 9 1833 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.03]
4.2 CMV Infection up to five
years
6 1454 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.70, 1.31]
4.3 Malignancy up to five years 7 1635 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.61, 1.52]
5 Kidney function 10   Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Serum creatinine (mg/dL)
up to one year
5 735 Std. Mean Difference (IV, Random, 95% CI) 0.02 [-0.12, 0.17]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5.2 Serum creatinine (mg/dL)
one to five years
3 688 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.16, 0.14]
5.3 Creatinine clearance (mL/
min) up to one year
6 1104 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.23, 0.08]
5.4 Creatinine clearance (mL/
min) one to five years
3 563 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.25, 0.08]
 
 
Analysis 2.1.   Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 1 Death and graA loss.
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 Death up to one year  
ATLAS Study 2005 3/151 0/147 4.43% 6.82[0.36,130.81]
De Vecchi 1986 0/25 4/26 4.68% 0.12[0.01,2.04]
FRANCIA Study 2007 1/98 3/103 7.66% 0.35[0.04,3.31]
FREEDOM Study 2008 7/226 2/109 15.98% 1.69[0.36,7.99]
Kumar 2005 0/45 0/32   Not estimable
Montagnino 2005 0/65 1/68 3.81% 0.35[0.01,8.4]
Nematalla 2007 0/50 0/50   Not estimable
Nott 1985 8/59 8/58 46.6% 0.98[0.4,2.44]
Schulak 1989 3/32 2/35 13% 1.64[0.29,9.2]
Vincenti 2003a 0/40 1/43 3.84% 0.36[0.01,8.54]
Subtotal (95% CI) 791 671 100% 0.96[0.52,1.8]
Total events: 22 (Avoidance), 21 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=6.22, df=7(P=0.51); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
   
2.1.2 Death one to five years  
ATLAS Study 2005 3/139 5/139 16.17% 0.6[0.15,2.46]
De Vecchi 1986 0/25 5/26 3.98% 0.09[0.01,1.62]
Kim 2002 0/11 1/12 3.35% 0.36[0.02,8.04]
Montagnino 2005 0/65 2/68 3.54% 0.21[0.01,4.27]
Nematalla 2007 0/49 0/49   Not estimable
Ponticelli 1997 3/115 9/117 19.65% 0.34[0.09,1.22]
Woodle 2005 11/191 13/195 53.3% 0.86[0.4,1.88]
Subtotal (95% CI) 595 606 100% 0.57[0.32,1.01]
Total events: 17 (Avoidance), 35 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=3.9, df=5(P=0.56); I2=0%  
Test for overall effect: Z=1.92(P=0.05)  
   
2.1.3 GraA loss including death up to one year  
ATLAS Study 2005 9/151 6/147 16.29% 1.46[0.53,4]
FRANCIA Study 2007 5/98 7/103 13.33% 0.75[0.25,2.29]
FREEDOM Study 2008 13/226 5/109 16.35% 1.25[0.46,3.43]
Kumar 2005 2/45 1/32 2.98% 1.42[0.13,15.02]
Nematalla 2007 0/50 0/50   Not estimable
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Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Nott 1985 17/59 16/58 49.41% 1.04[0.59,1.86]
Vincenti 2003a 0/40 1/43 1.64% 0.36[0.01,8.54]
Subtotal (95% CI) 669 542 100% 1.08[0.72,1.62]
Total events: 46 (Avoidance), 36 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=1.37, df=5(P=0.93); I2=0%  
Test for overall effect: Z=0.36(P=0.72)  
   
2.1.4 GraA loss including death one to five years  
ATLAS Study 2005 11/139 15/139 18.94% 0.73[0.35,1.54]
De Vecchi 1986 1/25 7/26 3.66% 0.15[0.02,1.12]
Montagnino 2005 3/65 10/68 8.7% 0.31[0.09,1.09]
Nematalla 2007 0/49 0/49   Not estimable
Ponticelli 1997 18/115 24/117 26.53% 0.76[0.44,1.33]
Schulak 1989 9/32 8/35 16.47% 1.23[0.54,2.8]
Woodle 2005 22/191 20/195 25.7% 1.12[0.63,1.99]
Subtotal (95% CI) 616 629 100% 0.79[0.53,1.18]
Total events: 64 (Avoidance), 84 (Maintenance)  
Heterogeneity: Tau2=0.08; Chi2=7.39, df=5(P=0.19); I2=32.38%  
Test for overall effect: Z=1.16(P=0.25)  
   
2.1.5 GraA loss excluding death up to one year  
ATLAS Study 2005 7/151 6/147 24.64% 1.14[0.39,3.3]
FRANCIA Study 2007 5/98 5/103 19.19% 1.05[0.31,3.52]
FREEDOM Study 2008 6/226 3/109 15% 0.96[0.25,3.78]
Kumar 2005 2/45 1/32 5.04% 1.42[0.13,15.02]
Nematalla 2007 0/50 0/50   Not estimable
Nott 1985 9/59 8/58 36.13% 1.11[0.46,2.67]
Vincenti 2003a 0/40 0/43   Not estimable
Subtotal (95% CI) 669 542 100% 1.09[0.64,1.86]
Total events: 29 (Avoidance), 23 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=0.09, df=4(P=1); I2=0%  
Test for overall effect: Z=0.33(P=0.74)  
   
2.1.6 GraA loss excluding death one to five years  
ATLAS Study 2005 9/139 10/139 20.44% 0.9[0.38,2.15]
De Vecchi 1986 1/25 2/26 2.83% 0.52[0.05,5.38]
Montagnino 2005 3/65 8/68 9.39% 0.39[0.11,1.41]
Nematalla 2007 0/49 0/49   Not estimable
Ponticelli 1997 15/115 15/117 34.64% 1.02[0.52,1.98]
Schulak 1989 6/32 6/35 14.7% 1.09[0.39,3.05]
Woodle 2005 11/191 7/195 18% 1.6[0.64,4.05]
Subtotal (95% CI) 616 629 100% 0.98[0.66,1.45]
Total events: 45 (Avoidance), 48 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=3.42, df=5(P=0.63); I2=0%  
Test for overall effect: Z=0.12(P=0.91)  
Test for subgroup differences: Chi2=4.33, df=1 (P=0.5), I2=0%  
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Analysis 2.2.   Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 2 Rejection.
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 Acute rejection up to one year  
ATLAS Study 2005 60/151 19/147 18.77% 3.07[1.93,4.89]
De Vecchi 1986 19/25 13/26 19.24% 1.52[0.98,2.37]
FRANCIA Study 2007 25/98 13/99 15.52% 1.94[1.06,3.57]
Kumar 2005 7/45 4/32 7.65% 1.24[0.4,3.9]
Laftavi 2005 4/32 3/28 5.58% 1.17[0.29,4.77]
Stiller 1983 25/33 24/36 22.5% 1.14[0.84,1.54]
Vincenti 2003a 8/40 8/43 10.73% 1.08[0.45,2.59]
Subtotal (95% CI) 424 411 100% 1.58[1.08,2.3]
Total events: 148 (Avoidance), 84 (Maintenance)  
Heterogeneity: Tau2=0.14; Chi2=16.23, df=6(P=0.01); I2=63.04%  
Test for overall effect: Z=2.39(P=0.02)  
   
2.2.2 Biopsy-proven acute rejection up to one year  
ATLAS Study 2005 48/151 12/147 22.51% 3.89[2.16,7.03]
FRANCIA Study 2007 17/98 7/99 15.8% 2.45[1.06,5.65]
FREEDOM Study 2008 65/226 16/109 25.69% 1.96[1.19,3.22]
Laftavi 2005 4/32 3/28 7.52% 1.17[0.29,4.77]
Nematalla 2007 8/50 8/50 14.44% 1[0.41,2.46]
Vincenti 2003a 8/40 7/43 14.04% 1.23[0.49,3.08]
Subtotal (95% CI) 597 476 100% 1.94[1.26,2.98]
Total events: 150 (Avoidance), 53 (Maintenance)  
Heterogeneity: Tau2=0.12; Chi2=9.08, df=5(P=0.11); I2=44.9%  
Test for overall effect: Z=3.01(P=0)  
Test for subgroup differences: Chi2=0.5, df=1 (P=0.48), I2=0%  
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Analysis 2.3.   Comparison 2 Steroid avoidance versus steroid maintenance,
Outcome 3 New-onset diabetes aAer transplantation and cardiovascular events.
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 New onset diabetes after transplantation up to five years  
ATLAS Study 2005 6/127 4/126 8.11% 1.49[0.43,5.15]
FRANCIA Study 2007 6/98 15/103 13.32% 0.42[0.17,1.04]
FREEDOM Study 2008 19/227 16/109 21.6% 0.57[0.31,1.06]
Kumar 2005 0/30 3/23 1.7% 0.11[0.01,2.04]
Montagnino 2005 6/65 4/68 8.36% 1.57[0.46,5.31]
Nematalla 2007 2/50 8/50 5.86% 0.25[0.06,1.12]
Nott 1985 1/59 2/58 2.52% 0.49[0.05,5.27]
Ponticelli 1997 9/115 9/117 13.71% 1.02[0.42,2.47]
Woodle 2005 23/107 18/86 24.84% 1.03[0.59,1.78]
Subtotal (95% CI) 878 740 100% 0.75[0.51,1.1]
Total events: 72 (Avoidance), 79 (Maintenance)  
Heterogeneity: Tau2=0.08; Chi2=10.51, df=8(P=0.23); I2=23.92%  
Test for overall effect: Z=1.49(P=0.14)  
   
2.3.2 Cardiovascular events up to five years  
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Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ATLAS Study 2005 6/139 4/139 20.26% 1.5[0.43,5.2]
Nott 1985 3/59 4/58 15.72% 0.74[0.17,3.15]
Ponticelli 1997 6/115 18/117 33.14% 0.34[0.14,0.82]
Woodle 2005 6/191 14/195 30.88% 0.44[0.17,1.11]
Subtotal (95% CI) 504 509 100% 0.56[0.3,1.05]
Total events: 21 (Avoidance), 40 (Maintenance)  
Heterogeneity: Tau2=0.11; Chi2=4.02, df=3(P=0.26); I2=25.42%  
Test for overall effect: Z=1.81(P=0.07)  
Test for subgroup differences: Chi2=0.57, df=1 (P=0.45), I2=0%  
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Analysis 2.4.   Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 4 Infection and malignancy.
Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 Infection (all) up to five years  
ATLAS Study 2005 30/139 26/139 4.41% 1.15[0.72,1.85]
FRANCIA Study 2007 66/98 75/103 29.54% 0.92[0.77,1.11]
FREEDOM Study 2008 144/227 71/109 33.99% 0.97[0.82,1.15]
Montagnino 2005 9/65 13/68 1.6% 0.72[0.33,1.58]
Nott 1985 5/59 15/58 1.09% 0.33[0.13,0.84]
Ponticelli 1997 39/115 47/117 8.53% 0.84[0.6,1.18]
Schulak 1989 8/32 7/35 1.22% 1.25[0.51,3.06]
Vincenti 2003a 13/40 12/43 2.26% 1.16[0.6,2.24]
Woodle 2005 75/191 86/195 17.35% 0.89[0.7,1.13]
Subtotal (95% CI) 966 867 100% 0.93[0.84,1.03]
Total events: 389 (Avoidance), 352 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=7.57, df=8(P=0.48); I2=0%  
Test for overall effect: Z=1.42(P=0.16)  
   
2.4.2 CMV Infection up to five years  
ATLAS Study 2005 25/151 17/147 29.46% 1.43[0.81,2.54]
FRANCIA Study 2007 16/98 20/103 27.17% 0.84[0.46,1.53]
FREEDOM Study 2008 20/227 9/109 17.05% 1.07[0.5,2.27]
Montagnino 2005 1/65 2/68 1.71% 0.52[0.05,5.63]
Nematalla 2007 1/50 3/50 1.95% 0.33[0.04,3.1]
Woodle 2005 14/191 20/195 22.65% 0.71[0.37,1.37]
Subtotal (95% CI) 782 672 100% 0.96[0.7,1.31]
Total events: 77 (Avoidance), 71 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=4.04, df=5(P=0.54); I2=0%  
Test for overall effect: Z=0.25(P=0.81)  
   
2.4.3 Malignancy up to five years  
ATLAS Study 2005 4/139 6/139 13.23% 0.67[0.19,2.31]
FRANCIA Study 2007 0/98 5/103 2.46% 0.1[0.01,1.7]
FREEDOM Study 2008 3/227 1/109 4.03% 1.44[0.15,13.69]
Montagnino 2005 4/65 2/68 7.39% 2.09[0.4,11.04]
Ponticelli 1997 5/115 3/117 10.31% 1.7[0.41,6.93]
Stiller 1983 0/33 0/36   Not estimable
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Study or subgroup Avoidance Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Woodle 2005 20/191 22/195 62.56% 0.93[0.52,1.64]
Subtotal (95% CI) 868 767 100% 0.97[0.61,1.52]
Total events: 36 (Avoidance), 39 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=4.47, df=5(P=0.48); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
Test for subgroup differences: Chi2=0.06, df=1 (P=0.97), I2=0%  
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Analysis 2.5.   Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 5 Kidney function.
Study or subgroup Avoidance Maintenance Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.5.1 Serum creatinine (mg/dL) up to one year  
ATLAS Study 2005 151 1.6 (0.9) 147 1.5 (0.8) 40.63% 0.13[-0.1,0.35]
FRANCIA Study 2007 98 1.8 (1.4) 99 1.9 (1.5) 26.9% -0.07[-0.35,0.21]
Kumar 2005 45 2 (0.8) 32 2.1 (1) 10.21% -0.11[-0.57,0.34]
Nematalla 2007 50 1.2 (0.5) 50 1.2 (0.5) 13.67% 0[-0.39,0.39]
Schulak 1989 30 1.8 (0.6) 33 1.8 (0.8) 8.59% 0[-0.49,0.49]
Subtotal *** 374   361   100% 0.02[-0.12,0.17]
Heterogeneity: Tau2=0; Chi2=1.56, df=4(P=0.82); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
2.5.2 Serum creatinine (mg/dL) one to five years  
ATLAS Study 2005 139 1.6 (0.9) 139 1.6 (0.8) 40.44% 0.04[-0.2,0.27]
Montagnino 2005 53 1.8 (0.6) 49 2 (1.1) 14.76% -0.17[-0.56,0.21]
Woodle 2005 156 1.5 (0.6) 152 1.5 (0.7) 44.8% 0[-0.22,0.22]
Subtotal *** 348   340   100% -0.01[-0.16,0.14]
Heterogeneity: Tau2=0; Chi2=0.84, df=2(P=0.66); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
   
2.5.3 Creatinine clearance (mL/min) up to one year  
ATLAS Study 2005 151 63.5 (21.7) 147 67.7 (24) 24.62% -0.18[-0.41,0.04]
FRANCIA Study 2007 98 58.2 (16.6) 99 57.8 (20.4) 19.47% 0.02[-0.26,0.3]
FREEDOM Study 2008 226 55.6 (23.4) 109 58.8 (20.5) 24.48% -0.14[-0.37,0.09]
Laftavi 2005 10 80.7 (29.3) 11 61.5 (25.6) 2.93% 0.67[-0.21,1.56]
Nematalla 2007 50 74.9 (23.1) 50 71.3 (10.9) 12.09% 0.2[-0.2,0.59]
Ponticelli 1997 76 58.9 (16.1) 77 64 (21.3) 16.41% -0.27[-0.59,0.05]
Subtotal *** 611   493   100% -0.08[-0.23,0.08]
Heterogeneity: Tau2=0.01; Chi2=7.53, df=5(P=0.18); I2=33.63%  
Test for overall effect: Z=0.96(P=0.34)  
   
2.5.4 Creatinine clearance (mL/min) one to five years  
Montagnino 2005 53 52.3 (17.1) 49 52 (21.5) 18.12% 0.02[-0.37,0.4]
Ponticelli 1997 76 57.3 (16.3) 77 61.2 (23.3) 27.1% -0.19[-0.51,0.12]
Woodle 2005 156 58.6 (17.9) 152 59.8 (20.5) 54.78% -0.06[-0.29,0.16]
Subtotal *** 285   278   100% -0.08[-0.25,0.08]
Heterogeneity: Tau2=0; Chi2=0.74, df=2(P=0.69); I2=0%  
Test for overall effect: Z=0.99(P=0.32)  
Test for subgroup differences: Chi2=1.28, df=1 (P=0.73), I2=0%  
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Comparison 3.   Steroid avoidance versus steroid withdrawal
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death and gra@ loss 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to one year 1 222 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.98]
1.2 Death one to five years 2 152 Risk Ratio (M-H, Random, 95% CI) 2.67 [0.63, 11.32]
1.3 Gra@ loss including death up
to one year
1 222 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.32, 2.29]
1.4 Gra@ loss including death
one to five years
2 152 Risk Ratio (M-H, Random, 95% CI) 2.44 [0.89, 6.70]
1.5 Gra@ loss excluding death
up to one year
1 222 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.40, 6.68]
1.6 Gra@ loss excluding death
one to five years
2 152 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.48, 7.67]
2 Rejection 2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Acute rejection up to one
year
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Biopsy-proven acute rejec-
tion up to one year
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 New-onset diabetes after
transplantation, infection, ma-
lignancy
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 New onset diabetes after
transplantation up to five years
3 351 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.36, 1.09]
3.2 Infection (all) up to five years 3 374 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.76, 1.50]
3.3 CMV Infection up to five
years
2 284 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.30, 0.92]
3.4 Malignancy up to five years 1 90 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.28, 8.94]
4 Kidney function 2   Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Serum creatinine (mg/dL)
up to one year
2 88 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.47, 0.37]
4.2 Creatinine clearance (mL/
min) up to one year
2 206 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.41, 0.14]
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Analysis 3.1.   Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 1 Death and graA loss.
Study or subgroup Avoidance Withdrawal Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 Death up to one year  
DOMINOS Study 2012 2/112 5/110 100% 0.39[0.08,1.98]
Subtotal (95% CI) 112 110 100% 0.39[0.08,1.98]
Total events: 2 (Avoidance), 5 (Withdrawal)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.13(P=0.26)  
   
3.1.2 Death one to five years  
Boots 2002 2/28 0/34 23.19% 6.03[0.3,120.75]
Sandrini 2009 4/44 2/46 76.81% 2.09[0.4,10.85]
Subtotal (95% CI) 72 80 100% 2.67[0.63,11.32]
Total events: 6 (Avoidance), 2 (Withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%  
Test for overall effect: Z=1.34(P=0.18)  
   
3.1.3 GraA loss including death up to one year  
DOMINOS Study 2012 7/112 8/110 100% 0.86[0.32,2.29]
Subtotal (95% CI) 112 110 100% 0.86[0.32,2.29]
Total events: 7 (Avoidance), 8 (Withdrawal)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.76)  
   
3.1.4 GraA loss including death one to five years  
Boots 2002 5/28 2/34 41.78% 3.04[0.64,14.47]
Sandrini 2009 6/44 3/46 58.22% 2.09[0.56,7.85]
Subtotal (95% CI) 72 80 100% 2.44[0.89,6.7]
Total events: 11 (Avoidance), 5 (Withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=1.73(P=0.08)  
   
3.1.5 GraA loss excluding death up to one year  
DOMINOS Study 2012 5/112 3/110 100% 1.64[0.4,6.68]
Subtotal (95% CI) 112 110 100% 1.64[0.4,6.68]
Total events: 5 (Avoidance), 3 (Withdrawal)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
   
3.1.6 GraA loss excluding death one to five years  
Boots 2002 3/28 2/34 65.45% 1.82[0.33,10.15]
Sandrini 2009 2/44 1/46 34.55% 2.09[0.2,22.25]
Subtotal (95% CI) 72 80 100% 1.91[0.48,7.67]
Total events: 5 (Avoidance), 3 (Withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.93); I2=0%  
Test for overall effect: Z=0.91(P=0.36)  
Test for subgroup differences: Chi2=5.49, df=1 (P=0.36), I2=8.95%  
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Analysis 3.2.   Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 2 Rejection.
Study or subgroup Avoidance Withdrawal Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.2.1 Acute rejection up to one year  
Sandrini 2009 22/44 14/46 1.64[0.97,2.78]
   
3.2.2 Biopsy-proven acute rejection up to one year  
DOMINOS Study 2012 13/112 8/110 1.6[0.69,3.7]
Favours avoidance 100.1 50.2 20.5 1 Favours withdrawal
 
 
Analysis 3.3.   Comparison 3 Steroid avoidance versus steroid withdrawal,
Outcome 3 New-onset diabetes aAer transplantation, infection, malignancy.
Study or subgroup Avoidance Withdrawal Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 New onset diabetes after transplantation up to five years  
Boots 2002 2/25 10/33 14.98% 0.26[0.06,1.1]
DOMINOS Study 2012 9/103 13/100 47.14% 0.67[0.3,1.5]
Sandrini 2009 7/44 9/46 37.88% 0.81[0.33,1.99]
Subtotal (95% CI) 172 179 100% 0.63[0.36,1.09]
Total events: 18 (Avoidance), 32 (Withdrawal)  
Heterogeneity: Tau2=0; Chi2=1.79, df=2(P=0.41); I2=0%  
Test for overall effect: Z=1.65(P=0.1)  
   
3.3.2 Infection (all) up to five years  
Boots 2002 26/28 24/34 39.34% 1.32[1.03,1.67]
DOMINOS Study 2012 68/112 78/110 42.35% 0.86[0.71,1.04]
Sandrini 2009 14/44 13/46 18.31% 1.13[0.6,2.12]
Subtotal (95% CI) 184 190 100% 1.07[0.76,1.5]
Total events: 108 (Avoidance), 115 (Withdrawal)  
Heterogeneity: Tau2=0.06; Chi2=7.96, df=2(P=0.02); I2=74.88%  
Test for overall effect: Z=0.37(P=0.71)  
   
3.3.3 CMV Infection up to five years  
Boots 2002 2/28 6/34 13.44% 0.4[0.09,1.85]
DOMINOS Study 2012 14/112 25/110 86.56% 0.55[0.3,1]
Subtotal (95% CI) 140 144 100% 0.53[0.3,0.92]
Total events: 16 (Avoidance), 31 (Withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%  
Test for overall effect: Z=2.25(P=0.02)  
   
3.3.4 Malignancy up to five years  
Sandrini 2009 3/44 2/46 100% 1.57[0.28,8.94]
Subtotal (95% CI) 44 46 100% 1.57[0.28,8.94]
Total events: 3 (Avoidance), 2 (Withdrawal)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.51(P=0.61)  
Test for subgroup differences: Chi2=6.08, df=1 (P=0.11), I2=50.68%  
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Analysis 3.4.   Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 4 Kidney function.
Study or subgroup Avoidance Withdrawal Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.4.1 Serum creatinine (mg/dL) up to one year  
Boots 2002 18 1.4 (0.3) 28 1.4 (0.5) 51.15% 0[-0.59,0.59]
DOMINOS Study 2012 20 1.5 (0.4) 22 1.6 (1.2) 48.85% -0.1[-0.71,0.51]
Subtotal *** 38   50   100% -0.05[-0.47,0.37]
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
   
3.4.2 Creatinine clearance (mL/min) up to one year  
Boots 2002 18 55.3 (21.6) 28 53.2 (17.9) 21.56% 0.11[-0.49,0.7]
DOMINOS Study 2012 79 56 (18) 81 60 (22) 78.44% -0.2[-0.51,0.11]
Subtotal *** 97   109   100% -0.13[-0.41,0.14]
Heterogeneity: Tau2=0; Chi2=0.79, df=1(P=0.37); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.75), I2=0%  
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Comparison 4.   Steroid withdrawal versus maintenance in children
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death and gra@ loss 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death up to five years 2 174 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.02, 1.35]
1.2 Gra@ loss including death up
to five years
2 174 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 0.69]
1.3 Gra@ loss excluding death
up to five years
2 174 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.00, 1.64]
2 Rejection, malignancy 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Acute rejection up to one
year
2 174 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.13, 1.02]
2.2 Biopsy-proven acute rejec-
tion up to one year
1 42 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.01, 3.27]
2.3 Malignancy (PTLD) up to five
years
1 132 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.51, 6.98]
3 Kidney function 1   Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Creatinine clearance (mL/
min) up to five years
1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 4.1.   Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 1 Death and graA loss.
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Death up to five years  
Benfield 2005 1/73 5/59 100% 0.16[0.02,1.35]
Höcker 2009 0/23 0/19   Not estimable
Subtotal (95% CI) 96 78 100% 0.16[0.02,1.35]
Total events: 1 (Withdrawal), 5 (Maintenance)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.69(P=0.09)  
   
4.1.2 GraA loss including death up to five years  
Benfield 2005 1/73 9/59 100% 0.09[0.01,0.69]
Höcker 2009 0/23 0/19   Not estimable
Subtotal (95% CI) 96 78 100% 0.09[0.01,0.69]
Total events: 1 (Withdrawal), 9 (Maintenance)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.32(P=0.02)  
   
4.1.3 GraA loss excluding death up to five years  
Benfield 2005 0/73 4/59 100% 0.09[0,1.64]
Höcker 2009 0/23 0/19   Not estimable
Subtotal (95% CI) 96 78 100% 0.09[0,1.64]
Total events: 0 (Withdrawal), 4 (Maintenance)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.63(P=0.1)  
Test for subgroup differences: Chi2=0.18, df=1 (P=0.91), I2=0%  
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Analysis 4.2.   Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 2 Rejection, malignancy.
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.2.1 Acute rejection up to one year  
Benfield 2005 4/73 9/59 80.95% 0.36[0.12,1.11]
Höcker 2009 1/23 2/19 19.05% 0.41[0.04,4.21]
Subtotal (95% CI) 96 78 100% 0.37[0.13,1.02]
Total events: 5 (Withdrawal), 11 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=1.93(P=0.05)  
   
4.2.2 Biopsy-proven acute rejection up to one year  
Höcker 2009 0/23 2/19 100% 0.17[0.01,3.27]
Subtotal (95% CI) 23 19 100% 0.17[0.01,3.27]
Total events: 0 (Withdrawal), 2 (Maintenance)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.18(P=0.24)  
   
4.2.3 Malignancy (PTLD) up to five years  
Benfield 2005 7/73 3/59 100% 1.89[0.51,6.98]
Subtotal (95% CI) 73 59 100% 1.89[0.51,6.98]
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Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 7 (Withdrawal), 3 (Maintenance)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.95(P=0.34)  
Test for subgroup differences: Chi2=4.53, df=1 (P=0.1), I2=55.88%  
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Analysis 4.3.   Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 3 Kidney function.
Study or subgroup Withdrawal Maintenance Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
4.3.1 Creatinine clearance (mL/min) up to five years  
Höcker 2009 23 95.5 (24) 17 94.4 (28.4) 1.1[-15.6,17.8]
Favours withdrawal 2010-20 -10 0 Favours maintenance
 
 
Comparison 5.   Publication bias
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Funnel plots 20 5288 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.15, 1.62]
1.1 Death, steroid withdrawal versus
maintenance
10 1913 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.29]
1.2 Acute rejection steroid withdrawal
versus maintenance
10 1913 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [1.28, 1.87]
1.3 Death, steroid avoidance versus main-
tenance
10 1462 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.52, 1.63]
 
 
Analysis 5.1.   Comparison 5 Publication bias, Outcome 1 Funnel plots.
Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.1.1 Death, steroid withdrawal versus maintenance  
Ahsan 1999 0/134 1/132 0.78% 0.33[0.01,7.99]
Bouma 1996 0/42 1/42 0.78% 0.33[0.01,7.96]
del Castillo 2005 1/70 0/72 0.26% 3.08[0.13,74.46]
Isoniemi 1990 3/32 4/32 2.07% 0.75[0.18,3.09]
Lebranchu 1999 4/252 8/248 4.18% 0.49[0.15,1.61]
Maiorca 1988 0/35 1/31 0.82% 0.3[0.01,7.02]
Matl 2000 1/45 0/42 0.27% 2.8[0.12,67]
Pelletier 2006 1/59 0/59 0.26% 3[0.12,72.18]
Pisani 2001 1/15 0/15 0.26% 3[0.13,68.26]
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Study or subgroup Withdrawal Maintenance Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
THOMAS Study 2002 3/279 6/277 3.12% 0.5[0.13,1.97]
Subtotal (95% CI) 963 950 12.8% 0.7[0.39,1.29]
Total events: 14 (Withdrawal), 21 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=4.51, df=9(P=0.88); I2=0%  
Test for overall effect: Z=1.14(P=0.25)  
   
5.1.2 Acute rejection steroid withdrawal versus maintenance  
Ahsan 1999 26/134 7/132 3.66% 3.66[1.65,8.14]
Bouma 1996 11/42 1/42 0.52% 11[1.49,81.44]
del Castillo 2005 17/70 13/72 6.64% 1.35[0.71,2.56]
Isoniemi 1990 6/32 1/32 0.52% 6[0.77,47.05]
Lebranchu 1999 76/252 52/248 27.17% 1.44[1.06,1.95]
Maiorca 1988 16/35 3/31 1.65% 4.72[1.52,14.69]
Matl 2000 3/45 2/42 1.07% 1.4[0.25,7.97]
Pelletier 2006 3/59 3/59 1.56% 1[0.21,4.75]
Pisani 2001 1/15 2/15 1.04% 0.5[0.05,4.94]
THOMAS Study 2002 67/279 60/277 31.22% 1.11[0.82,1.51]
Subtotal (95% CI) 963 950 75.05% 1.55[1.28,1.87]
Total events: 226 (Withdrawal), 144 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=19.74, df=9(P=0.02); I2=54.4%  
Test for overall effect: Z=4.58(P<0.0001)  
   
5.1.3 Death, steroid avoidance versus maintenance  
ATLAS Study 2005 3/151 0/147 0.26% 6.82[0.36,130.81]
De Vecchi 1986 0/25 4/26 2.29% 0.12[0.01,2.04]
FRANCIA Study 2007 1/98 3/103 1.52% 0.35[0.04,3.31]
FREEDOM Study 2008 7/226 2/109 1.4% 1.69[0.36,7.99]
Kumar 2005 0/45 0/32   Not estimable
Montagnino 2005 0/65 1/68 0.76% 0.35[0.01,8.4]
Nematalla 2007 0/50 0/50   Not estimable
Nott 1985 8/59 8/58 4.18% 0.98[0.4,2.44]
Schulak 1989 3/32 2/35 0.99% 1.64[0.29,9.2]
Vincenti 2003a 0/40 1/43 0.75% 0.36[0.01,8.54]
Subtotal (95% CI) 791 671 12.15% 0.92[0.52,1.63]
Total events: 22 (Withdrawal), 21 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=6.22, df=7(P=0.51); I2=0%  
Test for overall effect: Z=0.27(P=0.78)  
   
Total (95% CI) 2717 2571 100% 1.36[1.15,1.62]
Total events: 262 (Withdrawal), 186 (Maintenance)  
Heterogeneity: Tau2=0; Chi2=35.73, df=27(P=0.12); I2=24.43%  
Test for overall effect: Z=3.59(P=0)  
Test for subgroup differences: Chi2=8.15, df=1 (P=0.02), I2=75.45%  
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  Death GraA loss Acute rejection Biopsy-proven acute rejection
  Stud-
ies
RR 95% CI Stud-
ies
RR 95% CI Stud-
ies
RR 95% CI Stud-
ies
RR 95% CI
Publication status
Peer reviewed jour-
nal
8 0.60 0.31 to 1.17 7 1.25 0.73 to 2.13 8 2.02 1.23 to 3.23 4 1.32 0.66 to 2.66
Abstract only 2 3.04 0.33 to 28.29 1 0.82 0.23 to 2.94 2 1.25 0.67 to 2.32 1 1.37 0.70 to 2.69
ITT analysis
ITT analysis used 6 0.69 0.30 to 1.61 6 1.31 0.69 to 2.46 6 2.07 1.10 to 3.91 3 1.37 0.64 to 2.94
ITT analysis not
used/unclear
4 0.67 0.25 to 1.81 2 1.00 0.46 to 2.17 4 1.65 0.81 to 3.36 2 1.04 0.24 to 4.59
Calcineurin inhibitor
CsA 9 0.75 0.36 to 1.54 7 0.90 0.50 to 5.14 9 2.08 1.29 to 3.35 4 1.60 0.87 to 2.92
TAC 1 0.50 0.13 to 1.97 1 2.13 0.88 to 5.14 1 1.11 0.82 to 1.51 1 0.89 0.61 to 1.30
Antimetabolite
MMF or EC-MPS 6 0.67 0.31 to 1.47 5 1.25 0.75 to 2.08 6 1.41 1.02 to 1.94 3 1.27 0.81 to 2.00
AZA 2 0.93 0.26 to 3.40 2 0.25 0.03 to 2.18 2 2.61 0.62 to 10.91 1 0.33 0.04 to 2.56
MMF or EC-MPS or
AZA
8 0.73 0.38 to 1.43 7 1.15 0.70 to 1.89 8 1.46 1.07 to 1.98 4 1.19 0.75 to 1.90
none 2 0.31 0.03 to 2.95 1 3.00 0.13 to 71.61 2 5.80 2.16 to 15.57 1 9.00 1.19 to 67.93
Induction treatment
Induction (yes) 2 3.00 0.32 to 27.87 1 0.33 0.01 to 8.02 2 0.80 0.22 to 2.91 NA -- --
Induction (no) 8 0.60 0.31 to 1.17 7 1.21 0.74 to 1.99 8 1.93 1.26 to 2.94 NA -- --
Table 1.   Steroid withdrawal versus steroid maintenance - stratified subgroup and sensitivity analysis for death, graA loss and acute rejection up to
one year aAer transplantation 
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AZA - azathioprine; CI - confidence interval; CsA - cyclosporin A; EC-MPS - enteric-coated mycophenolate sodium; ITT - intention to treat; MMF - mycophenolate mofetil; NA - not
available; RR - risk ratio; TAC - tacrolimus
 
 
  Death GraA loss Acute rejection Biopsy-proven acute rejection
  Stud-
ies
RR 95% CI Stud-
ies
RR 95% CI Stud-
ies
RR 95% CI Stud-
ies
RR 95% CI
ITT analysis
ITT analysis used 7 1.16 0.48 to 2.83 5 1.09 0.56 to 2.11 4 1.92 1.18 to 3.14 4 2.31 1.47 to 3.63
ITT analysis not
used/unclear
3 0.51 0.07 to 3.83 2 1.11 0.46 to 2.67 3 1.24 0.97 to 1.59 2 1.05 0.49 to 2.23
Calcineurin inhibitor
CsA 8 0.88 0.47 to 1.66 5 1.08 0.59 to 1.99 5 1.31 1.05 to 1.63 3 1.89 1.29 to 2.79
TAC 2 6.82 0.36 to 130.81 2 1.14 0.39 to 3.3 2 2.40 1.05 to 5.49 3 1.81 0.66 to 4.99
Antimetabolite
MMF or EC-MPS 6 1.15 0.36 to 3.69 6 1.09 0.56 to 2.11 5 1.87 1.20 to 2.91 6 1.94 1.26 to 2.98
AZA 1 1.64 0.29 to 9.2 NA -- -- NA -- -- NA -- --
MMF or EC-MPS or
AZA
8 1.16 0.48 to 2.83 NA -- -- NA -- -- NA -- --
None 2 0.51 0.07 to 3.83 1 1.11 0.46 to 2.67 2 1.26 0.95 to 1.65 NA -- --
Induction treatment
Induction (yes) 7 0.97 0.38 to 2.48 5 1.06 0.45 to 2.46 4 1.50 0.97 to 2.32 5 1.67 1.19 to 2.36
Induction (no) 3 0.92 0.17 to 5.01 2 1.12 0.57 to 2.2 3 1.72 0.89 to 3.32 1 3.89 2.16 to 7.03
Table 2.   Steroid avoidance versus steroid maintenance - stratified subgroup and sensitivity analysis for death, graA loss and acute rejection up to
one year aAer transplantation 
AZA - azathioprine; CI - confidence interval; CsA - cyclosporin A; EC-MPS - enteric-coated mycophenolate sodium; ITT - intention to treat; MMF - mycophenolate mofetil; NA - not
available; RR - risk ratio; TAC - tacrolimus
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Steroid avoidance or w
ithdraw
al for kidney transplant recipients (Review
)
Copyright ©
 2016 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
136
 
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. Kidney Transplantation [MESH]
2. kidney transplant*
3. 1 or 2
4. (avoid* or minim* or free* or withdraw* or spar* or discontinu* or taper* or conversion* or con-
vert*) near25 (predniso* or corticosteroid* or steroid*)
5. 3 and 4
MEDLINE 1. Kidney Transplantation/
2. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or
convert$) adj25 (predniso$ or corticosteroid$ or steroid$)).tw.
3. and/1-2
EMBASE 1. exp kidney transplantation/
2. Drug Withdrawal/
3. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or
convert$) adj25 (predniso$ or corticosteroid$ or steroid$)).tw.
4. or/2-3
5. and/1,4
 
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
Unclear: Insufficient information about the sequence generation process to permit judgement.
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
Unclear: Randomisation stated but no information on method used is available.
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Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Selective reporting
Reporting bias due to selective
outcome reporting
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not cov-
ered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of bias.
  (Continued)
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High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
  (Continued)
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Date Event Description
15 February 2016 New search has been performed New studies included (20)
15 February 2016 New citation required and conclusions
have changed
New studies added; paediatric studies included
 
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 1, 2009
 
Date Event Description
14 July 2008 Amended Converted to new review format.
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External sources• ERBP-Fellowship to assist guideline development process (Ghent University, Renal Division, Belgium), Belgium.
Dr Maria C. Haller and Dr Evi V. Nagler are ERBP research fellows. European Renal Best Practice (ERBP) is the oMicial guidance issuing
body of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA)
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the earlier version of this review (Pascual 2009), we did not specifically include CMV infection as an outcome. Recent publications include
reporting of CMV infection as a specific outcome, and this has been translated to our review.
Since this review was last published (in 2009), the Cochrane risk of bias tool has been updated, and the current tool has been used in
assessments for this update.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Kidney Transplantation  [mortality];  Gra@ Rejection  [immunology]  [*prevention & control];  Gra@ Survival  [drug eMects]
 [immunology];  Immunosuppression;  Immunosuppressive Agents  [*administration & dosage]  [adverse eMects];  Randomized
Controlled Trials as Topic;  Steroids  [*administration & dosage]  [adverse eMects];  Withholding Treatment
MeSH check words
Adult; Child; Humans
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